Synthesis, DNA interactions and activation of novel cytotoxic anthraquinones. by Giles, Yvonne
SYNTHESIS, DNA INTERACTIONS AND ACTIVATION 
OF NOVEL CYTOTOXIC ANTHRAQUINONES 
Yvonne Giles B.Sc (Hons) 
A thesis submitted in part fulfillment of the requirements of 
De Montfort University for the degree of Doctor of Philosophy 
August 1999 
School of Pharmacy and Pharmaceutical Sciences, 
De Montfort University, Leicester 
DECLARATION 
The work reported in this thesis is original, except where due reference is made, and has 
not been submitted in whole or in part to any other degree awarding body or institution. 
CONTENTS 
Acknowledgements 
Abstract 
CHAPTER 1: Introduction 
1.1 Cancer 
1.2 DNA intercalating agents 
1.2.1 The anthracycline antitumour agents 
1.2.2 The anthraquinone antitumour agents 
1.2.3 Involvement of biotransformation in the antitumour 
activity of mitoxantrone 
1.3 DNA topoisomerases as targets for chemotherapy 
1.3.1 The structure and function of DNA topoisomerases 
1.3.2 Inhibition of topoisomerases 
1.3.2.1 Topoisomerase poisons 
1.3.2.2 Structural requirements for drug activity 
1.3.2.3 Mechanisms involved in the cytotoxicity of to poi some rase II 
pOisons 
1.3.2.4 Determinants of sensitivity to topoisomerase II poisons 
1.4 Problems associated with chemotherapy 
1.4.1 Drug toxicity 
1.4.1.1 General effects 
1.4.1.2 Major toxicities of the anthracyclines 
1.4.1.3 Toxic effects of the anthraquinones 
1.4.1.4 Development of the anthrapyrazoles 
1.4.2 Multidrug resistance 
1.4.2.1 Drug efflux-mediated multi drug resistance 
1.4.2.2 Clinical evaluation ofP-glycoprotein- and MRP-mediated 
drug resistance 
1.4.2.3 The at-MDR phenotype 
1 
2 
3 
3 
4 
5 
8 
11 
15 
15 
18 
18 
20 
21 
23 
26 
26 
26 
26 
31 
33 
35 
35 
38 
40 
1.4.2.4 Other mechanisms of resistance to topoisomerase II 
inhibitors 
1.5 The use of metabolically activated antitumour 
agents in the treatment of cancer 
1.5.1 Enzymes involved in drug metabolism 
1.5.2 Prodrugs 
1.5.2.1 Prodrug strategies 
1.5.2.2 Cyclophosphamide; the archetypal anticancer prodrug 
1.5.3 Metabolically activated anthracyclines; the morpholino 
analogues 
1.5.3.1 Metabolic activation of morpholino doxorubicin 
1.5.3.2 Metabolic activation of methoxymorpholino doxorubicin 
1.5.3.3 Circumvention of toxicity and multi drug resistance by 
42 
43 
43 
47 
47 
48 
50 
52 
53 
morpholino anthracyclines 55 
1.5.4. Bioreductive agents as anticancer prodrugs 56 
1.5.4.1 Hypoxia in solid tumours 56 
1.5.4.2 AQ4N: A hypoxia-selective cytotoxin 58 
1.6 ~ims 61 
CH~PTER 2: Topoisomerase II inhibition and DNA 
binding of alkylaminoanthraquinones 63 
2.1 Introduction 63 
2.2 Methods and materials 63 
2.2.1 Topoisomerase II inhibition studies 66 
2.2.1.1 Isolation of topoisomerase II from V79 cell nuclei 66 
2.2.1.2 Optimization of the concentration of topoisomerase II required 
for decatenation of kDNA 67 
2.2.1.3 Optimization of the incubation time for decatenation ofkDNA 67 
2.2.1.4 Optimization of ATP and magnesium ion levels for decatenation 
ofkDNA 68 
2.2.1.5 The effect of alkylaminoanthraquinones on the decatenating 
activity of to poi some rase II 68 
11 
2.2.2 DNA binding studies 
2.2.2.1 The effect of calf thymus DNA on the spectral properties 
of alkylaminoanthraquinones 
2.2.2.2 Spectrophotometric titration of alkylaminoanthraquinones 
against calf thymus DNA 
2.2.2.3 The effect of alkylaminoanthraquinones on the thermal 
denaturation of calf thymus DNA 
2.3 Results 
2.3.1 Topoisomerase II inhibition studies 
2.3.1.1 The decatenation assay 
2.3.1.2 The effect of alkylaminoanthraquinones on topoisomerase II 
activity 
2.3.2 DNA binding studies 
2.3.2.1 DNA-drug interactions 
2.3.2.2 Spectral properties of alkylaminoanthraquinones 
2.3.2.3 Determination of the affinity of alkylaminoanthraquinones 
for calf thymus DNA by spectrophotometric titration 
2.3.2.4 Thermal denaturation of calf thymus DNA in the presence of 
alky laminoanthraquinones 
2.4 Discussion 
2.4.1 Topoisomerase II inhibition studies 
2.4.2 DNA binding studies 
CHAPTER 3: Synthesis of acetal- and 
methoxymorpholino-anthraquinones 
3.1 Introduction 
3.2 Methods and materials 
3.2.1 Synthesis of alkylamino side chains 
3.2.1.1 Synthesis of 2-[N'-(2,2-dimethoxyethyl)amino ]ethylamine 
3.2.1.2 Synthesis of N-[2-(2' -methoxymorpholinyl)ethyl] amine 
3.2.2 Synthesis of alkylaminoanthraquinone derivatives 
111 
68 
68 
69 
69 
70 
70 
70 
70 
73 
73 
74 
78 
83 
90 
90 
93 
101 
101 
101 
102 
102 
102 
103 
3.2.2.1 Synthesis of I-N-{2-[N'-(2,2-dimethoxyethyl)amino]-
ethylamino }-anthracene-9, 1 O-dione (YCG7) 103 
3.2.2.2 Synthesis of 1 ,4-Bis-N-{2-[N'-(2,2-dimethoxyethyl)amino]-
ethyl amino }-anthracene-9, 1 O-dione (YCG8) 104 
3.2.2.3 Synthesis of 1 ,5-Bis-N-{2-[N'-(2,2-dimethoxyethyl)amino]-
ethylamino }-anthracene-9, 1 O-dione (YCG9) 105 
3.2.2.4 Attempted synthesis of I-N-{2-[N'-(2,2-dimethoxyethyl)amino]-
ethyl amino }-5,8-dihydroxy-anthracene-9,1 O-dione (YCG5) 106 
3.2.2.5 Attempted synthesis of 1,4-Bis-N-{2-[N'-(2,2-dimethoxyethyl)-
amino ] ethyl amino }-5,8-dihydroxy-anthracene-9,lO-dione (YCG6) 106 
3.2.2.6 Attempted synthesis of 1,4-Bis-N-{[2-(2'-methoxymorpholinyl)-
ethyl] amino }-5,8-dihydroxy-anthracene-9,1 O-dione (YCG4) 107 
3.3 Results and discussion 107 
3.3.1 Synthesis of alkylamino side chains 107 
3.3.2 General synthesis of alkylaminoanthraquinones 113 
3.3.3 Synthesis of acetalanthraquinones 119 
CHAPTER 4: Chemical and metabolic activation of 
acetalanthraquinones 
4.1 Introduction 
4.2 Methods and materials 
4.2.1 Separation of acetalanthraquinones and validation of the 
HPLC system 
4.2.2 Chemical hydrolysis of acetalanthraquinones 
4.2.3 Oxidative metabolism of acetalanthraquinones 
4.3 Results 
4.3.1 Validation of the HPLC system 
4.3.2 Chemical hydrolysis of the acetalanthraquinones 
4.3.3 Physico-chemical parameters of the hydrolysis reaction 
4.3.4 Oxidative metabolism of the acetalanthraquinones 
4.4 Discussion 
IV 
126 
126 
126 
127 
127 
128 
128 
128 
130 
134 
139 
1.t1 
4.4.1 Chemical hydrolysis of the acetalanthraquinones 
4.4.2 Oxidative metabolism of the acetalanthraquinones 
CHAPTER 5: DNA binding and cytotoxicity of 
acetalanthraquinones 
5.1 Introduction 
5.2 Methods and materials 
5.2.1 DNA binding studies 
5.2.1.1 The effect of acetalanthraquinones on the thermal denaturation 
of calf thymus DNA 
5.2.2 Cytotoxicity studies 
5.2.2.1 Maintenance ofV79 cells 
5.2.2.2 MTT formazan calibration curve 
5.2.2.3 Calibration of MTT formazan production and V79 cell density 
5.2.2.4 Determination of V79 cell growth characteristics and cell 
doubling time 
5.2.2.5 Effect of acetalanthraquinones on V79 cell viability 
5.2.2.6 Effect of acid-hydrolysed acetalanthraquinones on V79 cell 
viability 
5.2.2.7 Effect of acetal anthraquinone metabolites on V79 cell viability 
5.3 Results 
5.3.1 DNA binding studies 
5.3.2 Cytotoxicity studies 
5.3.2.1 The MTT assay 
5.3.2.2 The effect of the acetalanthraquinones on V79 cell viability 
5.3.2.3 The effect of hydrolysed acetalanthraquinones on V79 cell 
viability 
5.3.2.4 The effect of metabolized acetalanthraquinones on V79 cell 
viability 
5.4 Discussion 
5.4.1 DNA binding studies 
5.4.2 Cytotoxicity studies 
v 
141 
148 
152 
152 
153 
153 
153 
154 
154 
154 
154 
155 
156 
156 
157 
158 
158 
167 
167 
170 
173 
177 
178 
178 
182 
CHAPTER 6 
6.1 Conclusions 
6.2 Future work 
Appendices 
At. The trypan blue dye exclusion assay 
A2. The Biorad assay 
A3 Synthesis of starting materials (chapter 3) 
A4 NMR- and mass spectra for selected acetal- and methoxymorpholino-
189 
194 
198 
198 
199 
200 
anthraquinones 204 
AS Spectral determination of cytochrome P-450 content of Balb C mouse 
liver micro somes 209 
A6 Determination of the overall order of the reaction for the hydrolysis 
of the acetalanthraquinones 
A 7. Maintenance of V79 cells 
A8. Abbreviations 
Bibliography 
VI 
210 
214 
215 
217 
TABLES 
CHAPTER! 
Table 1.1 Modulators ofP-gp mediated multi drug resistance 37 
Table 1.2 Types of malignancy in which MDR11P-gp have 
prognostic value 39 
Table 1.3 Summary of phenotypic alterations displayed by at-MDR cells 41 
CHAPTER 2 
Table 2.1 Inhibition of to poi some rase II-mediated decatenation of 
kDNA by bis-substituted alkylaminoanthraquinones 
Table 2.2 Spectral properties ofbis-substituted alkylamino-
anthraquinones in the presence of calf thymus DNA 
Table 2.3 Values ofK and n for bis-substituted alkylamino-
anthraquinones obtained by spectrophotometric titration with 
calf thymus DNA 
Table 2.4 i1Tm values of calf thymus DNA in the presence ofbis-
substituted alkylaminoanthraquinones 
CHAPTER 4 
Table 4.1 Rate constants and activation energies for the 
acetalanthraquinones 
VIl 
71 
75 
80 
85 
134 
CHAPTERS 
Table 5.1 Spectral properties of acetalanthraquinones in the presence 
of calf thymus DNA 
Table 5.2 ~ Tm values of calf thymus DNA in the presence of the 
acetalanthraquinones 
Table 5.3 The effect of the acetalanthraquinones and ametantrone on 
V79 cell survival following drug incubation periods of 4 and 
24 hours 
Table 5.4 The effect of the acetalanthraquinones and their hydrolysed 
products on V79 cell survival in the presence of foetal calf serum 
Table 5.5 The effect of the acetalanthraquinones and their hydrolysed 
products on V79 cell survival in the absence of foetal calf serum 
Table 5.6 The effect of the acetalanthraquinones and their metabolites 
on V79 cell survival 
V\ll 
159 
163 
170 
173 
174 
177 
FIGURES 
CHAPTER! 
Figure 1.1 Intercalation of ethidium bromide into double-stranded DNA 5 
Figure 1.2 The anti tumour anthracyclines doxorubicin and daunorubicin 
and their analogues epirubicin and idarubicin 6 
Figure 1.3 The anthraquinone antitumour agents mitoxantrone and 
ametantrone 
Figure 1.4 The mono- and di-carboxylic acid metabolites of 
9 
mitoxantrone 12 
Figure 1.5 The TNQ metabolite of mitoxantrone 14 
Figure 1.6 A two gate mechanism for the catalytic reaction of 
topoisomerase II 17 
Figure 1.7 The catalytic cycle of type II DNA topoisomerases, showing 
the modes of action of the inhibitors and poisons of the enzyme. 19 
Figure 1.8 Formation of protein-associated double strand breaks 
following denaturation of the DNA-topoisomerase II cleavable 
complex 20 
Figure 1.9 Models for the lethal interaction of topoisomerase II 
cleavable complexes with replication and transcription 
machineries 22 
Figure 1.10 Base pair cleavage preferences of various topoisomerase II 
inhibitors 25 
Figure 1.11 Model showing the theoretical interaction of different drug 
pharmacophores with double stranded DNA within the topoisomerase II 
cleavage site 25 
Figure 1.12 Redox cycling of quinone-based anticancer agents 29 
Figure 1.13 The anthracycline 5-iminodaunorubicin 33 
Figure 1.14 The anthrapyrazole antitumour agent CI941 34 
IX 
Figure 1.15 The catalytic cycle of cytochrome PA50 45 
Figure 1.16 Metabolic activation of cyclophosphamide to produce the 
active phosphoramide mustard 49 
Figure 1.17 Structural modification of doxorubicin to produce 
morpholino doxorubicin and methoxymorpholino doxorubicin 51 
Figure 1.18 Hypothetical chemical and metabolic conversion 
of morpholino anthracyclines to alkylating species 54 
Figure 1.19 AQ4N, showing the electrically neutral N-oxide 
functionality 58 
Figure 1.20 Proposed route ofbioreduction of AQ4N by 
cytochrome PA50 59 
CHAPTER 2 
Figure 2.1 Bis-substituted alkylaminoanthraquinones investigated in 
this study 64 
Figure 2.2 Inhibition of to poi some rase II-mediated decatenation of 
kDNA by mitoxantrone 72 
Figure 2.3 Inhibition of to poi some rase II-mediated decatenation of 
kDNA by AQ4 and AQ4N 72 
Figure 2.4 Inhibition of topoisomerase II -mediated decatenation of 
kDNA by AQ6 and AQ6N 73 
Figure 2.5 Spectral properties of AQ 15 in the presence of calf thymus 
DNA and O.008M Trisl O.05M NaCI 76 
Figure 2.6 Spectral properties of AQ15 in the presence of calf thymus 
DNA and O.008M Trisl O.5M NaCI 76 
Figure 2.7 Spectral properties of AQ16 in the presence of calf thymus 
DNA and O.008M Trisl O.05M NaCI 77 
Figure 2.8 Spectral properties of AQ 16 in the presence of calf thymus 
DNA and O.008M Trisl O.5M NaCI 77 
Figure 2.9 Scatchard plot obtained from spectrophotometric titration 
x 
of mitoxantrone with calf thymus DNA 81 
Figure 2.10 Scatchard plot obtained from spectrophotometric titration 
of ametantrone with calf thymus DNA 81 
Figure 2.11 Scatchard plot obtained from spectrophotometric titration 
of AQ6 with calf thymus DNA 82 
Figure 2.12 Scatchard plot obtained from spectrophotometric titration 
of AQ6N with calf thymus DNA 82 
Figure 2.13 Melting profile of calf thymus DNA 86 
Figure 2.14 Melting profile of calf thymus DNA in the presence of 
mitoxantrone 86 
Figure 2.15 Melting profile of calf thymus DNA in the presence of AQ4 87 
Figure 2.16 Melting profile of calf thymus DNA in the presence of AQ4N 87 
Figure 2.17 Melting profile of calf thymus DNA in the presence of AQ6 88 
Figure 2.18 Melting profile of calf thymus DNA in the presence of AQ6N 88 
Figure 2.19 Melting profile of calf thymus DNA in the presence of AQll 89 
Figure 2.20 Melting profile of calf thymus DNA in the presence of AQ12 89 
Figure 2.21 Proposed mechanism of Schiffs base formation between the 
mono-aldehyde intermediate of mitoxantrone and topoisomerase II 92 
Figure 2.22 Three-site binding model showing intercalation, external 
binding and self-association for ellipticine derivatives with poly[d(A-T)] 94 
CHAPTER 3 
Figure 3.1 Synthesis of 2-[N'-(2,2-dimethoxyethyl)amino ]ethylamine by 
nucleophilic substitution of bromo acetaldehyde dimethyl acetal with 
diaminoethane 108 
Figure 3.2 Synthesis of N-[2-(2' -methoxymorpholinyl)ethyl] amine by 
the method devised by Slusarska and Zwierzak 110 
Figure 3.3 Synthesis of the methane sulphonate ester of N-[2-(2'-
Xl 
methoxymorpholinyl)]ethanol followed by N-alkylation to produce N-
alkyldiphenyl-phosphinamide 112 
Figure 3.4 Delocalization of positive charge within the anthraquinone 
ring system 114 
Figure 3.5 Electron withdrawing effect of the anthraquinone carbonyl 
group 114 
Figure 3.6 Reaction scheme showing the synthesis of 1,4-bis-substituted 
derivatives from 1,4-dihydroxyanthraquinone 116 
Figure 3.7 Reaction scheme showing nucleophilic substitution of 
leucoquinizarin with N-alkyl-l ,2-diaminoethane derivatives, followed by 
cyclisation to produce the tetrahydronaphtho-quinoxaline (TNQ) 
derivative at higher temperatures 118 
CHAPTER 4 
Figure 4.1 Relationship between peak area and drug concentration for 
YCG7 129 
Figure 4.2 Relationship between peak area and drug concentration for 
YCG8 129 
Figure 4.3 Relationship between peak area and drug concentration for 
YCG9 130 
Figure 4.4 HPLC chromatograms for YCG7 after 0, 45 and 90 minutes 
incubation with O.IM HCI at 90°C 131 
Figure 4.5 HPLC chromatograms for YCG8 after 0, 45 and 90 minutes 
incubation with O.IM HCI at 90°C 131 
Figure 4.6 HPLC chromatograms for YCG9 after 0, 45 and 90 minutes 
incubation with O.IM HCI at 90°C 132 
Figure 4.7 UV -visible absorbance spectrum for YCG8 before and after 4 
hours incubation with O.IM HCI at 90°C 133 
Figure 4.8 Rate constants for the hydrolysis ofYCG7 at 70°C, 80°C, and 
90°C 136 
Figure 4.9 Activation energy for the hydrolysis of YCG7 136 
XII 
Figure 4.10 Rate constants for the hydrolysis ofYCG8 at 70°C, 80°C, 
and 90°C 137 
Figure 4.11 Activation energy for the hydrolysis ofYCG8 137 
Figure 4.12 Rate constants for the hydrolysis of YCG9 at 70°C, 80°C, 
and 90°C 138 
Figure 4.13 Activation energy for the hydrolysis ofYCG9 138 
Figure 4.14 HPLC chromatograms for YCG7 after 60 minutes 
incubation with Balb C mouse liver micro somes +/- NADPH 140 
Figure 4.15 HPLC chromatograms for YCG8 after 60 minutes 
incubation with Balb C mouse liver micro somes +/- NADPH 140 
Figure 4.16 HPLC chromatograms for YCG9 after 60 minutes 
incubation with Balb C mouse liver micro somes +/- NADPH 141 
Figure 4.17 Scheme for the conversion of an acetal to the corresponding 
aldehyde by acid-catalyzed hydrolysis via SN 1 nucleophilic substitution 143 
Figure 4.18 Scheme for the conversion of an acetal to the corresponding 
aldehyde by acid-catalyzed hydrolysis via SN2 nucleophilic substitution 144 
Figure 4.19 Proposed route for the hydrolysis of YCG8 via hemiacetal 
intermediates 146 
Figure 4.20 Proposed pathway for the metabolic conversion of the 
acetalanthraquinones to their corresponding aldehyde derivatives 149 
CHAPTER 5 
Figure 5.1 Spectral properties ofYCG7 in the presence of calf thymus 
DNA and 0.008MTris/ O.05M NaCI 160 
Figure 5.2 Spectral properties ofYCG7 in the presence of calf thymus 
DNA and O.008MTris/ 0.5M NaCI 160 
Figure 5.3 Spectral properties of YCG8 in the presence of calf thymus 
DNA and 0.008MTris/ O.05M NaCI 161 
Figure 5.4 Spectral properties of YCG8 in the presence of calf thymus 
DNA and 0.008MTris/ O.5M NaCI 
XIII 
161 
Figure 5.5 Spectral properties of YCG9 in the presence of calf thymus 
DNA and O.008MTrisl O.OSM NaCI 162 
Figure 5.6 Spectral properties of YCG9 in the presence of calf thymus 
DNA and O.008MTrisl O.SM NaCI 162 
Figure 5.7 Melting profile of calf thymus DNA in the presence of 
ametantrone 163 
Figure 5.8 Melting profile of calf thymus DNA in the presence ofYCG7 
before drug hydrolysis 164 
Figure 5.9 Melting profile of calf thymus DNA in the presence ofYCG7 
after drug hydrolysis 164 
Figure 5.10 Melting profile of calf thymus DNA in the presence of 
YCG8 before drug hydrolysis 165 
Figure 5.11 Melting profile of calf thymus DNA in the presence of 
YCG8 after drug hydrolysis 165 
Figure 5.12 Melting profile of calf thymus DNA in the presence of 
YCG9 before drug hydrolysis 166 
Figure 5.13 Melting profile of calf thymus DNA in the presence of 
YCG9 after drug hydrolysis 166 
Figure 5.14 Relationship between MTT formazan concentration and 
absorbance at 492nm 168 
Figure 5.15 Relationship between V79 cell density and MTT formazan 
production 168 
Figure 5.16 Growth characteristics ofV79 cells seeded at various 
densities over a S day period 169 
Figure 5.17 Effect of YCG7 on V79 cell survival following drug 
incubation periods of 4 and 24 hours 171 
Figure 5.18 Effect of YCG8 on V79 cell survival following drug 
incubation periods of 4 and 24 hours 171 
Figure 5.19 Effect of YCG9 on V79 cell survival following drug 
incubation periods of 4 and 24 hours 172 
XIV 
Figure 5.20 Effect ofYCG7 on V79 cell survival before and after drug 
hydrolysis 175 
Figure 5.21 Effect of YCG8 on V79 cell survival before and after drug 
hydrolysis 176 
Figure 5.22 Effect of YCG9 on V79 cell survival before and after drug 
hydrolysis 176 
Figure 5.23 Computer graphics modelling illustrating DNA intercalation 
of 1,4- and 1 ,5-bis-substituted alkylaminoanthraquinones 180 
Figure 5.24 Proposed mechanism of Schiffs base formation between the 
aldehyde product of an acetal anthraquinone and nucleophilic centres of 
molecules such as topoisomerase II 186 
xv 
ACKNOWLEDGEMENTS 
I would like to thank Professor Laurence Patterson and the Association for 
International Cancer Research for giving me the opportunity to carry out this research. I 
would also like Laurence to know his patience has been much appreciated. Thanks to Dr 
M. R. Craven for his helpful suggestions throughout the practical work in H2.15, and to 
Wan for all his help, especially with the computer! Thanks also to the technical staff, 
particularly Richard Webster and Paul Hodgkinson for their support, and to all the staff 
at the Centre for Educational Technology and Development (CETD). Thanks to Stuart 
Fairall at the computer node for all his time and effort in helping me to print this thesis. 
Lastly, a big thank-you to Zennia "D'ya funcy a brew?" Panawynk for all her advice and 
encouragement (and for her great sense of humour). 
ABSTRACT 
Mitoxantrone is a dihydroxyanthracenedione derivative with significant clinical 
activity against advanced breast cancer, lymphoma and several types of leukaemia. 
However, as with all conventional anticancer agents, its non-specific nature results in 
dose-limiting systemic toxicity. The pharmacological (and toxicological) effects of 
mitoxantrone are thought to be mediated through its interaction with DNA and the DNA 
processing enzyme, topoisomerase II. Hence, an investigation of the DNA binding 
properties of mitoxantrone and related bis-substituted alkylaminoanthraquinones was 
undertaken with a view to developing agents with reduced toxicity to normal cells. 
DNA intercalation was evaluated using spectrophotometric and DNA thermal 
denaturation (Tm) techniques with calf thymus DNA. Overall, compounds that were 
hydroxylated at the 5 and 8 positions of the anthraquinone chromophore had increased 
DNA binding affinity compared to their non-hydroxylated analogues. The ~ Tms of 
mitoxantrone and its non-hydroxylated analogue ametantrone, were 26.4 °C and 21.5°C 
respectively. The affinity constants (K) for the chromophore-hydroxylated compounds 
were between 3.94 and 4.95 xl06M-1 while K values for their non-hydroxylated 
analogues were between 1.63 and 3.25 xl06M-l. For the di-N-oxide, AQ4N, 
intercalation was not detectable. The mono-N-oxide, AQ6N, showed modest DNA 
binding activity, with a ~Tm of7.0°C and an affinity constant of 3.64 Xl06M-l. Several 
of the alkylaminoanthraquinones were further investigated for their ability to inhibit 
decatenation of kDNA by topoisomerase II. Mitoxantrone and its analogues, AQ4 and 
AQ6, inhibited decatenation at concentrations ofO.75IlM, 1.51lM and 1.0llM 
respectively. In contrast, total inhibition of decatenation by the N-oxides, AQ4N and 
AQ6N, required concentrations of 50llM and 1 OIlM respectively. Hence modification of 
the terminal nitrogen on both alkylamino side chains to form a di-N-oxide resulted in a 
large decrease in DNA binding affinity and topoisomerase II inhibition. In view of the 
importance of the cationic alkyl amino side chains in intercalative binding and the 
enhanced ability of mitoxantrone to inhibit topoisomerase II, a series of 
acetalanthraquinones were synthesized. These compounds, referred to as YCG7 (1-
substituted), YCG8 (l,4-bis-substituted), and YCG9 (l,5-bis-substituted), possessed 
dimethoxy groups in place of the alcohol groups of mitoxantrone, and were designed to 
be converted to their respective aldehydes, which should increase their cytotoxic activity 
due to their potential to form Schiffs bases with intracellular targets. The 
acetalanthraquinones were relatively poor DNA intercalators compared to the parent 
compound, ametantrone. The ~Tm values for YCG7, YCG8 and YCG9 were 3.6 °C, 
14.2 °C and 15.7 °C respectively. The bathochromic shifts for the acetalanthraquinones 
in the presence of calf thymus DNA and 0.5M NaCl/0.008M Tris at a DNA:drug ratio 
of 10:1 were 1.4nm, 3.5nm and 3.6nm respectively for YCG7, YCG8 and YCG9 
(ametantrone=12.2nm). Oxidative metabolism by NADPH-fortified mouse liver 
micro somes provided an effective route for the oxidation of acetalanthraquinones, 
producing two polar metabolites for YCG7 and three polar metabolites for both YCG8 
and YCG9. The metabolites ofYCG7 and YCG8 were considerably more cytotoxic 
against the V79 Chinese hamster lung cell line than their respective 
acetalanthraquinones (4.4-fold for both compounds).YCG9 was found to be relatively 
cytotoxic per se, possibly due to its different mode of DNA binding, involving 
'straddling' of the DNA helix. The increase in cytotoxicity of the metabolized products 
compared with the acetalanthraquinones supports the concept t?at they were conv.e~ed 
to their corresponding aldehydes. This leads the way to the deSIgn of acetal-contammg 
cytotoxic agents which can be selectively activated in tumours. 
2 
CHAPTER 1: INTRODUCTION 
1.1 CANCER 
Cancer can be defined as a collection of diseases characterized by uncontrolled 
cell proliferation leading to dissemination (metastasis) to other parts of the body, which 
eventually compromises normal body function. The spread of primary growths to 
secondary locations distinguishes cancer from benign tumours and makes its eradication 
far more difficult. In the European Community, the current mortality rate from cancer is 
1 in 4 deaths, a figure set to rise. The commonest malignancy in British women is breast 
cancer, which affects 1 in 12, whereas in the Greek population the number is only half 
that (Cancer Research Campaign Scientific Yearbook, 1993). Contrary to the belief that 
various populations are genetically predisposed to particular types of cancer, incidence 
rates are largely dependent on environmental factors such as diet and lifestyle. 
Carcinogenesis, the process leading to cancer formation, is complex and not yet 
fully understood, but often involves phenotypic alterations that give cancer cells a 
selective advantage for growth over normal cells. These may include overcompetitive 
behaviour for growth factors, overproduction of intracellular growth signals or errors in 
genes which regulate programmed cell death (apoptosis) e.g. bcl-2, c-myc, p53 (see 
reviews by Ellis et aI, 1996; Dixon et aI, 1997). This is usually accompanied by 
modifications which enable cells to invade surrounding tissue and metastasize to other 
parts of the body to form new tumours (King, 1996). Due to a high level of genetic 
instability, generation of errors continues as the cancer progresses. 
The prognosis for patients treated when their cancer is in an early stage is 
invariably better, due to the smaller number and less malignant nature of the tumour. 
Surgery is the usual starting point for treatment of solid tumours, followed by either 
radiation therapy and/or chemotherapy, depending on the site and nature of the disease. 
As a majority of tumours cells have a higher proportion of dividing cells than normal 
tissue, they are generally more susceptible to the lethal effects of chemotherapeutic 
agents. However, rapidly dividing normal cells, such as those of the bone marrow, 
., 
J 
digestive tract and hair follicles are also affected, causing unwanted side effects such as 
myelosuppression, vomiting, gastrointestinal disturbances and alopecia (see section 
1.4.1). This poses limitations on the dose of a particular drug that can be administered. 
which in turn reduces the effectiveness of the treatment. 
The problem of systemic toxicity has been partially alleviated by combination 
therapy, which usually involves the administration of two or three cytotoxic agents with 
different mechanisms of action. This strategy also enhances overall tumour cell kill, but 
rarely eradicates all cells, and the small clones of progenitor cells which survive 
treatment frequently redivide to form a new, drug resistant tumour (section 1.4.2). 
Unfortunately, this means that with the exception of prostate cancer, Hodgkin's 
lymphoma and childhood leukaemia, cancer is often fatal. As a consequence, extensive 
research is being carried out to find new drugs that overcome the problems of toxicity 
and resistance associated with chemotherapy (see section 1.5). Many of these are based 
on compounds already in clinical use. 
1.2 DNA INTERCALATING AGENTS 
Among the agents currently used in the treatment of cancer are the DNA 
intercalating agents. These possess a polycyclic aromatic ring system that allows 
reversible non-covalent interdigitation between adjacent base pairs in the hydrophobic 
interior of the DNA double helix (Lerman, 1961). This results in local distortion and an 
overall lengthening of the DNA helix as it unwinds to accommodate the drug molecule 
(Waring, 1970; Reinert, 1983; figure 1.1). Compounds with tri - and tetracyclic 
chromophores, which are of approximately the same dimensions as the purine-
pyrimidine base pairs, show optimal binding. In some cases, the drug may contain 
additional constituents attached to the chromophore which strengthen intercalation by 
interacting with the anionically charged DNA phosphate backbone (Foye et ai, 1982; 
Pachter et ai, 1982; Pohle et ai, 1990). However, this type of binding is much weaker 
than intercalation because it occurs on the exterior surface of the DNA helix, and is thus 
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influenced to a large extent by the conditions of the surrounding medium (Jones et aI, 
1980). 
Ethidium bromide 
Nucleotide 
Backbone 
> 
Intercalated 
molecule 
Figure 1.1: Intercalation of ethidium bromide into double-stranded DNA, showing 
lengthening of the DNA helix (reproduced from Watson et aI, 1987). 
1.2.1 THE ANTHRACYCLINE ANTITUMOUR AGENTS 
The anthracycline antibiotics daunorubicin and doxorubicin were isolated from 
Streptomyces species in the 1960s, and are still among the most widely used and 
effective chemotherapeutic agents in the clinic today (for a review, see Lown, 1993). 
Chemically, the anthracyclines contain an amino sugar attached to an aglycone ring, 
the latter consisting of a non-aromatic (A) ring conjugated with an anthraquinone 
moiety (figure 1.2). Doxorubicin is the 14-hydroxy derivative of daunorubicin, and this 
structural modification significantly increases its spectrum of activity. Thus, while the 
use of daunorubicin is limited to the treatment of haematological malignancies (Bassan 
5 
et ai, 1996), doxorubicin can also be used alone or in combination to treat a wide ranoe 
b 
of solid tumours, including cancers of the breast (Fisher et ai, 1989) and ovary (A'Hem 
& Gore, 1995). 
I 
1 
OH 
Doxorubicin: R1= OH; R2= OCH3 
Epirubicin: R 1 = OH; R2 = OCH 3; OH at 4' = equatorial 
Figure 1.2: The antitumour anthracyclines doxorubicin and daunorubicin, and their 
analogues, epirubicin and idarubicin. 
The principal mode of action of the anthracyclines is thought to be mediated 
through intercalation of the aglycone portion of the molecule between adjacent DNA 
base pairs. Intercalation occurs preferentially between CAiT bases with the 
chromophore perpendicular to the base pair axes and the daunosamine sugar positioned 
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in the minor groove (Frederick et ai, 1990; Gao & Wang, 1991). This presumably 
provides a means for the inhibition of DNA- and RNA polymerase activities observed 
for the anthracyclines, resulting in the cessation of DNA and RNA synthesis 
respectively (Meriweather & Bachur, 1972; Zunino et ai, 1975). It also allows 
doxorubicin and daunorubicin to stabilize the covalent complex formed between DNA 
and topoisomerase II during the strand passage reaction (see section 1.3.2.1). 
In addition to its intercalative mechanism of action, doxorubicin can mediate 
cytotoxicity without entering L1210 leukaemia cells (Tritton & Yee, 1982). This has 
raised the possibility that it can mediate cell death purely through activating signal 
transduction pathways at the plasma membrane (Tritton, 1991). Doxorubicin and 
daunorubicin also produce DNA damage through the generation of free radicals, 
although the importance of this process in their anti tumour activity remains 
controversial and is generally considered to be more closely associated with their 
undesirable side effects, particularly their severe cardiotoxicity, which can be dose-
limiting (see section 1.4.1.2). 
As a result of the highly undesirable features associated with the use of the 
anthracyclines in chemotherapy, much time and effort has been devoted to developing 
derivatives of doxorubicin and daunorubicin in the hope of enhancing antitumour 
activity and/or lowering toxic side effects. Some of the most successful derivatives 
include epirubicin (4'-epidoxorubicin) and idarubicin (4-demethoxydaunorubicin) 
which are currently available for the treatment of advanced cancers (Cersosimo, 1992; 
Bonadonna et ai, 1993; see figure 1.2). Unfortunately, despite the reduced 
cardiotoxicity of epirubicin (see section 1.4.1.2) and the superior activity of idarubicin 
compared to doxorubicin and daunorubicin in several cell lines (Supino et ai, 1977; 
Curtis et ai, 1995), neither of these analogues has an improved therapeutic index or a 
significantly different spectrum of activity to doxorubicin in vivo. 
In the 1970s, it was surmised that the unwanted cardiotoxic effects of the 
anthracyclines may be caused by their amino sugar. This supposition was based on the 
7 
observation that the aglycones of digitalis produced more transient and less potent 
myocardial damage than the glycosides (Adamson, 1974). However, it was also noted 
that if separated, neither the aglycone nor daunosamine sugar of the anthracyc1ines 
retained antitumour activity (Zee-Cheng & Cheng, 1970). Wishing to design new series 
of compounds, two research groups (Zee-Cheng & Cheng, 1978; Murdock et at, 1979) 
decided to remove the daunosamine sugar and replace the amino function, which was 
essential for activity, with another, appropriately positioned amino group. In addition, 
the non-aromatic portion of the molecule was also omitted, since this was not required 
for intercalation (or activity) and caused synthetic complications due to its 
stereochemical configuration. An intensive screening programme of compounds 
incorporating these structural modifications soon ensued. 
1.2.2 THE ANTHRAQUINONE ANTITUMOUR AGENTS 
The two most successful anticancer agents to emerge from the 1970s screening 
programme were the bis-substituted alkylaminoanthraquinones mitoxantrone and 
ametantrone (figure 1.3). Both these compounds contain 2'-(hydroxyethylamino)-
ethyl amino side chains at the 1 and 4 positions of the chromophore, but differ in the 
fact that mitoxantrone is hydroxylated at the 5 and 8 positions, whereas ametantrone is 
unsubstituted. This structural alteration is fundamental to the 10 to 50-fold increase in 
potency of mitoxantrone compared with ametantrone in vivo (Johnson et at, 1979; 
Krapcho et at, 1991) and its activity against advanced breast cancer, non-Hodgkin's 
lymphoma and several types of chronic and acute leukaemia (reviewed by Shenkenberg 
& von Hoff, 1986, Faulds et at, 1991). Mitoxantrone also has superior antitumour 
efficacy to compounds where the methylene bridge spacer group is more than two 
carbons in length, compounds with side chains not containing a terminal nitrogen, or 
those containing a primary or tertiary terminal nitrogen (see Cheng & Zee-Cheng, 
1983; Randall et at, 1983). 
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mitoxantrone: R=OH 
ametantrone R =H 
Figure 1.3: The anthraquinone antitumour agents mitoxantrone and ametantrone. 
In common with the anthracyclines, biochemical evidence indicates that nucleic 
acids are among the principal targets of the anthraquinones and that DNA-drug 
interactions contribute significantly to cytotoxic activity. Confocal imaging studies on 
drug uptake and distribution in intact human cells have shown that mitoxantrone 
accumulates in the nucleus, particularly the nucleolus (Smith et ai, 1992; Fox & Smith, 
1995; Feofanov et ai, 1997). This is consistent with preferential binding of the drug to 
nucleolar DNA and condensation of ribopolymers (Chegini & Safa, 1987). A 
considerable proportion of the drug is also contained within small cytoplasmic 
inclusions grouped around the periphery of the nucleus, where it is sequestered for long 
periods. Mitoxantrone is also associated with the hydrophobic cytoskeleton (Cress et 
ai, 1988; Roberts et ai, 1989) and along these lines, it has been reported that it can 
mediate its intracellular effect through the inhibition of microtubule assembly (Ho et 
ai, 1991). 
The majority of theoretical and experimental data indicate that l,4-bis-substituted 
alkylaminoanthraquinones intercalate with the chromophore perpendicular to the long 
axes of the base pairs and both side chains projecting into the major groove extending 
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in the 5' direction (Lown & Hanstock, 1985; Chen et ai, 1986; Fox et ai, 1986). In this 
configuration, the cationic amino groups of the side chains are believed to interact with 
DNA via the negatively charged DNA phosphate groups which stabilizes the DNA-
drug interaction (Lown & Hanstock, 1985). The most recent evidence, obtained by 
means of a novel transcriptional assay, indicates that intercalation of mitoxantrone 
occurs preferentially at 5'-(AlT)CA and 5'-(AlT)CG sites (Panousis & Phillips, 1994) 
with some indication that binding to the latter of these sites is dependent on the two 
chromophore hydroxyl groups (Bailly et ai, 1996). 
Numerous studies have been conducted in an attempt to shed light on molecular 
basis for the superior activity of mitoxantrone compared with its analogues, with some 
interesting results. For example, mitoxantrone-DNA intercalation complexes dissociate 
three or four times more slowly than those of ametantrone, due to prolonged retention 
of the mitoxantrone chromophore in the hydrophobic interior of the double helix 
(Denny & Wake lin, 1990). This has been attributed to the bulky nature of hydroxy 
groups (Denny & Wakelin, 1990) and the increased lipophilicity of the mitoxantrone 
chromophore (Patterson, 1993). More recently, Mazerski et ai (1998) have suggested 
that the increase in chromophore width conferred by the hydroxy groups may keep the 
drug in a more coplanar orientation within the intercalation site, resulting in greater 
electrostatic interactions with the DNA base pairs. The slower dissociation of 
mitoxantrone from DNA may increase its cytotoxicity by prolonging the arrest of DNA 
and RNA synthesis (Fox & Smith, 1990) and by enhancing stabilization of the DNA-
topoisomerase II cleavable complex (see section 1.3.2). 
The pharmacological activity of mitoxantrone and ametantrone may also be 
mediated through their ability to form inter-DNA cross-links, which leads to 
compaction and distortion of chromatin (Lown et ai, 1984; Kapuscinski & 
Darzynkiewicz, 1986). This property is attributed to the alkyl amino side chains 
containing two basic (amino) groups separated by two carbons, which promotes 
electrostatic interactions between the drug and DNA (Lown et ai, 1984). However. the 
10 
process of cross-linking is also influenced by the chromophore hydroxy groups, 
inasmuch as mitoxantrone condenses nucleic acids at 5-40-fold lower concentrations 
than ametantrone, another factor which may contribute to their difference in potency 
(Kapuscinski & Darzynkiewicz, 1986). 
Early evidence indicated that mitoxantrone was significantly less cardiotoxic than 
doxorubicin and daunorubicin (see reviews by Shenkenberg & von Hoff, 1986; Faulds 
et ai, 1991). This was attributed partly to the fact that it lacks the amino sugar moiety 
and tetracyclic A ring of the anthracyclines, and partly to its more negative reduction 
potential in aqueous solution (-0.79V) compared to the anthracyclines (-0.6V). The 
lower reduction potential of mitoxantrone diminishes its ability to undergo cytochrome 
P-450-mediated reductive activation to generate free radicals (Sinha et ai, 1983; 
Nguyen & Gutierrez, 1990) a process that has been connected with the cardiotoxicity 
of the anthracyclines (see section 1.4.1.2). However, recent studies have shown that 
mitoxantrone is considerably more cardiotoxic than was previously suggested 
(Andersson et ai, 1999; see section 1.4.1.3). 
1.2.3 INVOLVEMENT OF BIOTRANFORMATION IN THE ANTITUMOUR 
ACTIVITY OF MITOXANTRONE 
Many attempts have been made to characterize the biotransformation of 
mitoxantrone, and it is now well established that the two major metabolites of this drug 
in humans are the mono- and dicarboxylic acid derivatives, resulting from oxidation of 
the alcohol groups of the alkyl amino side chains (figure 1.4). These derivatives have 
been detected in urine and plasma samples from cancer patients (reviewed by Ehninger 
et ai, 1990) and are both devoid of antitumour activity (Chicarelli et ai, 1986). In 
addition, several other metabolites of mitoxantrone have been detected which are not 
well characterized. Using a high-performance liquid chromatography method, Ehninger 
et al (1986) discovered a metabolite in urine and serum samples of breast cancer 
patients which was more polar than mitoxantrone, but less polar than either of the 
11 
carboxylic acid derivatives. Up to several hours after drug administration, this 
compound was the predominant metabolite. In contrast, the levels of the carboxylic 
acid derivatives did not peak until some time later and were still present in urine 
samples taken 4 weeks after treatment. The fact that peak levels of the carboxylic acid 
derivatives were not reached for a considerable time after drug administration suggests 
a sequence of metabolic events could be involved in their formation. Conceivably, the 
third metabolite may be a precursor of the carboxylic acid derivatives, since it is less 
polar than either of these derivatives but more polar than mitoxantrone, and is 
comparatively short -lived. 
OH o 
OH o 
qO 
NH-CH2-CH2-NH-CH2~ 
OH 
NH-CH2-CH2-NH-CH2-CH2-0H 
qO 
NH-CH2-CH2-NH-CH2~ 
OH 
qO 
NH-CH2-CH2-NH-CH2~ 
OH 
Figure 1.4: The mono- and di-carboxylic acid metabolites of mitoxantrone, produced 
by oxidation of the alcohol groups of the side chains. 
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Using human hepatocytes in primary culture, Richard et al (1991) obtained a 
similar pattern of metabolism of mitoxantrone to the one described by Ehninger et al 
(1986). However, in rat hepatocytes the predominant metabolites were found to be two 
highly polar compounds, corresponding to the glutathione- and glucuronide-conjugates 
of mitoxantrone whereas only trace amounts of the carboxylic acid derivatives were 
present. These conjugates were also detected in the human samples, but represented 
only minor amounts of drug product. The biotransformation pathway in rabbits was 
also different from that in humans, indicating a large interspecies variability exists in 
the metabolism of mitoxantrone. Even within humans, the levels of mono- and 
dicarboxylic acid metabolites excreted varies considerably (Ehninger et ai, 1986; 
Schleyer et ai, 1994). This has led to the speculation that interindividual variation in 
the formation of metabolites might underlie differences in clinical response to 
mitoxantrone. 
Only one other mitoxantrone metabolite has been detected in significant amounts 
in human urine, by Blanz et al (1991a). This has been identified as the 
tetrahydronaphthoquinoxaline (TNQ) derivative, formed by intramolecular cyclization 
of one of the alkyl amino side chains in the oxidized, diiminoquinone form of the drug 
(figure 1.5). The TNQ derivative can also be generated in vitro by horseradish 
peroxidase-catalysed oxidation of mitoxantrone with hydrogen peroxide (Reszka et ai, 
1986; Kolodziejczyk et ai, 1988). This occurs via the formation of free radical 
intermediates, and produces DNA damage (Fisher & Patterson, 1991) and DNA cross-
links (Reszka et ai, 1989). Several other enzymes have been shown to generate the 
TNQ derivative, including a human lactoperoxidaselhydrogen peroxide system (Reszka 
et ai, 1997), and a myeloperoxidase-dependent mechanism in human neutrophils 
(Panousis et ai, 1994). In the latter system, TNQ formation was accompanied by 
covalent incorporation of the drug into cellular DNA and RNA (Panousis et aI, 1995, 
1997). 
1 ~ 
Figure 1.5: The TNQ metabolite of mitoxantrone. 
Formation of the TNQ derivative in HepG2 cells is inhibited by metyrapone. 
demonstrating that oxidative activation is cytochrome P-450-dependent (Mewes et ai, 
1993; Zeller et ai, 1994). The cytotoxicity of mitoxantrone in HepG2 cells is also 
significantly reduced in presence of metyrapone (Duthie & Grant, 1989; Zeller et ai, 
1994) which indicates, at least in vitro, that oxidative activation of mitoxantrone is 
involved in its mechanism of action. However, as the presence of metyrapone is also 
likely to inhibit other possible routes of cytochrome P-450- dependent oxidative 
metabolism of mitoxantrone, it can not be unequivocally proven that the TNQ is the 
only active metabolite, and thus its contribution to the cytotoxicity of mitoxantrone in 
vivo remains unclear. In any case, most evidence indicates the principal mechanism of 
action of the alkylaminoanthraquinones is related to DNA intercalation and subsequent 
stabilization of the DNA-topoisomerase II cleavable complex. 
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1.3 DNA TOPOISOMERASES AS TARGETS FOR 
CHEMOTHERAPY 
1.3.1 THE STRUCTURE AND FUNCTION OF DNA TOPOISOMERASES 
In mammalian cells, genetic material exists as an intricate series of coils and 
loops arranged so that the ends of the DNA strands are tightly anchored to the nuclear 
matrix (Verheijen et ai, 1988). While maintaining this high level of organization, the 
DNA strands must be able to unwind in order for events such as transcription and 
replication to occur, and must also be able to separate at cell division. This is achieved 
by topoisomerases, enzymes which catalyse topological and conformational changes to 
DNA through the introduction of transient DNA strand breaks. 
Human cells contain four types of topoisomerase: topoisomerase I, a 100KDa 
monomeric protein encoded by a single copy gene located on chromosome 20q12-13.2 
(Juan et ai, 1988), topoisomerase III, encoded by a single copy gene located on 
chromosome 1 7p 11.2-12 (Hanai et ai, 1996) and two isoforms of topoisomerase II 
(a and ~). Topoisomerase I and topoisomerase III both achieve conformational changes 
to DNA by passing a single-stranded DNA segment through a transient single-stranded 
break made in the complementary strand (Wang, 1996; Li & Wang, 1998). In contrast, 
topoisomerase II enzymes each consist of homologous dimers and are characterized by 
their ability to transport a DNA duplex through the double-stranded break of a second 
DNA duplex, an event known as strand passing (reviewed by Watt & Hickson, 1994, 
Wang, 1996). As a result, they can resolve catenanes and knots in DNA as well as 
relaxing supercoils, and since decatenation is essential for the separation of replicated 
DNA at mitosis and meiosis, topoisomerase II is essential for the viability of all 
eukaryotic cells (Holm et ai, 1989; Downes et ai, 1991). 
Until the discovery of the 180kDa topoisomerase II~ by Drake et al (1987), it 
was thought that only the 170kDa isoform of topoisomerase II existed in eukaryotic 
cells (now known as topoisomerase IIa) and at present this is still believed to be the 
case for yeast (Hammonds et aI, 1998). The single-copy gene for human topoisomerase 
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II~ has since been mapped to chromosome position 3p 24 (Jenkins et ai, 1992), and its 
topoisomerase IIa counterpart to 17q 21.22 (Tsai-Pflugfelder et ai, 1988). The two 
isoforms possess distinct biochemical properties, nuclear distribution, cell cycle 
regulation and biological roles (Drake et ai, 1989; Woessner et ai, 1991; Danks et al. 
1994). Nonetheless, structurally speaking they are quite similar, and the topoisomerase 
II monomer can be divided into three distinct domains (Caron & Wang, 1993). The N-
terminal domain contains the consensus sequences for ATP binding, while the central 
domain contains the tyrosine residue that forms the covalent linkage with DNA during 
the strand passage reaction, located at amino acid position 804 for topoisomerase IIa 
and 821 for topoisomerase II~ (Beck et ai, 1993; Withoff et aI, 1996). The main 
difference between the two isoforms resides in the C-terminal domain, which is longer 
for topoisomerase II~ than for topoisomerase IIa (Watt & Hickson, 1994). This region 
contains the serine and threonine residues phosphorylated by enzymes such as casein 
kinase II and protein kinase C, which regulates topoisomerase II catalytic activity 
(Enomoto et aI, 1993). There is also mounting evidence that the C-terminal plays a role 
in enzyme dimerization and nuclear localization (Watt & Hickson, 1994). 
Based on crystal structure information and several pieces of biochemical 
evidence (Roca & Wang, 1992; Roca et aI, 1996), a two gate model has been proposed 
for the strand passage reaction of topoisomerase II (Berger et aI, 1996). The two gates 
are provided by dimerization of the topoisomerase II monomers to form a heart shaped 
structure with a large, hydrophobic hole at the centre (figure 1.6). The resulting ATP-
modulated clamp permits tightly controlled passage of an intact DNA duplex (T-
segment) through a cleaved DNA duplex (G-segment). The topological integrity of the 
cleaved DNA segment is maintained during strand passing by transesterification 
between a pair of tyrosyl residues, one in each half of the topoisomerase II dimer. and a 
pair of DNA phosphoryl groups, staggered by four base pairs on opposite DNA strands. 
The phenolic oxygens of the tyrosine residues are covalently linked to the phosphoryl 
groups at the 5' end of the strands, leaving a pair of hydroxyl groups on the recessed 3' 
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ends. The covalent DNA-protein complex is described as the cleavable complex. as 
denaturation of this complex with NaOH or SDS leads to protein-linked D A breaks 
(see section l.3 .2 .1). Although strand passage can be achieved using non-hydrolysable 
ATP analogues, enzyme turnover absolutely requires hydrolysis of A TP (Osheroff. 
1986). Enzyme activity also requires the presence of a divalent metal cation. usually 
Mg2+ (Osheroff, 1987). 
___ _ IIIJ G 1Jt111 
Figure 1.6: A two-gate mechanism for the catalytic reaction of to poi some rase II . 
Reproduced from Berger et aI, 1996. 
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1.3.2 INHIBITION OF TOPISOMERASES 
1.3.2.1 TOPOISOMERASE POISONS 
One of the major advances in cancer research over the past two decades has been 
the discovery that topoisomerases are inhibited by a wide variety of chemical agents, 
including a number of those currently employed in chemotherapy (reviewed by Wang 
et ai, 1997, Gatto et ai, 1999). The most fully characterized topoisomerase I inhibitors 
are the plant alkaloid camptothecin, originally isolated from the Chinese tree 
Camptotheca acuminata (Wall et ai, 1966) and several of its analogues, which show 
promise against human solid tumours previously refractive to chemotherapy (see 
Muggia et ai, 1996). 
The main types of topoisomerase II inhibitors can be catagorised according to 
their modes of action against the enzyme (figure 1.7). Topoisomerase II-binding 
inhibitors act on the enzyme directly, by preventing protein conformational transitions. 
In contrast, DNA-binding inhibitors hinder binding of the enzyme to the DNA 
substrate. However, DNA intercalators such as doxorubicin, mitoxantrone, and non-
intercalating agents such as the epipodophyllotoxins, exert their effect by stabilizing 
the covalent DNA-topoisomerase II cleavable complex formed during the strand 
passage reaction (Chen et ai, 1984; Nelson et ai, 1984; Tewey et at, 1984a, 1984b). 
Due to this mechanism of action, they are known as topoisomerase poisons, as their 
cytotoxicity is thought to stem from interference with essential metabolic processes 
such as replication and transcription, which literally 'poisons' the cell (see section 
1.3.2.3). The addition of a protein denaturant such as SDS or alkali to the drug-trapped 
complex generates protein-associated single- and double stranded breaks consisting of 
topoisomerase II linked covalently to the DNA via a phosphotyrosine linkage at the 5' 
termini (Zhang et ai, 1990; figure 1.8). 
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Figure 1.7: The catalytic cycle of type II DNA topoisomerases , showing the 
modes of action of the inhibitors and poisons of the enzyme. DNA-binding 
inhibitors, such as groove binders, hinder binding of the enzyme to the DNA 
substrate (purple); topoisomerase II-binding inhibitors such as merbarone, 
aclarubicin and fostriecin act on the enzyme directly, by trapping the closed 
clamp conformation of the enzyme in the presence of ATPase (green) ; 
topoisomerase II poisons exert their effect by stabilizing the covalent DNA-
topoisomerase II cleavable complex formed during the strand passage reaction 
(red). Reproduced from Capranico et aI, 1997. 
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Figure 1.8: Formation of protein-associated double strand breaks following 
denaturation of the DNA-topoisomerase II cleavable complex: During the 
topoisomerase II catalytic reaction, the enzyme and DNA (A) combine to form the 
noncleavable complex (B, left) and subsequently the cleavable complex (C, left) which 
are all at equilibrium. Exposure of the cleavable complex to SDS results in the 
generation of DNA double strand breaks with their 5 'phosphoryl termini covalently 
linked to the denatured enzyme (C, right). In contrast, exposure of the noncleavable 
complex to SDS results in the regeneration of intact DNA strands, which are not 
associated with the enzyme (B, right). Adapted from Zhang et ai, 1990. 
1.3.2.2 STRUCTURAL REQUIREMENTS FOR DRUG ACTIVITY 
Investigations regarding the molecular aspects of anthracycline interference with 
topoisomerase II have established that the substituents at the C-7 and C-9 positions are 
the two main participants. At C-7, activity against the enzyme is determined by the 
nature of the substitutent at the 3'-N position of the daunosamine sugar (Bodley et ai, 
1989; Capranico et ai, 1994). At C-9, substitution of the hydroxyl group with a 
hydrogen atom considerably reduces topoisomerase II-mediated DNA cleayage with 
concomitant loss of biological activity (Capranico et ai, 1989). Several studies have 
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also established structure-activity relationships for the anthraquinones. Drug-induced 
cleavable complex formation by these compounds has been based on a bipartite 
structure, in which the chromophore serves as a DNA intercalator and the side chains 
associate with topoisomerase II, stabilizing the DNA-topoisomerase II interaction 
(D'Arpa & Liu, 1989; D'Arpa et aI, 1992). Religation of the DNA strands within the 
trapped complex is thought to be prevented by the intercalator-induced unwinding of 
the DNA helix, causing the broken DNA strands to become temporarily misaligned 
(D' Arpa & Liu, 1989). The topoisomerase II cleavage patterns for ametantrone and 
mitoxantrone are identical, but ametantrone shows a significantly lower capacity to 
induce cleavable complexes than mitoxantrone, which suggests a critical role for the 5 
and 8 hydroxy substituents of the chromophore in this process (De Isabella et ai, 1993). 
This is possibly related to a difference in the orientation of the chromophore within the 
DNA-drug intercalation site (Mazerski et aI, 1998; see section 1.2.2). 
1.3.2.3 MECHANISMS INVOLVED IN THE CYTOTOXICITY OF 
TOPOISOMERASE II POISONS 
The vast majority of evidence argues that the cytotoxic effects of to poi some rase 
II poisons such as mitoxantrone and doxorubicin are related to the generation of DNA-
topoisomerase II cleavable complexes, or the response to these complexes, rather than 
inhibition of to poi some rase II catalytic activity per se (discussed in detail by D'Arpa & 
Liu, 1989). However, the exact mechanism by which cleavable complexes are 
converted to cytotoxic lesions is still under debate. The extent of cleavable complex 
formation in response to topoisomerase II inhibitors usually reflects enzyme levels, 
which are highest in the G21M phases. However, at least for topoisomerase II poisons 
such as m-AMSA and etoposide, drug treatment is most effective at killing cells during 
S phase (Wilson & Whitmore, 1981; Chow & Ross, 1987. Estey et aI, 1987). 
Consequently, it has long been thought that ongoing DNA synthesis could be one of 
the elements essential for expression of cytotoxicity. The first direct eyidence for this 
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emerged in 1997, when Catapano and co-workers demonstrated that topoisomerase II-
DNA complexes stabilized by the epipodophyllotoxin teniposide acted as replication 
fork barriers in the c-myc gene of human leukaemia cells. They also found that drug-
treated cells were protected from death by the coadministration of the DNA polymerase 
inhibitor aphidicolin. The latter observation has previously been made by other groups 
(Schneider et aI, 1989; D ' Arpa et aI, 1990; Cortes & Pinero, 1994) and a working 
model for the conversion of topoisomerase II into lethal DNA damage via interaction 
with replication and transcription forks , proposed by D'Arpa et al (1992) is shown in 
figure l. 9. It is thought that arrest of replication forks may serve as a vehicle for the 
generation of chromosomal aberrations (Suzuki et aI, 1995), genetic mutations (Han el 
aI, 1993) and G2 phase arrest (Traganos et aI, 1980) observed in cells treated with 
topoisomerase II poisons, all of which may promote cell death (Bhalla et aI, 1993 ; Ling 
et aI, 1993 ; Bellosillo et aI, 1998). 
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Figure 1.9: Models for the lethal interaction of topoisomerase II cleavable complexes 
with (A) replication- and (B) transcription machineries. Reproduced from D'arpa el 01. 
1989. 
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Studies in vitro indicate that the cytotoxic activity of topoisomerase II poisons 
can be mediated by topoisomerase IIa and/or topoisomerase II~ (Brown et ai, 1995; 
Cornarotti et ai, 1996; Hammonds et ai, 1998). However, the relative involvement of 
the a and ~ isoforms in topoisomerase II poison-mediated cell killing in vivo is still 
unclear. Topoisomerase IIa is expressed at high levels in cycling cells, predominantly 
during G2/M (Woessner et ai, 1991), and is the isoform closely associated with 
chromosome metabolism, including DNA replication (Danks et ai, 1994; Qiu et ai, 
1996). In contrast, topoisomerase II~ is expressed at low levels in proliferating cells 
and is found mainly in the nucleolus (Negri et ai, 1992; Zini et ai, 1992). Moreover, in 
vivo studies have shown that topoisomerase IIa activity is elevated during the 
malignant transformation of ovarian tumours (van der Zee et ai, 1991, 1994) and that 
topoisomerase IIa is over-expressed in lung cancer (Giaccone et ai, 1995) and breast 
tumours (Murphy et ai, 1995; Jarvinen et ai, 1996). All this would suggest that the a 
isoform is likely to mediate drug sensitivity in the clinical setting. However, many 
investigators have been unable to find a relationship between either topoisomerase 
IIa or topoisomerase II~ levels and sensitivity to topoisomerase II poisons either in cell 
lines (e.g. Houlbrook et ai, 1995) or in tumour specimens from patients (e.g. Kaufmann 
et ai, 1994). Clearly, a great deal more research is required in this area. 
1.3.2.4 DETERMINANTS OF SENSITIVITY TO TOPOISOMERASE II POISONS 
A major discrepancy which has come to light in the study of to poi some rase II 
poisons is the variation in cytotoxic potency for drugs of different classes, even when 
the initial number of to poi some rase II-mediated DNA strand breaks is the same. 
Generally speaking, the anthracyclines and mitoxantrone appear to be more potent than 
compounds such as m-AMSA or ellipticine (Binaschi et ai, 1990; Fox & Smith, 1990). 
This anomaly may also be partly due to the sequence-specific cleavage of DNA 
displayed by topoisomerase II poisons (figure 1.10). For example, mitoxantrone has a 
base preference for cytosine or thymine at the -1 (5') position of the cleavage site 
(Capranico et ai, 1993; De Isabella et ai, 1993) whereas doxorubicin shows specificity 
for adenine at this position (Capranico et ai, 1990). A main determinant of sequence 
specificity is thought to be the drug pharmacophore, i.e the spatial arrangement and 
electronic distribution of the drug. Capranico et al (1997) have proposed three different 
types of pharmacophore for topoisomerase II inhibitors, all of which interact with the 
base pairs from -2 to +2 at the cleavage site (figure 1.11). 
In vivo, it could be envisaged that site-selective drug activity would lead to 
damage of specific genes. In this respect, preferential topoisomerase II-mediated DNA 
cleavage of c-myc by m-AMSA may explain the hypersensitivity of cells that 
overexpress c-myc such as promyelocytic HL-60 cells, to this agent (Riou et ai, 1989; 
Pommier et ai, 1992). 
Since the duration of exposure to cleavable complexes is probably a determinant 
of cytotoxicity, the prolonged cleavable complex formation observed for mitoxantrone 
and doxorubicin compared with other agents may also contribute their enhanced 
potency. Reversal of doxorubicin-induced breaks in small cell lung cancer cell lines is 
found to be much slower than those produced by ellipticine in two human small cell 
lung cancer lines (Binaschi et ai, 1990). Similarly, while mitoxantrone and m-AMSA 
show comparable levels of cleavable complex formation, complexes formed by 
mitoxantrone are found to be far more persistent and consistently more lethal than 
those produced by m-AMSA (Fox & Smith, 1990; Smith et ai, 1990). This may be 
relate to persistent intracellular retention of mitoxantrone, involving slow releasing 
pools from cytoplasmic inclusions (see section 1.2.2) or different rates of repair of m-
AMSA and mitoxantrone-induced DNA breaks (Bohr et ai, 1987; Wassermann, 1994). 
Alternatively, it may reflect a difference in the mode of DNA-drug binding for 
mitoxantrone and m-AMSA within the ternary complex (Fox & Smith, 1990). Whether 
this is related to the structure of mitoxantrone per se or to one or more active 
metabolites of the drug is yet to be determined (see section 1.2.3). 
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Figure 1.10: Base pair cleavage preferences of various topoisomerase II inhibitors 
(reproduced from Pommier et aI, 1994) . 
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Figu re 1.11: Model showing the theoretical interaction of different drug 
pharmacophores with double stranded DNA (black) within the topoisomerase II 
cleavage site (representation of the enzyme has been omitted for clarity). The DNA 
strands are cleaved with a stagger of four base pairs between the two strand cuts. 
Positive and negative numbers indicate the base numbering on either side of the 
cleavage site. Poisons with -1 position specificity (red) mainly interact with -1/-2 
bases; those with + 1 specificity (yellow) interact with + 1 base; those with +2 
specificity (blue) interact externally with the DNA. Reproduced from Capranico e/ ai, 
1997. 
1.4. PROBLEMS ASSOCIATED WITH CHEMOTHERAPY 
1.4.1 DRUG TOXICITY 
1.4.1.1 GENERAL EFFECTS 
The non-discriminatory nature of conventional anticancer agents such as 
doxorubicin and mitoxantrone means that as well as acting on cancerous cells, they are 
also extremely toxic to rapidly proliferating normal tissues. As a result, patients treated 
with these drugs experience a whole range of undesirable side effects, including nausea 
and vomiting, gastrointestinal disturbances, radiation recall and severe local reaction 
following extravasation (see reviews by Posner et at, 1985; Abraham et at, 1996). 
Anticancer agents can also produce conditions such as alopecia and discolouration of 
the skin, which may seem relatively minor, but can be very distressing for the patient. 
Moreover, both the anthracyclines and mitoxantrone are highly potent in producing 
malignant tr~nsformation and mutation, which presents the risk of secondary 
malignancies developing some time after the initial treatment (Vallagussa & 
Bonnadonna, 1995). 
1.4.1.2 MAJOR TOXICITIES OF THE ANTHRACYCLINES 
One of the most serious side effects encountered when using chemotherapeutic 
agents is myelosuppression. In the case of the anthracyclines, this is manifest 
principally as neutropenia (Abraham et at, 1996). The condition can be particularly 
severe with idarubicin, which is more toxic against normal bone marrow progenitor 
cells than either doxorubicin (Minderman et at, 1994) or daunorubicin (Curtis et at, 
1995). The incidence and severity of immunosuppression is dependent on the drug 
dose, occurring in 60 to 80% of patients receiving conventional treatment regimens 
(Abraham et at, 1996). As well as affecting absolute numbers of neutrophils, there have 
also been reports that doxorubicin and daunorubicin reduce the phagocytic function of 
circulating neutrophils and macrophages (Vaudaux et at, 1984). This is highly 
undesirable situation as it is likely to impair the patient's own immunological defence 
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against the malignancy. 
Haematological toxicity associated with high dose intensity regimens may be 
partially alleviated by intermittent administration of haemopoietic growth factors in 
combination with peripheral blood progenitor cells (Crown et ai, 1992). Alternatively, 
it may soon be possible to protect haemopoietic progenitor cells from the effects of 
anticancer drugs by introducing the multi drug resistance gene MDRl (Boesen et ai, 
1993: Banerjee et ai, 1994). 
The other major toxicity associated with the use of the anthracyclines is their 
effect on cardiac tissue, which is manifest as acute, chronic or late-onset cardiotoxicity 
(reviewed by Shan et ai, 1996). Mortality directly relating to doxorubicin-induced 
cardiac failure is substantial, with several reports of death rates above 20%. Various 
acute and sub-acute cardiotoxic effects of anthracyclines have been documented. These 
include electrophysiological abnormalities, which may cause non-specific ST and T 
wave changes, decreased QRS voltage and a prolonged QT interval. The most common 
rhythm disturbance is sinus tachycardia, but arrhythmias, such as ventricular, 
supraventricular and junctional tachycardias, have also been reported (F errans, 1978). 
However, electrophysiological alterations such as these are rarely fatal. In clinical 
terms, the most significant problem is chronic cardiotoxicity, which develops within 
about a year of therapy. Chronic cardiotoxicity is characterized by irreversible 
cardiomyopathy, and the incidence of congestive heart failure secondary to 
anthracycline-induced cardiomyopathy is closely related to the lifetime anthracycline 
dose. The current recommended cumulative dose of doxorubicin is 550mg/m2 body 
surface area. However, the problem with standardizing the dose in this manner is that a 
wide variation exists in inter-individual sensitivity to anthracyclines. This means that 
whereas some individuals can tolerate cumulative doses twice as high as those 
recommended (Bristow et ai, 1978; Henderson et ai, 1989), others experience cardiac 
damage at doses as low as 183mg/m2 (Friedman et aI, 1978). Of the many factors 
proposed to increase chronic anthracycline-induced cardiotoxicity, higher rates of drug 
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administration, underlying cardiovascular disease and previous cardiac irradiation 
appear to present most risk (Von Hoff et aI, 1979; Von Hoff & Layard, 1981). 
Contrary to Adamson's hypothesis regarding the cardiac activity of glycosides 
(see section 1.2.1), the cardiotoxic properties of anthracyclines are currently believed to 
be mediated by the formation of the semiquinone free radical, generated by one 
electron reduction of the quinone group of the drug chromophore. Generation of this 
radical has been demonstrated in vitro using NADPH-fortified human liver micro somes 
(Basra et aI, 1985) and perfused heart tissue (Doroshow, 1983; Rajagopalan et aI, 
1988). It can also be generated non-enzymically by chelation of the hydroquinone 
portion of the anthracycline molecule with intracellular ferric iron (Muindi et aI, 1984). 
The role of the semiquinone radical in anthracycline cardiotoxicity stems from the fact 
that it can redox cycle with molecular oxygen to form superoxide anions, which in the 
presence of metal ions, give rise to highly reactive species such as singlet oxygen, 
hydrogen peroxide and hydroxyl radicals (Kappus, 1986; figure 1.12). These species 
are capable of producing non-protein associated DNA strand breaks, but more to the 
point, they are highly effective in initiating peroxidation of unsaturated membrane 
lipids, particularly those of the mitochondrial membrane (Goodman & Hochstein, 
1977; Mimnaugh et aI, 1985). The reason why myocardial tissue is particularly 
susceptible to damage by free radicals is thought to be because of its deficiency in the 
antioxidant enzymes present in many normal tissues, including catalase, superoxide 
dismutase and glutathione-S-transferase, which detoxify free radicals and prevent or 
limit tissue damage (Doroshow et aI, 1980). However, myocyte death has also been 
linked to anthracycline-induced intracellular overload of calcium, caused by 
deregulation of the membrane-bound calcium pump of the sarcoplasmic reticulum 
(Boucek et aI, 1987). 
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Figure 1.12: Redox cycling of quinone-based anticancer agents to produce reactive 
oxygen species. 
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The iron-chelating agent dexrazoxane (lCRF-187) protects against cardiac 
damage by depleting intracellular iron, thus reducing free radical formation via 
anthracycline-iron complexes (see Lewis, 1994; DOff, 1996). In eight comparative 
clinical studies, this agent reduced the incidence of doxorubicin-induced cardiotoxicity 
in a total of more than 1500 patients (Hellmann, 1996). However, in a group of patients 
with breast cancer, combination therapy using doxorubicin, cyclophosphamide and 
fluorouracil in conjunction with dexrazoxane resulted in lower response rate than 
patients treated without dexrazoxane (Hortobagyi, 1997). 
Various other strategies for reducing anthracycline-induced cardiotoxicity include 
an administration schedule that produces low peak plasma drug concentrations such as 
continuous infusion over 48 to 96 hours (Legha et ai, 1992) or weekly, rather than 
three- or four-weekly administration (Torti et ai, 1983). However, there is some 
concern as to whether drug efficacy is maintained using this approach (Bielack et ai, 
1989). More recently, liposomal formulations have been used to alter the 
pharmacokinetic properties of anthracyclines. Results to date have demonstrated an 
improvement in anti tumour efficacy using these formulations compared to 
unencapsulated doxorubicin (Papahadjopoulos et ai, 1991; Muggia, 1997). 
Coincidentally, owing to the fact that tumour blood vessels are often leaky, liposomes 
of 100nm diameter or less are small enough to permeate the tumour vasculature, 
thereby enhancing drug accumulation in tumours (Yuan et ai, 1994). Severalliposomal 
anthracycline preparations have been developed, including the polyethylene glycol-
coated liposome Doxil (Gabizon et ai, 1994: Gabizon & Martin, 1997). Unfortunately, 
a new side effect associated with this preparation is painful dermatitis of the hands and 
feet, possibly due to deposition of drug in the skin (Gabizon et ai, 1994). 
Several clinical studies have indicated that agents such as epirubicin (Coukell & 
Faulds, 1997), menogaril (Mazurek et ai, 1993) and the morpholino anthracyclines 
(section 1.5.3) are less cardiotoxic than doxorubicin at equivalent doses. The reduced 
cardiotoxicity of epirubicin is believed to result from the different orientation of the 4'-
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hydroxyl group, which is equatorial instead of axial. As a result, when administered in 
vivo, epirubicin is readily detoxified to the 4'-O-~-D-glucuronide (Cassinelli et ai, 
1984). Nevertheless, all anthracyclines have cardiotoxic potential, and this remains the 
major limiting factor associated with their use. 
1A.1.3 TOXIC EFFECTS OF THE ANTHRAQUINONES 
In most cases, mitoxantrone displays an improved tolerability profile compared 
with doxorubicin and other anthracyclines, with respect to the severity of nausea, 
vomiting and alopecia (reviewed by Shenkenberg & von Hoff, 1986; Faulds et ai, 
1991). However, leucopenia (particularly granulocytopenia) may be dose limiting in 
patients with solid tumours, and stomatitis may be dose limiting in patients with 
leukaemia. 
Most studies indicate that anthraquinones show insufficient reductive metabolism 
and redox cycling (Kharash & Novak, 1983; Nguyen & Gutierrez, 1990) and even 
where reactive oxygen species have been produced (Sinha et ai, 1983: Basra et ai, 
1985), it has been at levels that do not cause lipid damage (Kharash & Novak, 1982, 
1985). In accordance with this, many of the preclinical and earlier clinical studies 
indicated that mitoxantrone was less cardiotoxic than doxorubicin (see Shenkenberg & 
von Hoff, 1986; Faulds et ai, 1991). However, from recent studies, it has become 
apparent that mitoxantrone poses a significant risk to the cardiovascular system, 
especially in patients who have pre-existing cardiovascular disease or a history of 
treatment with anthracyclines or radiotherapy. For example, in a patient with a history 
of arterial hypertension and previous inferior myocardial infarction, two 20mg doses of 
mitoxantrone administered four weeks apart caused increasing dyspnea with 
consecutive left heart failure, pulmonary congestion and lowered blood pressure 
(Kahles et ai, 1997). This was accompanied by the appearance of down-sloping ST 
segments and inverted T waves. Clinical recovery was achieved after six days, but the 
changes to the electrocardiogram took four weeks to normalise. 
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The dose of mitoxantrone given in conjunction with other anticancer agents is 
also critical. In a study by Bowers et al (1993) breast cancer patients were treated with 
increasing amounts of mitoxantrone in conjunction with 900 mgm-2 thiotepa, following 
treatment with 160-492 mgm-2 of doxorubicin. When 50 mgm-2 mitoxantrone was 
administered, no acute cardiotoxic effects were observed. In contrast, when 60 mgm-2 
mitoxantrone was received, congestive heart failure occurred in 4 of the 31 patients. 
Another patient developed acute pericarditis, and four patients had more than a 10% 
decline in left ventricular ejection fraction, so that the overall incidence of acute 
cardiotoxicity at the higher dose was 29%. Although acute cardiotoxicity induced by 
mitoxantrone is rarely life threatening, mortality has been reported. For example, a 42 
year old patient, treated with a cumulative dose of 300mgm-2 doxorubicin and 50mgm-2 
of mitoxantrone, died after being admitted to hospital with rapidly progressive CHF (de 
Graaf et ai, 1997). Moreover, she did not receive radiotherapy and had no pre-existing 
heart disease. 
While the propensity of mitoxantrone to undergo reductive metabolism may be 
relatively low, a recent study of anthraquinone-induced cell injury in cardiomyocytes 
revealed that mitoxantrone is capable of altering both the membrane integrity and the 
morphology of these cells (Andersson et al ,1999). In fact, the acute toxicity of 
mitoxantrone in myocytes was found to be considerably greater than either doxorubicin 
or daunorubicin. Further studies of the metabolism of anthraquinones by cardiac tissue 
are needed before the full implications of these results are known. 
Unfortunately, dexrazoxane has been shown not to afford cardioprotective 
activity against mitoxantrone (Alderton et ai, 1992). The use of liposomal preparations 
of mitoxantrone (Chang et ai, 1997), mitoxantrone-loaded micro spheres (Jameela et ai, 
1996) and mitoxantrone-loaded nanoparticles (Zhang et ai, 1996) is currently under 
investigation. 
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1.4.1.4 DEVELOPMENT OF THE ANTHRAPYRAZOLES 
The anthrapyrazole antitumour agents were developed following in vivo studies 
with the anthracycline 5-iminodaunorubicin, which showed it possessed a reduced 
cardiotoxic potential compared with other anthracyclines (Tong et ai, 1979; figure 
1.13). Using this principle, the same structural modification was then applied to the 
anthraquinone chromophore, by substituting one of the quinone carbonyl groups for an 
imino group. This allowed ring closure with the 2-nitrogen to form a fourth ring 
system, and thus the anthrapyrazole chromophore was created. 
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Figure 1.13: The anthracycline 5-iminodaunorubicin 
Preclinical studies demonstrated a number of anthrapyrazoles had a similar 
activity to doxorubicin, and superior activity to mitoxantrone, in terms of both potency 
and their spectrum of activity (Showalter et ai, 1987). Among these were CI941 and 
CI942 which bare close structural resemblance to mitoxantrone (figure l.14). Like , 
mitoxantrone, CI941 was found to be a potent topoisomerase II inhibitor, generating 
double stranded DNA breaks by stabilisation of the DNA-topoisomerase II cleavable 
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complex (Leteurtre et ai, 1994). Studies employing NADPH fortified liver microsomes 
and purified cytochrome P-450 reductase showed that not only was CI941 resistant to 
metabolic reduction, but it actually inhibited doxorubicin stimulated lipid peroxidation 
(Graham et ai, 1987). Thus, it was speculated that this anthrapyrazole could have a 
protective role if used in combination with doxorubicin. 
In clinical trials, CI941 demonstrated good clinical efficacy in the treatment of 
breast cancer (Talbot et ai, 1991). Unfortunately though, it has subsequently been 
found to be cardiotoxic (Walsh et ai, 1995). Among the newer anthrapyrazole 
analogues are the 9-aza-anthrapyrazoles, which contain a nitrogen atom in the 
chromophore but lack the chromophore hydroxy groups. A preclinical study carried out 
by Krapcho et al (1998) indicated that these analogues possess minimal or negligible 
delayed cardiotoxicity, and at least two of the compounds were identified as potential 
clinical candidates. 
Figure 1.14: The anthrapyrazole antitumour agents CI941 and CI942 
1.4.2 MULTIDRUG RESISTANCE 
Of the many obstacles to the successful treatment of malignant disease, the most 
difficult to overcome is drug resistance. Some types of cancer (e.g. renal, colon, 
hepatoma) are inherently resistant to chemotherapy. Others initially respond well to 
treatment but become increasingly resistant as therapy progresses (see review by Ozols, 
1995). This is believed to be due to the presence of small clones of resistant cells in the 
original tumour which expand by selection during treatment and eventually re-establish 
the malignancy. 
The mechanisms involved in multi drug resistance have been the subject of 
numerous investigations in vitro and to a lesser extent in the clinical setting. The in 
vitro models are provided by cultured cell lines selected for drug resistance by stepwise 
exposure to a single cytotoxic agent over a long period of time (Schoenlein, 1993). 
These lines often display multiple resistance mechanisms and develop cross-resistance 
to a wide variety of structurally and functionally unrelated cytotoxic agents, a 
phenomenon known as multidrug resistance (MDR). Exposure of cultured cells to 
topoisomerase II inhibitors usually induces drug efflux-mediated resistance 
mechanisms, or alterations to the target enzyme itself. 
1.4.2.1 DRUG EFFLUX-MEDIATED MUL TIDRUG RESISTANCE 
The archetypal mechanism of resistance to anticancer agents is mediated by P-
glycoprotein, a 170KDa plasma membrane-bound protein belonging to the ATP-
binding cassette (ABC) superfamily of transporter systems (Higgins, 1992). P-gp acts 
as a unidirectional, energy-dependent drug efflux pump, thereby reducing intracellular 
drug concentrations to a tolerable level (Endicott & Ling, 1989; Gottesman & Pastan, 
1993). Cancer cells which overexpress P-glycoprotein are said to manifest the classical 
MDR phenotype, characterized by cross-resistance to drugs such as the anthracyclines, 
anthraquinones, vinca alkaloids and epipodophyllotoxins, but not to alkylating agents, 
anti metabolites or cisplatin (Nooter & Stoter, 1996). P-glycoprotein is also found in 
35 
normal tissues including the liver, small intestine and kidneys (Thiebaut et al. 1987) 
where it is thought to have physiological roles in the elimination ofxenobiotics and 
transport of steroid hormones (Borst et aI, 1993). Thus it is hardly surprising that the 
malignancies resulting from these tissues often express the highest levels of P_gp 
(Goldstein et aI, 1989). 
Elevated levels of P-gp are commonly due to up-regulation of the MDRI gene 
located on human chromosome 7. Direct proof that the MDRI gene is responsible for 
P-gp-mediated MDR has been obtained by transfection of a full-length cDNA clone of 
the human MDRl gene into a drug sensitive cell line, which thereafter became drug 
resistant (Ueda et aI, 1987). However, P-gp expression can also be regulated through 
stabilization of P-gp mRNA, or via post-translational stabilization mechanisms 
(McClean & Hill, 1993). Also in cell lines, expression ofP-gp can be induced by 
antitumour drugs (Hu et aI, 1993). This may be one of the reasons why tumour cells 
that are initially sensitive to treatment become resistant after repeated exposure to these 
agents. It could also be of clinical significance because chemotherapy often fails due to 
the survival of a relatively small number of drug resistant cells in the original tumour, 
which subsequently proliferate to form a far more aggressive malignancy that is 
unresponsive to chemotherapy. 
To some extent, P-gp-mediated resistance can be overcome by intensifying the 
drug dose. However, this almost invariably leads to reduced tolerability. Numerous 
anthracycline analogues have been developed in an attempt to circumvent drug 
resistance associated with doxorubicin and daunorubicin, including the morpholino 
anthracyclines (see section 1.5.3), iododoxorubicin (Schott et aI, 1990) and idarubicin 
(see section 1.2.1). These analogues are more lipophilic than the parent compounds, 
which improves their intracellular uptake and accumulation, and hence their cytotoxic 
activity (Fukushima et aI, 1993; Smith et aI, 1994a). Also, since the discovery that the 
calcium channel blocker verapamil can reverse classical MDR, much research has 
focused on the development of chemical modulators of P-gp (reviewed by Beck, 1990; 
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see table 1.1). Many of these agents possess a planar aromatic ring system with m-o or 
more rings, a tertiary nitrogen and a positive charge at physiological pH and appear to 
overcome resistance by competing with drugs for binding to P-gp (Zamora et ai, 1988). 
Table 1.1 Modulators of P-gp mediated multidrug resistance* 
Type of modulator 
Detergents 
Calcium channel blockers 
Calmodulin inhibitors 
Coronary vasodilators 
Indole alkaloids 
Quinolines 
Acridines 
Lysomotropic agents 
Steroids 
Triparanol analogues 
Cephalosporins 
Cyclosporins 
* Reproduced from Beck, 1990. 
Example 
cremophore EL 
phenylalkylamines (e.g verapamil); dihydropyridines 
phenothiazines 
dipyridamole, perhexiline, amiodarone 
reserpme 
chloroquine, quinine 
qumacnne 
. . .. 
monensm, mgencm 
progesterone 
tamoxifen, clomiphene 
cefoperazone, ceftriaxone 
cyclosporins A, C, G 
Verapamil has been found to reverse p-gp-mediated doxorubicin resistance in 
several human cell lines including ovarian cancer cells (Rogan et ai, 1984) and a 
multiple myeloma cell line (Bellamy et ai, 1988). However, it has less effect on 
idarubicin (Boiron et ai, 1994) and has little effect on the cytotoxicity of mitoxantrone 
(Gibby et ai, 1987). Moreover, mitoxantrone is only partially cross-resistant with 
doxorubicin in the P-gp-positive cell line P388IDx (Testi et ai, 1995). These 
observations indicate that resistance to mitoxantrone in some cell lines may be 
mediated by a drug efflux mechanism discrete from P-gp. Indeed, in 1992, Cole and 
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her colleagues discovered a novel type of multi drug resistance phenotype, 
characterized by overexpression of the 190kDa multi drug resistance associated protein. 
MRP (reviewed by Kavallaris, 1997). Rather like P-gp, MRP is a member of the ABC 
superfamily, which acts as a drug efflux pump and is located primarily in the plasma 
membrane. However, it has also been speculated that it may promote drug 
accumulation in specific compartments within the cell in order to aid efflux or limit the 
interaction of drugs with intracellular target molecules (Almquist et ai, 1995). MRP 
can also mediate resistance by promoting the export of glutathione-conjugated drugs 
from cells and therefore has a connection with drug resistance mechanisms involving 
glutathione and glutathione-related enzymes (see section 1.4.2.4). Broadly speaking, 
MRP displays cross-resistance to a similar range of cytotoxic agents to P-gp (Nooter & 
Stoter, 1996), but their susceptibility to reversing agents differs considerably. Chemical 
modulators of MRP include genestein (Versantvoort et ai, 1993) and difloxacin 
(Gollapudi et ai, 1995). 
1.4.2.2 CLINICAL EVALUATION OF P-GL YCOPROTEIN- AND MRP-
MEDIATED DRUG RESISTANCE 
While P-gp-mediated multi drug resistance has been extensively characterized in 
vitro, relatively few studies have been performed to evaluate its clinical significance. 
The expression of MDRl has been detected in a wide range of malignancies, either 
treated or untreated (Nooter & Stoter, 1996). However, this seems to be of prognostic 
value in relatively few types of cancer (table 1.2). 
Presently, information on the clinical role ofMRP expression is relatively sparse. 
Although elevated MRP expression has been reported in haematological malignancies. 
NSCLC, and cancers of the breast and ovary (Nooter & Stoter, 1996), the association 
between MRP and clinical resistance has yet to be determined. Preliminary evidence 
indicates that in patients with non-small-celliung cancer, MRP overexpression of the 
tumours predicted a worse outcome ofvindesine/etoposide chemotherapy (Ota et ai, 
38 
1995). The absence of MRP expression was also suggested to be the reason for good 
outcome of an AML subtype (Kuss et ai, 1994). Just to confuse matters, it has recently 
been reported that the expression of another MDR-associated transporter protein, the 
110kDa LRP, predicted clinical outcome in AML (List et ai, 1996) and advanced 
ovarian carcinoma (Izquierdo et ai, 1995). 
Table 1.2 Types of malignancy in which MDR1IP-gp have prognostic value 
AML 
ALL 
Childhood soft tissue sarcoma 
Neuroblastoma 
Osteosarcoma 
Breast cancer 
Non-Hodgkin's lymphomas 
Multiple myeloma 
Although modest reversal of drug resistance has been achieved in the clinic 
employing verapamil, its use is limited by its adverse effects on the cardio-vascular 
system (Miller et ai, 1991). The immunosuppressant cyclosporin A has also been 
employed in clinical trials, but again displays a variety of toxic side-effects (Sonneveld 
et ai, 1992). Second generation analogues of both these chemical modulators are now 
under clinical investigation, including the D- stereoisomer ofverapamil and the 
cyclosporin analogue PSC 833 (Ozols, 1995). However, as clinical MDR is generally 
multifactorial, the presence of non-P-glycoprotein mediated drug resistance 
mechanisms insensitive to these compounds may limit the success of such treatment 
strategies. 
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1.4.2.3 THE AT -MDR PHENOTYPE 
Cells which are only cross-resistant to topoisomerase II-inhibiting drugs and 
show no alterations in drug transport or accumulation are said to display atypical 
multidrug resistance (at-MDR). Cell lines selected for at-MDR are resistant to DNA 
intercalating agents and epipodophyllotoxins, but unlike the classical MDR- and non-
P-gp phenotypes, are not cross-resistance with vinca alkaloids (Nooter & Stoter, 1996). 
The at-MDR phenotype is characterized by a reduction in topoisomerase II levels 
or changes that alter the interaction of the enzyme with drug or DNA. In addition, cells 
such those in hypoxic tumour regions are inherently resistant to topoisomerase 
inhibitors as they are non-cycling (see section 1.5.4.l). Resistant cells use a multitude 
of strategies to impair enzyme-DNA or -drug interactions, several of which may 
operate simultaneously (table 1.3). These strategies aim to achieve a reduction in the 
level of drug-induced DNA cleavage without overall loss of catalytic activity. For 
example, HL-60/MX2, a human leukaemia cell line selected for resistance to 
mitoxantrone, has been found to contain a novel 160KDa topoisomerase IIa-related 
protein localized in the cytoplasm, which is thought to be missing the nuclear 
recognition signals located in the COOH terminus of the protein (Harker et ai, 1995). 
Although the 160KDa protein retains catalytic activity, cytosolic localization may 
preclude its involvement in the important drug-DNA-enzyme interactions necessary for 
DNA cleavage and eventual cell death. In addition, cytoplasmic topoisomerase II may 
act as a drug sump which prevents or delays drug entry into the nucleus. This is 
supported by the fact that mitoxantrone-induced DNA cleavage in the HL-60/MX2 
nuclear extract is reduced 3-4-fold compared to the parental HL-60 cells (Harker et ai, 
1991). 
Enzyme mutations also appear to be a common feature of topoisomerase II-
mediated resistance in vitro. Point mutations in the gene for topoisomerase IIa have 
been observed in cultured cell lines selected for resistance to intercalating agents. 
epipodophyllotoxins or both (reviewed by Prost 1995). The majority of these are 
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located around the consensus B sequence of the A TP binding fold and the dinucleotide-
binding ~a~ unit, or near the reactive tyrosine residue. This is not surprising in view of 
the fact that these regions are involved in A TP-, DNA- or drug binding to the enzyme. 
Having said that, mutations can also alter the physiological properties of the enzyme, 
such as the pH optimum for catalytic activity (Boege et al, 1993). 
Table 1.3 Summary of phenotypic alterations displayed by at-MDR cells 
reduction in topoisomerase II levels 
alterations in the proportion of topoisomerase IIa and/or ~ 
enzyme mutation 
post-translational modification of topoisomerase II (e.g. phosphorylation) 
alterations in subcellular distribution of topoisomerase IIa 
It is known that non-cycling cells, which contain low levels of topoisomerase 
IIa, lack sensitivity to topoisomerase inhibitors (see section 1.3.2.3). This would 
suggest that this isoform may playa predominant role in the action of these agents in 
the clinical environment. Moreover, the use of genetic suppressor elements to decrease 
the a isoform was shown to result in expression of resistance (Hill, 1996). However, 
the observation that topoisomerase II~ was undetectable in the HL-601MX2 model 
mentioned above and three other mitoxantrone resistant cell lines has prompted 
speculation that the ~ isoenzyme may be involved in resistance to mitoxantrone 
(Harker et al, 1995; Withoff et al, 1996). In addition, VP-16-resistant H209N6 cells, 
that contain no normal topoisomerase IIa enzyme but display topoisomerase II~ 
enzyme levels that are comparable to the H209 parent, are not cross-resistant to 
mitoxantrone (Mirski et al, 1993; Feldhoff et al, 1994). 
Very few mutations have been found in patients' tumours and this would seem to 
indicate that clinical resistance is primarily due to a reduction in topoisomerase II 
expression (e.g. see Potesmil et al, 1988). However, two point mutations have been 
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found in a SCLC lung cancer patient at nucleotide positions 1457 and 1481 (Kubo et 
ai, 1995). Also, in an AML patient, the argenine residue at amino acid position 773 of 
topoisomerase IIa was replaced by isoleucine (Danks et ai, 1993). The roles of the two 
topoisomerase II isoforms in clinical drug resistance is relatively sparse and studies in 
this area are currently underway (see Holden, 1997). Another issue that needs to be 
resolved is whether the bulk topoisomerase II content in a patient's tumour can be 
correlated with sensitivity of the tumour to drug treatment. This has been difficult to 
demonstrate due to the large cell-to-cell topoisomerase IIa expression within tumour 
samples, which is thought to result from the presence of large numbers of GO phase-
arrested cells (Kaufmann et ai, 1994; Stammler et ai, 1994). 
In general, chemical modulators of P-gp- and MRP-mediated resistance can not 
be used in cells expressing only at-MDR. One exception is the P-gp inhibitor 
dipyridamole, which significantly potentiates the cytotoxicity of mitoxantrone, 
doxorubicin and etoposide in multi drug resistant melanoma cells (Damle & Desai, 
1994). As the morpholino anthracyclines act by a mechanism which is largely unrelated 
to topoisomerase II, they can also circumvent resistance in at-MDR cells (see section 
1.5.3) as can some amino acridine analogues (Baguley et ai, 1990). The potential for 
using inhibition of protein kinases to overcome resistance by controlling the 
phosphorylation status of to poi some rase II (and P-gp) is also under investigation 
(Grunicke et ai, 1994). 
1.4.2.4 OTHER MECHANISMS OF RESISTANCE TO TOPOISOMERASE II 
INHIBITORS 
Several other mechanisms of resistance to mitoxantrone have been observed in 
vitro. These include an alteration in the expression of cytokeratin networks in mouse L 
fibroblasts (Bauman et ai, 1994) and altered cytoplasmic mitoxantrone sequestration in 
drug resistant murine cell lines (Smith et ai, 1992) and human colon carcinoma cells 
(Fox & Smith, 1995). There is also evidence for reduced drug accumulation in 
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association with drug resistance to mitoxantrone in MCF -7 human breast cancer cells 
without associated P-glycoprotein or MRP expression (Lee et ai, 1997) 
Elevated expression and activity of glutathione-peroxidase, an enzyme important 
in the detoxification of lipid peroxides and free radicals, has been shown in several 
doxorubicin-resistant cell lines, suggesting it may contribute to drug resistance in these 
cells (see review by Zhang et ai, 1998). The use of the glutathione synthesis inhibitor 
buthionine sulfoximine (BSO) was found to partially reverse resistance to daunorubicin 
in HL-601 AR anthracycline resistant human leukaemia cells (Lutzky et ai, 1989). The 
development of similar agents which could be used for this purpose may be an area 
worth exploring. 
Topoisomerase II inhibitors are known to induce programmed cell death (see 
section 1.3.2.3) and a decrease in apoptosis has already been reported in numerous cell 
lines resistant to topoisomerase poisons, including an AML cell sub-line which 
displays natural resistance to mitoxantrone (Bailly et ai, 1997). It is likely that many 
other resistance mechanisms will be discovered in both cell lines and in vivo. Wherever 
possible, the resistance profiles of clinical tumours should be assessed on an individual 
basis, because this is likely to provide the best chance of successful treatment. 
1.5 THE USE OF METABOLICALLY ACTIVATED 
ANTITUMOUR AGENTS IN THE TREATMENT OF CANCER 
1.5.1 ENZYMES INVOLVED IN DRUG METABOLISM 
Upon entering the body, therapeutic agents undergo a series of metabolic 
transformations, mainly in the liver. Phase I (functionalization) reactions, as their name 
suggests, serve to introduce a reactive functional group into the molecule thereby 
converting the drug into a more polar form. Common phase I reactions include 
oxidation, reduction, hydrolysis and hydration (see Gibson & Skett, 1986). The 
products of phase I reactions often go on to be used as substrates for phase II 
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(conjugation) reactions such as glucuronidation, sulfation, acetylation and glutathione 
conjugation. These are widely considered as the true detoxification pathways as they 
give rise to the bulk of the inactive drug, which is then excreted. 
In vitro, the majority of knowledge regarding drug metabolism has been obtained 
using subcellular fractions of the liver. The two subcellular organelles which are the 
most important in this respect are the endoplasmic reticulum and the cytosol (soluble 
fraction). Phase I oxidative enzymes are almost exclusively located in the endoplasmic 
reticulum, along with the phase II enzyme glucuronyl transferase. Other phase II 
enzymes are found predominantly in the cytosol (Lebsanft et ai, 1989). In the intact 
cell, endoplasmic reticulum consists of a continuous network of filamentous 
membrane-bound channels (Alberts et ai, 1983). Physical disruption of endoplasmic 
reticulum results in the formation of artificial vesicles, operationally described as 
microsomes, which can be separated from the cytosolic fraction by consecutive 
differential centrifugation. 
The most extensively studied phase I drug metabolism reaction is cytochrome P-
450-mediated mixed function oxidation, which catalyses the hydroxylation of hundreds 
of structurally diverse compounds (see Gibson & Skett, 1986). Cytochrome P-450 is a 
haemoprotein, with iron protoporphoryn IX as the prosthetic group. The central feature 
of the cytochrome P-450 catalytic cycle is the ability of the haem iron to undergo cyclic 
oxidation/reduction reactions in conjunction with the associated flavoprotein reductase, 
NADPH-cytochrome P-450 reductase (figure 1.15). The end result is the incorporation 
of one atom of molecular oxygen into the substrate and the reduction of the other 
oxygen atom to water. 
So far, more than 20 different human isoenzymes of cytochrome P-450 have been 
identified, and divided into four main families (1-4) and further into sub-families (A-E) 
according to their amino acid homologies (Nelson et ai, 1993). Of the human 
cytochrome P-450 enzymes, CYP3A accounts for approximately 60% of the total P-
450 and CYP3A4 is the predominant isoform associated with the metabolism of 
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chemotherapeutic agents (Guengerich, 1992; Spatzenegger & Jaeger, 1995). Although 
each isoform has a particular substrate specificity, the existence of multiple P-450 
isoforms means that the range of drugs susceptible to cytochrome P-450 phase I 
biotransformation is diverse. As well as varying from species to species. there is also a 
large interindividual variability in cytochrome P-450 expression, as the genes encoding 
many of these enzymes are polymorphically expressed (Wrighton et ai, 1989; Smith et 
ai, 1994b). This largely accounts for differences in drug metabolism (and perhaps 
clinical response) observed among patients who are given identical treatment 
(Cholerton et ai, 1992). 
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Figure 1.15: The catalytic cycle of cytochrome P-450 (reproduced from Gibson & 
Skett, 1986). RH represents the drug substrate, ROH the corresponding hydroxylated 
metabolite. 
In order to determine the relative contribution of the various isoforms to the 
metabolism of a particular drug, the expression of specific cytochrome P-450 isoforms 
(and non-P-450 drug metabolizing enzymes) can be enhanced by various chemical 
inducers, well known examples being dexamethazone and phenobarbital (Spatzenegger 
& Jaeger, 1995). For similar purposes, cytochrome P-450 isoenzymes can also be 
inhibited. For example, cyclosporin A and erythromycin are both competitive 
substrates of P-450 3A (Kronbach et ai, 1988) whereas carbon monoxide is a general 
inhibitor ofhaemoproteins (Gibson & Skett, 1986). 
So far, cytochrome P-450 enzymes have been implicated in the oxidative 
activation of a broad range of anticancer agents, including etoposide (Van Maanen et 
ai, 1985a, 1985b, 1987), cyclophosphamide (see section 1.5.2) and the morpholino 
anthracyclines (see section 1.5.3). However, they are by no means the only phase I 
enzymes involved in drug oxidation. Among the others are flavin monooxygenases. 
various oxidases (e.g. aldehyde-, xanthine- and monoamine oxidases) and 
dehydrogenases (see Beedham, 1997). NAD-dependent alcohol- and aldehyde 
dehydrogenases are mitochondrial and cytosolic enzymes which sequentially oxidize 
compounds containing primary alcohols to carboxylic acids via their aldehyde 
intermediates (Bosron & Li, 1980; Pietrusko et ai, 1991). Metabolism is usually 
extremely rapid, so that only the carboxylic acid metabolites are detected. Carboxylic 
acids are major metabolites for a number of anti-cancer drugs, including 
cyclophosphamide and mitoxantrone (see sections 1.2.3 and 1.5.2.2). 
Expression of cytochrome P-450 and other drug-metabolizing enzymes in tumour 
tissues may be different from that in normal tissues. Toussaint et al (1993) showed that 
cytochrome P-450 lAI11A2 levels in small cell lung cancer cells were three-fold lower 
than in the corresponding non-tumour cell samples. Similarly, El Mouelhi et al (1987) 
found significant reductions in both phase I and II enzymes in primary hepatic 
carcinomas, compared with normal hepatic tissue. Conversely, the bioreductive 
enzyme DT -diaphorase was reported to be expressed at high levels in some human 
tumours of the breast, lung liver and colon (Riley & Workman, 1992). Moreover, 
expression of the cytochrome P-450 3A isoform has been detected in human 
malignancies, such as colon, oesophagus and bladder, where the level of CYP3A in the 
corresponding normal tissues was undetectable (McKay et ai, 1993; Murray et ai, 
1994,1995). Recently, CYPIBI has been identified as a human tumour specific 
cytochrome P-450 isoform (Murray et ai, 1997). Obviously, the qualitative and 
quantitative expression of drug-metabolizing enzymes in tumour tissues will playa 
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major part in determining the degree of drug metabolism in a particular tumour and 
hence the antitumour efficacy of the drug (see Cholerton et ai, 1992). 
1.5.2 PRODRUGS 
1.5.2.1 PRODRUG STRATEGIES 
In contrast to serving as a means of pharmacological deactivation of a drug, in 
certain cases, biotransformation can result in an increase in the expression of 
pharmacological activity. This can be exploited in the treatment of cancer by designing 
pharmacologically inert compounds known as 'prodrugs', which are selectively 
activated in the body, either by chemical means or metabolism (reviewed by Denny, 
1996). With respect to cancer treatment, the ideal prodrug is one which is activated 
specifically in the tumour cell environment rather than in all tissues. This reduces the 
systemic toxicity associated with chemotherapy, which in tum should allow the 
administration of higher concentrations of drug, with a better chance of achieving 
tumour response. Obviously, to achieve selective activation, the tumour cell target must 
possess a functional characteristic not shared by normal cells. In this respect, several 
new techniques have emerged over recent years, including antibody- and genetic-based 
methods for targeting activating enzymes to tumours in a specific manner. Gene-
directed enzyme prodrug therapy (G-DEPT) involves targeting the activating enzyme 
to the tumour cell by incorporating the gene encoding the enzyme into the genome of 
the tumour cell using a suitable vector, usually a liposome or viral carrier (Denny & 
Wilson, 1998). Antibody-directed enzyme prodrug therapy (A-DEPT), on the other 
hand, works by introducing a foreign enzyme to tumour cells by linking it to 
monoclonal antibodies raised against tumour specific antigens. This is followed by 
administration of the prodrug which is activated specifically by the enzyme. 
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1.5.2.2 CYCLOPHOSPHAMIDE; THE ARCHETYPAL ANTICANCER PRODRUG 
One of the most widely used prodrugs in the clinic today is the DNA alkylating 
agent cyclophosphamide, which has a high therapeutic index and a broad spectrum of 
activity against a variety ofhaematological malignancies and solid tumours (Friedman 
et ai, 1979). The selectivity of cyclophosphamide towards cancer cells stems from the 
two alternative routes of biotransformation of its initial metabolite (figure 1.16), one 
leading to pharmacological activation, the other to deactivation (Cox et ai, 1976a). 
Cyclophosphamide is initially oxidized by cytochrome P-450 to 4-hydroxy-
cyclophosphamide which exists in equilibrium with an alicyclic aldehyde, 
aldophosphamide. Various studies have shown that members of the CYP2B, CYP2C 
and CYP3A subfamilies are all effective in catalysing this reaction (Spatzenegger & 
Jaeger, 1995). Under relatively anaerobic conditions in tumour cells, the aldehyde 
spontaneously decomposes to acrolein and phosphoramide mustard. Although acrolein 
can bind covalently to proteins (Marinello et ai, 1984; Ohno & Ormstad, 1985), the 
primary cytotoxic metabolite is almost certainly the phosphoramide mustard, which 
spontaneously decomposes to produce a positively charged aziridinium group, with the 
loss of chloride (Williamson & Witten, 1967). This reacts with DNA, predominantly 
with the N7 positions of guanine residues, in an SN2 alkylation step (Kohn et ai, 1987). 
As the reaction between the drug and DNA is covalent, DNA damage by 
cyclophosphamide is potentially more lethal than damage produced by agents that bind 
to DNA non-covalently, such as DNA intercalators. This is due to the fact that the 
lesions formed are far more persistent and cells must undergo extensive DNA repair to 
remove them (see reviews by Wassermann, 1994; Chaney & Sancar, 1996). In 
addition, being a bis(2-chloroethyl)amine, phosphoramide mustard contains two 
alkylating groups on each drug molecule, enabling it to cross-link nucleophilic atoms 
in nucleic acids, proteins or other biomolecules (Lawley & Brookes, 1967). Indeed, the 
effective nitrogen mustards are almost universally bifunctional, suggesting that their 
anticancer action involves the formation of cross-links between macromolecular sites. 
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Figure 1.16: Metabolic activation of cyclophosphamide to produce the active 
phosphoramide mustard (adapted from Gibson & Skett, 1986). 
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Perhaps the most important alkylation process is DNA-DNA interstrand cross-
linking, which inhibits DNA strand separation, and can thus constitute a complete 
block to DNA replication and transcription (Gralla et aI, 1987; Pieper et aI, 1989). The 
inability of complementary strands of cross-linked DNA to separate has been 
demonstrated experimentally (Kohn et aI, 1966) and both interstrand cross-links (Ewig 
& Kohn, 1977) and DNA-protein cross-links (Thomas et aI, 1978) have been observed 
in intact cells. 
Cyclophosphamide also undergoes several other biotransformations leading to 
pharmacological deactivation. By far the most important of these is the oxidation of 
aldophosphamide to the inactive metabolite carboxyphosphamide by cytosolic 
aldehyde dehydrogenase isoenzymes (Cox et aI, 1976b). This appears to be the key 
determinant in the selective toxicity of cyclophosphamide toward tumour cells, which 
are usually deficient in aldehyde dehydrogenase activity (Sladek, 1987). However. 
because oxidation of aldophosphamide is a detoxification reaction, elevated levels of 
class III aldehyde dehydrogenase levels in tumour cells can lead to acquired resistance 
to cyclophosphamide (Rekha et aI, 1994). 
1.5.3 MET ABOLICALL Y ACTIVATED ANTHRACYCLINES; THE 
MORPHOLINO ANALOGUES 
In an attempt to circumvent the toxic side effects and drug resistance associated 
with the use of the anthracyclines, a series of analogues have been synthesized in which 
the amino nitrogen at the 3' position of the daunosamine sugar is incorporated into a 
morpholino ring (see Acton et aI, 1984). These compounds, known as the morpholino 
anthracyclines, differ from conventional anthracyclines particularly in their 
mechanisms of action, cytotoxic potency and activity against MDR1-expressing 
doxorubicin-resistant cell lines. With respect to metabolic transformation, the two most 
important members of this group are morpholino doxorubicin (mdox) and 
methoxymorpholino doxorubicin (mmdox) (figure 1.17). In vitro. these compounds 
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have cytotoxic activity comparable to doxorubicin (Jesson et ai, 1987, Grandi et al. 
1990). However, when administered in vivo, their potency is far greater than that of 
doxorubicin (Acton et ai, 1984, Ripamonti et ai, 1992), suggesting that the parent 
compounds are biotransformed in situ to highly cytotoxic metabolites. 
R 
OH 
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Figure 1.17: Structural modification of doxorubicin to produce morpholino- and 
methoxymorpholino doxorubicin. 
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1.5.3.1 METABOLIC ACTIVATION OF MORPHOLINO DOXORUBICIN 
The effects of mdox in vivo can be emulated in vitro using microsomal enzyme 
systems. Incubation of the drug with NADPH-fortified human liver micro somes prior 
to addition to human ovarian carcinoma cell line ES-2 potentiates its cytotoxicity 44-
fold (Lau et al, 1989). The active species generated from metabolism of mdox is a 
potent DNA alkylator, capable of producing inter strand DNA cross-linking. The 
mechanism for biotransformation of mdox is known to involve hepatic mixed function 
oxidation. Metabolic potentiation and alkylating activity are abolished by the 
cytochrome P-450 3A-specific antibody and inhibitors of cytochrome P-450 3A, 
demonstrating this sub-family plays a vital role in the activation process, probably the 
CYP3A4 isoform in particular (Lewis et al, 1992). Cytotoxic potentiation is substrate 
specific, with mdox activation being one hundred-fold compared to one or two fold for 
its closely related analogues morpholino daunorubicin and morpholino oxaunomycin 
(Lewis et al, 1992). 
As yet, the active metabolite of mdox has not been identified, but it appears to 
cross-link DNA by a similar mechanism to that of the closely related analogue 
cyanomorpholino doxorubicin, which forms intra- and inter-strand cross-links without 
bioactivation (Begleiter & Johnston, 1985; Jesson et al, 1989). Structure-activity 
studies with several morpholino anthracyclines have indicated that the reactive sites 
involved in the DNA cross-linking process are the N-a carbon atoms located in 
morpholino ring (Lau et al, 1989; Westendorf et al, 1989). Acton et al (1988) have 
postulated that mdox is a-hydroxylated to a carbinolamine with subsequent conversion 
to a reactive iminium ion, which is capable of alkylating DNA. However, the nature of 
second alkylating substituent involved in cross-linking has not been speculated upon. 
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1.5.3.2 METABOLIC ACTIVATION OF METHOXYMORPHOLINO 
DOXORUBICIN 
Incubation ofmmdox with NADPH-fortified human or murine liver micro somes 
potentiates its cytotoxic potency 50-fold in the ES-2 cell line (Lau et ai, 1994a). 
Similar to mdox, cytotoxic potentiation is associated with the formation of a covalently 
reactive molecule, capable of forming DNA interstrand cross-links. Again, cytochrome 
P-450, principally the CYP 3A sub-family, appears to playa major role in the 
biotransformation process, since potentiation is inhibited by cyclosporin A (Lau et ai, 
1994a) and erythromycin (Lau et ai, 1991). 
The covalently reactive metabolite of mmdox is thought to be the O-demethyl 
derivative produced by oxidation of the ~-carbon atom of the morpholino ring (Lau et 
ai, 1991). Particularly under acidic conditions, the hemiacetal generated by 0-
demethylation of the ~-carbon atom could ring open to form an aldehyde (Fessenden & 
Fessenden, 1986). This may well be one of the species responsible for the observed 
DNA cross-linking, as aldehydes are known to react with nucleophilic groups such as 
those found in proteins and DNA to form Schiffs bases (Rawn, 1983; Fessenden & 
Fessenden, 1986). However, the exact mechanism of cross-linking has yet to be 
determined. DNA-drug adducts following metabolism have been detected by gel 
electrophoresis and HPLC (Graham et ai, 1992) and structural elucidation of the active 
metabolite is still under investigation. Possible metabolites of mdox and mmdox with 
the potential for alkylating DNA are shown in figure 1.18. 
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Figure 1.18: Hypothetical chemical and metabolic conversion of morpho Ii no 
doxorubicin (mdox), cyanomorpholino doxorubicin (mdox-CN) and 
methoxymorpholino doxorubicin (mmdox) into alkylating species. R denotes the rest 
of the anthracycline molecule (see figure 1.17). 
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1.5.3.3 CIRMVENTION OF TOXICITY AND MULTIDRUG RESISTANCE BY 
MORPHOLINO ANTHRACYCLINES 
As mdox and mmdox have intrinsic cytotoxicities comparable to doxorubicin, 
they can not be considered as true prodrugs. However, preclinical studies have 
indicated that the enhanced activity of these compounds in vivo is not associated with 
any substantial increase in cardiotoxicity (Sikic et al, 1985; Danesi et al, 1993). This is 
probably due to the improvement in therapeutic index of the morpholino compounds 
upon biotransformation. In addition, the morpholino anthracyclines per se are highly 
potent against doxorubicin-resistant tumour cells. For example, mmdox shows equal 
activity against the human uterine sarcoma cell line, MES-SA and its doxorubicin-
resistant P-glycoprotein positive subline, Dx5 (Lau et al, 1994a). Mdox and mmdox 
both maintain cytotoxicity against the P-gp expressing leukaemia cell line P388IDx 
(Streeter et al, 1986; Ripamonti et al, 1992). The ability of morpholino derivatives to 
overcome multidrug resistance is thought to relate to their increased lipophilicity, 
leading to enhanced intracellular uptake and retention (Coley et al, 1993; Lau et al, 
1994b ). Available data also suggest that the presence of the morpholino group lowers 
the affinity of these compounds for the P-glycoprotein pump (Lau et al, 1992). 
Moreover, as they exert their cytotoxic effect through a mode of action primarily 
involving topoisomerase I rather than topoisomerase II inhibition (Wasserman et al, 
1990; Duran et al, 1996), morpholino anthracyclines also lack cross-resistance against 
tumour cells presenting the at-MDR phenotype, including the CEM human leukaemia 
sub-line CEMNM-l (Capranico et al, 1994, Mariani et al, 1994). Studies of the 
relationship between different chemical modifications on morpholino anthracyclines 
and their ability to overcome multi drug resistance have demonstrated that while the 
derivatives containing a morpholino ring at the C-4' position are cytotoxic in vitro, 
unlike the C-3' derivatives, they are completely inactive against disseminated P388 
leukaemia (Suarato et al, 1995; Ripamonti et al, 1996). Thus it can be concluded that 
positioning of the 4-morpholino ring at the C-3' position of the daunosamine sugar is 
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essential for in vivo activity. 
A recent phase II study of the activity ofmmdox in non-small-celllung cancer. 
renal cancer and other solid tumours showed the main side effects at clinically active 
doses were myelosuppression, nausea and vomiting, rather than cardiotoxicity (Bakker 
et ai, 1998). Similar results were obtained in a previous phase I study (Vasey et ai, 
1995). These results are encouraging, although long-term monitoring is required, 
bearing in mind the occurrence of late onset of anthracycline-induced cardiotoxicity 
observed in some patients (see section 1.4.1.2). On a less positive note, the response 
rates in patients with tumours with intrinsic resistance to chemotherapy were 
disappointingly low (Bakker et ai, 1998). Further studies will be required before it can 
be established whether this is a widespread problem in the clinical use of morpholino 
anthracyclines. 
1.5.4. BIOREDUCTIVE AGENTS AS ANTICANCER PRODRUGS 
1.5.4.1 HYPOXIA IN SOLID TUMOURS 
One of the predominant features of solid tumours is their highly irregular and 
disorganized vascularisation, which is usually inadequate for the oxygen requirements 
of tumour mass. The result is a tendency for cells that are further than 120-150llm from 
a blood supply to suffer chronic (diffussion limited) hypoxia, which may persist over a 
period of hours to days (Thomlinson & Gray, 1955). In addition, due to the intermittent 
opening and closing of blood vessels, tumour cells also experience periods of acute 
(perfusion-limited) hypoxia, which occurs for up to a few minutes (Brown, 1979). 
Hypoxia has been demonstrated in a wide variety of human tumours, which may 
contain areas where oxygen partial pressure is less than 2.5mm Hg, well below the 
level in the corresponding normal tissues (Nordsmark et ai, 1994). 
Unfortunately, hypoxia presents a huge problem in the clinical environment, 
because it almost invariably results in a low response rate to therapy. One reason for 
this is that certain chemotherapeutic drugs (and radiation) require oxygen to be 
56 
maximally cytotoxic (Teicher et ai, 1981, 1990). Another reason is that most anticancer 
agents are effective against rapidly dividing cells, but lower oxygen delivery means 
that the total number of proliferating cells and/or the overall rate of cell proliferation in 
the tumour is reduced (Tannock, 1968; Bedford & Mitchell, 1974). One way to tackle 
the problem of hypoxia is by reoxygenation of the tumour between treatments (see 
Coleman, 1988) or by using radiosensitizers such as the nitroimidazoles, which 
sensitize hypoxic cells to the effects of radiation by mimicking the electron acceptor 
properties of oxygen (Jenkins, 1989). However, this technique has limited success 
because radiosensitization is only temporary. The opposing approach is to exploit 
hypoxia by developing compounds which are only activated under hypoxic conditions, 
known as bioreductive agents (reviewed by Brown & Siim, 1996). As these agents kill 
drug-resistant cells, the combination of a conventional agent and a hypoxia-selective 
cytotoxin can achieve much greater levels of cell kill than two agents which act on the 
same cell population. Moreover, drug action is tumour cell specific. Conventional 
bioreductive agents contain nitro-aromatic or quinone moieties, and can be activated to 
yield species capable of DNA interaction and/or alkylation (see section 1.5.2.2). 
Compounds of this type include the antitumour antibiotic mitomycin C, used in clinical 
cancer therapy since the 1960s (see Tomasz & Palom, 1997) and the indoloquinone 
E09, which has undergone clinical trials (Schellens et ai, 1994), but with disappointing 
results. The N-oxides, notably the benztriazine di-N-oxide tirapazamine (Brown, 1993) 
and the anthraquinone AQ4N, represent a newer class of agents, which will hopefully 
prove more successful. 
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1.5.4.2 AQ4N: A HYPOXIA-SELECTIVE CYTOTOXIN 
AQ4N, the di-N-oxide derivative of the l,4-bis-substituted anthraquinone AQ4, 
is among the most promising new bioreductive agents synthesized to date. The 
structure of the N -oxide differs from that of its parent compound by the addition of an 
oxygen atom to the terminal nitrogen of each of the alkylamino side chains. This 
effectively renders the side chains electrically neutral due to dative covalency between 
oxygen and the nitrogen lone pair (figure 1.19). The influence of the N-oxide 
functionality on DNA binding and hence the mechanism of action of AQ4N is 
discussed later (see section 2.4.2). 
e 
o 
I CH3 
NH-CH 2-CH2-N< 
~ CH3 
AQ4N 
Figure 1.19: AQ4N, showing the electrically neutral N-oxide functionality. 
In vitro, under anaerobic conditions, AQ4N undergoes cytochrome P-450-
dependent bioreductive activation (Raleigh et ai, 1996; figure 1.20). This results in an 
approximate 1000-fold increase in potency in human and rodent cell lines compared 
with the N-oxide (Patterson et ai, 1994; Wilson et ai, 1996). Conversely, under aerobic 
conditions, AQ4N is virtually non-cytotoxic. Preliminary evidence indicates that the 
CYP3A is the major subfamily responsible for AQ4N metabolism (Patterson & 
Raleigh, 1998). 
Preclinical studies have demonstrated that AQ4N produces an additive effect in 
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combination with radiotherapy, even when administered up to four days before 
radiotherapy is initiated (McKeown et ai, 1995, 1996). Under these conditions the 
, 
systemic toxicity is considerably less than that obtained with the other bioreductive 
agents used (McKeown et ai, 1995), or is absent altogether (McKeown et ai, 1996). 
The effectiveness of AQ4N in the treatment of human malignancies is soon to be 
determined by way of a phase I clinical trial in the treatment of non-small cell lung 
cancer (Professor Laurence Patterson, personal communication). 
+ Ie 
NADPH+H+-X FPOX. ~ 
P450 reductase 
NADP+ Fp red. 
AQ4N 
(di-N-oxide) 
Cyt P450 
haem-Fell 
AQM 
(mono-N-oxide) 
,"--~ AQ4 
haem-FeIV= 0 
Cyt P450 
+Ie 
Figure 1.20: Proposed route ofbioreduction of AQ4N by cytochrome P-450 
(reproduced from Patterson & Raleigh, 1998). Fp ox and Fp red denote the oxidised 
and reduced forms of the NADPH-cytochrome P-450 reductase flavoprotein. 
Hypoxia is only one of many properties unique to tumour tissue (see King, 1996). 
For example, as discussed earlier (in section 1.5.1), expression of cytochrome P-450 
and other drug-metabolizing enzymes may be altered as a consequence of malignancy. 
This presents considerable scope for the development of agents which are selectively 
activated in tumour cells or deactivated in normal cells. Compounds of this type 
already in use include the antitumour agent cyclophosphamide, which is believed to be 
pharmacologically deactivated to its metabolite carboxyphosphamide in normal tissues. 
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Over the last decade or so, the metabolism of the anthraquinone antitumour agent 
mitoxantrone has been studied extensively, and several products of this drug have been 
identified in humans which indicate metabolic activation may be involved in its 
mechanism of action (see section 1.2.3). Therefore, it may be feasible to synthesize 
derivatives of mitoxantrone which undergo selective activation in a similar manner to 
that already demonstrated for compounds such as cyclophosphamide, the morpholino 
anthracycline analogues and AQ4N. 
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1.6 AIMS 
In summary, it is now well-established that trapping of to poi some rase II-DNA 
cleavable complexes on cellular DNA is fundamental to the antitumour activity of 
drugs such as the anthraquinones and the anthracyclines. Moreover, since the longevity 
of cleavable complex stabilization is probably a determinant of cytotoxicity, the 
persistence of drug-induced cleavable complexes observed for mitoxantrone and 
doxorubicin compared with other topoisomerase inhibitors may contribute to their 
enhanced potency. Even so, in common with the majority of other topoisomerase II 
inhibitors, drug-mediated stabilization of cleavable complexes by the anthraquinones 
and anthracyclines is transitory. This inevitably has a bearing on drug efficacy, in that 
it allows topoisomerase poisons to be readily removed from the intracellular milieu by 
the multidrug resistance-associated efflux pumps P-gp and MRP. 
Investigation of the molecular aspects of topoisomerase II -anthracycline 
interactions have identified a number of substituents critical for interference with the 
enzyme. Drug-DNA interactions have also been studied in detail. The main reason for 
pursuing this area of research is to gain information that can be used to maximize 
anti tumour efficacy, by structural modification of the original drug. One approach to 
this has been to synthesize agents which interact with their target covalently, or which 
do so upon activation. This is true of mmdox, which is activated to a metabolite( s), 
capable of irreversible binding to DNA. Conceivably, then, it may be possible to design 
other topoisomerase inhibitors which interact irreversibly with DNA and/or 
topoisomerase II within the cleavable complex only upon activation. The implications 
of designing such compounds with respect to multi drug resistance are that permanently 
bound drug would be unavailable for drug efflux, and that lower levels of 
topoisomerase II should be required to achieve drug efficacy as the cleavable 
complexes formed would be more lethal. 
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Bearing the above information in mind, the aims of this study are 
1. To investigate the DNA binding affinity of structural analogues ofbis-substituted 
alkylaminoanthraquinones and to compare this with their ability to inhibit 
topoisomerase II. Particular attention will be focused on comparing drugs containing 
cationic alkylamino side chains and those with side chains incorporating an N-oxide 
moiety. This should (a) provide information regarding the structural requirements 
necessary to maximize drug activity and (b) lead to information on the effect of the N-
oxide functionality on DNA binding and topoisomerase II inhibition which can be used 
to develop other prodrugs. 
2. To synthesize intercalating agents designed to bind covalently to topoisomerase II 
(i.e. irreversible topoisomerase II inhibitors) in the form of prod rugs. These will 
contain a masked aldehyde function in the form of an acetal moiety, which can be 
activated to yield the corresponding aldehyde derivative. 
3. To determine the chemical and metabolic conditions under which these drugs 
(acetalanthraquinones) can be activated in vitro. 
4. To investigate the interactions of the acetalanthraquinones and their activated 
products with DNA and topoisomerase II and to relate this to their cytotoxicity. 
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CHAPTER 2: TOPOISOMERASE II INHIBITION AND 
DNA BINDING OF ALKYLAMINOANTHRAQUINONES 
2.1 INTRODUCTION 
The purpose of this study was to evaluate the influence of various chromophore 
and side chain configurations ofbis-substituted alkylaminoanthraquinones on DNA 
binding and topoisomerase II inhibition. The intention was to obtain information on the 
structural requirements necessary to maximize activity with the aim of developing more 
potent and selective compounds. In terms of DNA binding, drug structure is thought to 
influence both the affinity of binding (Kapuscinski et al, 1981; Kapuscinski & 
Darzynkiewicz, 1985; Lown et al, 1985) and the kinetic dissociation rate of the DNA-
drug intercalatant (Gandecha et al, 1985; Krishnamoorthy et al, 1986; Denny & 
Wake lin, 1990). These in tum may influence the longevity of drug-induced cleavable 
complexes. As the drug side chains may be in close association with topoisomerase II 
within the drug-trapped cleavable complex (see section 1.3.2.2) particular emphasis was 
placed on varying the side chain substituents. Since studies have shown that a 
HN(CH2hNR'R spacer group is essential for cytotoxic activity (Zee-Cheng & Cheng, 
1978) most side chains investigated were of this nature (see figure 2.1). 
2.2 METHODS AND MATERIALS 
V79 (CHL) fibroblasts were derived from Chinese hamster lung (see section 5.2 
for details). For preparation ofV79 cell nuclear extract, all buffer solutions, centrifuge 
tubes and utensils used during the extraction were steam sterilized at 110°C prior to use. 
For the decatenation assay, kinetoplast DNA was supplied by Topogen Inc, Columbus, 
Ohio, U.S.A. The agarose gel used was low melting. TAE buffer consisted of Tris base, 
39.6mM; glacial acetic acid, 18.3mM and EDTA, ImM. Solutions ofBSA (micro 
grade) were prepared in 100mM Tris buffer, pH 7.5, immediately prior to use. 
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mitoxantrone R 1 =R2= NHCH2CH2NHCH2CH20H 
AQ3 Rl= NHCH2CH2NHCH2CH20H, R2 = NHCH2CH2N(C2HSh 
AQ4 Rl =R2= NHCH2CH2N(CH3h 
AQ4N Rl =R2= NHCH2CH2N(O)(CH3h 
AQ6 Rl = NHCH2CH2NHCH2CH20H, R2= NHCH2CH2N(CH3h 
AQ6N Rl = NHCH2CH2NHCH2CH20H, R2= NHCH2CH2N(O)(CH3h 
AQll Rl=R2= NHCH2CH2N(CH2CH20Hh 
AQ13 Rl =R2= NHCH2CH2CH2N(C2HSh 
AQ14 Rl =R2= NHCH2CH2N(C2HSh 
AQ20 Rl=R2= NHCH2CH2N(CH3)CH2CH20H 
ametantrone Rl=R2=NHCH2CH2NHCH2CH20H, R3=R4= H 
AQll Rl =R2= NHCH2CH2N(CH2CH20Hh, R3=R4= H 
AQ15 Rl=R3= NHCH2CH2N(C2HSh, R2=R4= H 
AQ16 Rl=R2= NHCH2CH2N(C2HSh, R3=R4= H 
Figure 2.1: Bis-substituted alkylaminoanthraquinones investigated in this study. 
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'Mixture A' consisted of Tris-HCI buffer (500mM, pH 7.9) containing dithiothreitol 
(5mM), triton-Xl 00 (0.05% v/v), MgCl2 (IOOmM), EDTA (disodium salt; 5mM) and 
NaCI (final concentration 100mM). Photography of agarose gels was carried out under 
transillumination at 300nm (UVP Inc.) using a land camera (Kodak, MP-4) loaded with 
Kodak professional film (Pelica T max 1004052). For DNA binding studies, all 
glassware, of 'A' grade specification, was pre-silanized using dichloro-dimethyl silane in 
1,1, I-trichloroethane to prevent adsorption of materials to glass surfaces. Excess 
silanizing solution was removed using methanol (HPLC grade, Fisons, Loughborough. 
UK). All water was double distilled and stored in glass. The volumes of all solutions 
were measured using Hamilton glass syringes. The DNA used was calf thymus type 1, 
sodium salt. The molarity of DNA in solution was determined from the absorbance at 
260nm, using a molar extinction coeefficient of 6600 (the value supplied by Sigma 
Chemical Co.). Isosbestic point determinations were recorded on a Perkin-Elmer 
Lambda 16 spectrophotometer and spectrophotometric titration on a Beckman DU70 
spectrophotometer (single beam). Thermal denaturation studies were recorded on a 
Perkin-Elmer 552 spectrophotometer, fitted with a Peltier cell connected to a Perkin-
Elmer temperature programmer. Anthraquinones were synthesised by Dr M. R. Craven 
at De Montfort University, Leicester, and were 98-99% pure by HPLC. All other 
reagents were obtained from Sigma Chemical Co., Poole, Dorset, UK and Aldrich 
Chemical Co., Gillingham, Dorset, UK, unless otherwise stated, and were 98-99% pure. 
Where abbreviations have been used for reagents, full names can be found in appendix 
A8. 
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2.2.1 TOPOISOMERASE II INHIBITION STUDIES 
2.2.1.1 ISOLATION OF TOPOISOMERASE II FROM V79 CELL NUCLEI 
Nuclear extract was prepared from V79 cells by a method adapted from Drake et 
al (1987). Culture flasks (15 x 150cm3) of cells in exponential growth were harvested 
in non-supplemented RPMI 1640 culture medium (see section 5.2 for details) and the 
cell density of the suspension was determined using a particle counter (see appendix 
A7.3). The culture medium was then removed by centrifugation at 1000 x g for 5 min 
(A14 microcentrifuge, Jouan Ltd., Milan, Italy) and the cells washed with 5ml of O.OlM 
phosphate buffered saline (pH7.4), containing PMSF 1mM, and soybean trypsin 
inhibitor (1 Jlg/ml). The cells were centrifuged again at 1000 x g for 5 min and 
resuspended in 4ml of 5mM potassium phosphate buffer, pH 7.0, containing MgCl2 
(2mM), EDTA (O.lmM), PMSF (1mM), benzamidine (1mM), soybean trypsin inhibitor 
(10Jlg/ml), leupeptin (50Jlg/ml) and mercaptoethanol (10mM). The suspension was 
stirred slowly at 4°C for 15 min, and kept on ice for a further 45 min, with 
homogenization every 10 min. Lysis of the cells was ascertained using the trypan blue 
dye exclusion assay (see appendix Al for details). The lysate was centrifuged at 1000 x 
g for 10 min and the nuclei washed twice with 4ml of 1mM phosphate buffer, pH 6.5, 
containing MgCI2, (5mM), EGTA (1mM), glycerol (10% w/w), NaCI (100mM), PMSF 
(1mM), benzamidine (1mM), soybean trypsin inhibitor (1 o Jlg/ml), leupeptin (50Jlg/ml) 
and mercaptoethanol (10mM). The washed nuclei were then resuspended in 2ml of 
5mM phosphate buffer, pH 7.0, containing MgCl2 (2mM), EDTA (O.lmM), glycerol 
(10% w/w), PMSF (1mM), benzamidine (1mM), soybean trypsin inhibitor (10Jlg/ml), 
leupeptin (50Jlg/ml) and mercaptoethanol (10mM). The fraction containing 
topoisomerase II was extracted from the suspension by stirring with NaCI, at a final 
concentration of 0.35M, for 60 min. The extract was centrifuged at 2250 x g for 15 min. 
then at 20 000 x g for 40 min, and the supernatant stored in sterile vials at -70°C. The 
procedure followed for determining the protein content of the V79 cell nuclear extract 
was as described in appendix A2. 
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2.2.1.2 OPTIMIZATION OF THE CONCENTRATION OF TOPOISOMERASE II 
REQUIRED FOR DECATENATION OF KDNA 
The decatenation of kinetoplast DNA (kDNA; from Crithidiafasciculata) was 
used to assay the level of topoisomerase II activity of the V79 cell nuclear extract. 
Dilutions of nuclear extract (1 in 2 to 1 in 10) were prepared in Tris buffer (100mM, pH 
7.5). The assay components were carefully pipetted onto the side ofEppendorftubes in 
the order: 2.15111 kDNA (93 . 15I1g/ml), 2.0111 'Mixture A' , 2.0111 ATP (12.5mM; in 
sterile distilled water), 3.0111 BSA (200I1g/ml; in sterile distilled water), 2.0111 nuclear 
extract at various dilutions and sterile distilled water to 20111. 
The reaction was initiated by microcentrifugation at 14 000 x g for 10 sec, 
followed by incubation at 37°C for 30 min. The reaction was stopped by the addition of 
2.0111 of a solution containing SDS (10% w/v) bromophenol blue (0.25% w/v) and 
sucrose (l.2M) to the side of the tube, and centrifuging as described above. The samples 
(20.0111) were loaded onto a 1 % agarose gel submerged in TAE buffer containing 
ethidium bromide (0.5I1g/ml), and electrophoresed for 4 h at 37V/2mA. The gel was 
de stained in T AE buffer for 1 h, and then photographed under UV transillumination for 
30 sec. The negative was developed in the dark in ID11 developer (Ilford) for 1 min and 
fixed for 30 min (using Hypam fixer, Ilford) 
2.2.l.3 OPTIMIZATION OF THE INCUBATION TIME FOR DECATENATION OF 
KDNA 
All samples were incubated at 37°C for various time periods between 0 and 60 
min. Each incubate contained 2.15111 kDNA (93. 15I1g/ml), 2.0111 'Mixture A', 2.0111 
ATP (12.5mM; in sterile distilled water), 3.0111 BSA (200I1g/ml; in sterile distilled 
water), 2.0111 V79 nuclear extract (1 in 2 dilution) and sterile distilled water to 20111. The 
procedure thereafter was as described in section 2.2.1.2. 
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2.2.1.4 OPTIMIZATION OF ATP AND MAGNESIUM ION LEVELS FOR 
DECATENATION OF KDNA 
Samples were incubated at 37°C in the presence and absence of ATP and Mg2+ for 
o to 60 min. Each incubate consisted of2.1S~1 kDNA (93.1S~g/ml), 2.0~1 'Mixture A' 
with or without MgCl2 (l0.00-200mM), 2.0~1 ATP (O-lSmM), 3.0~1 BSA (200~g/ml; 
in sterile distilled water), 2.0~1 V79 nuclear extract (l in 2 dilution) and sterile distilled 
water to 20~1. The procedure thereafter was as described in section 2.2.1.2. 
2.2.1.S THE EFFECT OF ALKYLAMINOANTHRAQUINONES ON THE 
DE CATENATING ACTIVITY OF TOPOISOMERASE II 
Samples were incubated at 37°C for 30 min with various concentrations of drug, 
ranging from 1nM to 100~M. Each incubate consisted ofkDNA (93.1S~g/ml), 2.0~l 
'Mixture A' 2.0~l ATP (l2.SmM; in sterile distilled water), 3.0~l BSA (200~g/ml; in 
sterile distilled water), 2.0~1 of sterile filtered drug (in distilled water), 2.0~l V79 
nuclear extract (l in 2 dilution) and sterile distilled water to 20~1. Nuclear extract and/or 
drug were omitted from the control incubations, and replaced by 'extraction buffer' (see 
section 2.2.1.1) and/or sterile distilled water respectively. The procedure thereafter was 
as described in section 2.2.1.2. 
2.2.2 DNA BINDING STUDIES 
2.2.2.1 THE EFFECT OF CALF THYMUS DNA ON THE SPECTRAL PROPERTIES 
OF ALKYLAMINOANTHRAQUINONES 
Solutions of drug were prepared in Tris buffer (Tris base, 8mM and NaCI, O.OSM, 
pH 7.2, in double distilled water) and added to silanized 'A' grade volumetric flasks 
(lOml) to give a final drug concentration of 1.S x 10-SM. Calf thymus DNA (in the 
same buffer) at a concentration of approximately 1.S x 10-3M was added to each drug 
solution to give DNA to drug ratios of 0, 0.2, O.S, 1.0, 2.0, S.O, 10.0 and lS.0 to 1.0. The 
absorbance spectra of the solutions were then recorded between 400 and 700nm against 
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a Tris buffer blank, and superimposed. The procedure was repeated using DNA and 
drug solutions prepared in buffer containing Tris base, 8mM and NaCI, 0.5M, pH 7.2. 
2.2.2.2 SPECTROPHOTOMETRIC TITRATION OF ALKYLAMINO-
ANTHRAQUINONES AGAINST CALF THYMUS DNA 
A volume of precisely 3.0ml of drug solution at a concentration of2.5 x 10-5M in 
Tris buffer (Tris base 8mM and NaCI 0.5M, pH 7.2, in double distilled water) was 
added to three matched quartz cuvettes of 1 cm pathlength. Tris buffer (3ml) was used as 
a blank to calibrate the spectrophotometer. Volumes of 12 x 10,6 x 20, 8 x 40 and 5 x 
100~1 of calf thymus DNA (concentration 1.25 x 10-3M) in Tris buffer, were added 
sequentially to each of the drug solutions with a Hamilton syringe. Each solution was 
then mixed gently for 15 sec and left for 5 min to allow the DNA/drug mixture to 
equilibrate. After equilibration, the absorbance of each sample was measured at the 
Amax of the unbound drug. Scatchard plot analysis was use to determine the values of K 
(the affinity constant of drug for DNA) and n (the number of drug binding sites per 
DNA phosphate residue). 
2.2.2.3 THE EFFECT OF ALKYLAMINOANTHRAQUINONES ON THE 
THERMAL DENATURATION OF CALF THYMUS DNA 
A solution of drug (3.0ml) in Tris buffer (Tris base, 8mM and NaCI, 0.05M, pH 
7.2, in double distilled water) was added to approximately 6ml of double distilled water. 
and de-gassed by sonication for 15 min. A solution of calf thymus DNA in the same 
Tris buffer (600~l) at a concentration of 1.5 x 10-3M was then added and the mixture 
diluted to 10.0ml with double distilled water, to give a DNA to drug ratio of 10:1. 
Exactly 3.0ml of this solution was transferred to a quartz cuvette (lcm path1ength) 
which was then tightly stoppered and left to equilibrate at 60°C for 15 min. The 
absorbance was measured at 260nm against a non-heated Tris buffer blank, and further 
measurements were taken at 1°C intervals (0.5°C/min) up to 110°C or until there was no 
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further change in absorbance. In determining the melting temperature of DNA alone, 
drug solution was replaced by an equal volume of Tris buffer. 
2.3 RESULTS 
2.3.1 TOPOISOMERASE II INHIBITION STUDIES 
2.3.1.1 THE DECATENATION ASSAY 
The decatenation assay is based on the ability of type II topoisomerases to resolve 
high molecular-weight catenated DNA networks to individual DNA circles and 
intermediate-sized catenated complexes, which move rapidly into the gel upon 
electrophoresis (Miller et ai, 1981). In the presence of topoisomerase II poisons, 
decatenation is inhibited, and the intact networks remain in the loading well. The 
catenated DNA substrate used in this study was kinetoplast DNA extracted from the 
mitochondria of the trypanosome Crithidiafasciculata, which consists of2.5 kb 
minicircles (93-95%) and 40kb maxicircles (Marini et ai, 1980). 
A 2.0~1 volume of a 1 in 2 dilution ofV79 cell nuclear extract, corresponding to 
855ng of protein per incubate (see appendix A2), achieved complete decatenation of 
200ng kDNA in 30 min at 37°C (equivalent to 7.8 ~g DNA/min/mg protein). 
Decatenation was also found to be ATP- and Mg2+_ dependent, the optima being 
12.5mM and 100mM respectively. These conditions were maintained for the subsequent 
screening of drugs. 
2.3.1.2 THE EFFECT OF ALKYLAMINOANTHRAQUINONES ON 
TOPOISOMERASE II ACTIVITY 
The effect of the alkylaminoanthraquinones on the decatenation of kDNA is 
shown in table 2.1. It can be seen that mitoxantrone completely inhibited decatenation at 
a concentration ofO.75~M, indicated by intact networks remaining in the loading wells 
(figure 2.2). The mitoxantrone analogues AQ4 and AQ6 inhibited decatenating activity 
at 1.5~M and 1.0~M respectively, both within the same range as mitoxantrone (figures 
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2.3 and 2.4). In contrast, total inhibition of decatenation by the N-oxides AQ4N and 
AQ6N required concentrations of 50 11M and IOIlM respectively, 33 times and 10 times 
that required for their respective parent compounds (figures 2.3 and 2.4). Control 
incubations (without drug) did not inhibit decatenation ofkDNA, as indicated by 
migration of decatenated circles into the gel. 
Table 2.1: Inhibition of to poi some rase II-mediated decatenation ofkDNA by bis-
substituted alky laminoanthraquinones 
DRUG 
mitoxantrone R1= 
R2= 
AQ4 R1= 
R2= 
AQ4N R1= 
R2= 
AQ6 R1= 
R2= 
AQ6N R1= 
R2= 
alkylamino 
side chains 
a 
-NHCH2CH20H 
-NHCH2CH20H 
-N(CH3)2 
-N(CH3)2 
-NO(CH3)2 
-NO(CH3)2 
-NHCH2CH20H 
-N(CH3)2 
-NH CH2CH20H 
-NO(CH3)2 
b 
inhibitory drug 
concentration (11M) 
0.75 
1.5 
50.0 
1.0 
10.0 
a: structure of alkylamino side chains terminal to the aliphatic nitrogen at positions 
1 and 4 of the anthraquinone chromophore (see figure 2.1); b: drug concentration 
causing total inhibition of kDNA decatenation. 
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Figure 2.2: Inhibition of to poi some rase II-mediated decatenation of kDNA by 
mitoxantrone. Lane 1 (left): kDNA + topo II ; lanes 2-6: kDNA, topo II + 0.05 , 0. 1, 0.2. 
0.5 and 0.751lM mitoxantrone respectively. 
Figure 2.3: Inhibition of to poi some rase II-mediated decatenation ofkDNA by AQ4 
and AQ4N. Lane 1 (left): kDNA + topo II ; lanes 2-4: kDNA, topo II + 0.5 , 0.75 and 
1.0llM AQ4 respectively. Lanes 5-7: kDNA, topo II + 10, 25 and 50llM AQ4N 
respectively. 
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Figure 2.4: Inhibition of to poi some rase II-mediated decatenation ofkDNA by AQ6 
and AQ6N. From left: lanes 1-3: kDNA, topo II + 0.5 , 0.75 and 1.0!lM AQ6 
respectively. lanes 4-6 : kDNA, topo II + 5, 10 and 25!lM AQ6N respectively. 
2.3.2 DNA BINDING STUDIES 
2.3.2.1 DNA-DRUG INTERACTIONS 
Due to their amphipathic nature, alkylaminoanthraquinones can participate in two 
different types of DNA binding. Firstly, their planar tricyclic chromophore allows them 
to intercalate between the DNA base pairs (Double & Brown, 1975). This process is 
stabilized by hydrophobic interactions between the base pairs and the 7t orbitals of the 
drug chromophore. Intercalation induces several changes in the properties of 
alkylaminoanthraquinones, including changes in their absorption spectra, and also 
stabilizes the DNA helix to thermal denaturation. Secondly, the cationic (amino) 
functions of the drug side chains can interact with DNA via the negatively charged 
DNA phosphate groups, which further stabilizes the DNA-drug complex (Kapuscinski 
et aI, 1981 ; Foye et aI, 1982; Lown et aI, 1984). As this type of binding occurs on the 
exterior of the DNA helix, it is much weaker than intercalation, and is subject to the 
influence of the ionic concentration of the solution (Jones et aI, 1980). The significance 
of this will become apparent later. 
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2.3.2.2 SPECTRAL PROPERTIES OF ALKYLAMINO-ANTHRAQUINONES 
Due to the donation of electrons by the aromatic nitrogen atoms into their 1t 
conjugated ring system, anthraquinone-based compounds have a characteristic 
absorbance in the visible region of the spectrum. However, on binding to DNA, these 
UV and visible properties are altered (Waring, 1981). Upon intercalation, a 
bathochromic shift (a shift to a longer wavelength) usually occurs, and the molar 
extinction at the Amax decreases, producing a hypochromic shift. These shifts vary 
according to the ratio of DNA: drug present. In addition, the drug may display an 
isosbestic point. This is obtained by varying the concentration of DNA that is added to a 
fixed concentration of drug and superimposing the spectra recorded between two 
wavelengths. The presence of an isosbestic point indicates that one type of binding 
complex is formed between the drug and DNA (Waring, 1981). 
Table 2.2 shows the effect of calf thymus DNA on the spectral properties of the 
alkylaminoanthraquinones. Figure 2.5 shows the spectrum for AQ15 at DNA to drug 
ratios between 0: 1 and 15: 1 in the visible region of the spectrum, using buffer 
containing 0.05M NaCl. Figure 2.6 shows the spectrum for AQ15 at these DNA:drug 
ratios at an NaCI concentration ofO.5M NaCl. The spectra for AQ16 at ionic 
concentrations 0.05M and 0.5M are shown in figures 2.7 and 2.8 respectively. The red 
shift of the maxima and the hypochromicity are consistent with intercalative binding, 
and have previously been observed for mitoxantrone and ametantrone in the presence of 
double stranded polymers (Kapuscinski et aI, 1981; Kapuscinski & Darzynkiewicz, 
1985; Lown et aI, 1985). All parent compounds in the anthraquinone series showed 
hypochromic and bathochromic shifts in the presence of calf thymus DNA and were 
fully bound to DNA at a DNA:drug ratio of 15: 1. 
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Table 2.2: Spectral properties ofbis-substituted alkylaminoanthraquinones in the 
presence of calf thymus DNA 
DRUG 
mitoxantrone 
ametantrone 
AQ3 
AQ4 
AQ4N 
AQ6 
AQ6N 
AQll 
AQ12 
AQ13 
AQ14 
AQ15 
AQ16 
AQ20 
a 
isosbestic point (nm) shift in "-max (nm) 
621 17 
636 12 
623/667 18 
622 17 
620 17 
621 7 
659* 14 
642 2 
620/660 19 
667 18 
4 
639 4 
637 17 
0/0 decrease in 
extinction 
15 
16 
15 
15 
12 
9 
19 
8 
11 
16 
16 
15 
20 
b 
a: shift in Amax at a DNA to drug ratio of 15:1~ b: difference between Amax of free 
drug and fully bound drug (hypochromic shift). * indicates an isosbestic point was 
observed only at higher DNA:drug ratios. All experiments were performed in O.5M 
NaCl/ O.008M Tris buffer. 
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Figure 2.5: Spectral properties of A Q 15 in the presence of calf 
thymus DNA and O.008M Tris/O.05M NaCl. 
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Figure 2.6: Spectral properties of AQ15 in the presence of calf 
thymus DNA and O.008M Tris/O.5M NaCl. 
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Figure 2.8: Spectral properties of AQ16 in the presence of calf 
thymus DNA and O.008M Tris/O.SM NaCI. 
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Apart from AQll and AQ15, all parent compounds gave isosbestic points at a 
concentration ofO.5M NaCl, consistent with a single-type of DNA-drug binding 
complex. However, for a number of drugs, using O.05M NaCI, the isosbestic point \yas 
lost, particularly at lower DNA:drug ratios, indicating the presence of more than one 
form of DNA-drug complex (data not shown). This effect was observed only for 
compounds that were dihydroxylated at the 5 and 8 positions of the chromophore and 
was more evident for the compounds containing side chain hydroxy groups. 
Compounds hydroxylated at the 5 and 8 positions of the chromophore generally 
showed increased bathochromic and hypochromic shifts compared with the non-
hydroxylated analogues. The spectrum of the di-N-oxide, AQ4N, showed little change 
as the DNA concentration was increased, indicating intercalation did not take place, 
while the mono-N-oxide, AQ6N, showed moderate bathochromic and hypochromic 
shifts, and isosbestic points at both O.5M and O.05M NaCl. Although the spectra for 
AQ15 all converged at ~ 557nm, they did not cross and thus a true isosbestic point was 
not obtained. For AQll, the spectra crossed through a single point only at higher 
DNA:drug ratios. 
2.3.2.3 DETERMINATION OF THE AFFINITY OF ALKYLAMINO-
ANTHRAQUINONES FOR CALF THYMUS DNA BY SPECTROPHOTOMETRIC 
TITRATION 
On sequential addition of DNA to a solution of DNA intercalating agent, there is a 
progressive decrease in extinction (hypochromic shift) at the Amax of the unbound drug 
(as DNA-bound drug has different Amax to free drug-see section 2.3.2.2). When there is 
no further decrease in extinction, the drug is fully bound to DNA. The fraction of bound 
drug (a), at any particular DNA concentration can be calculated from the equation 
a = Ef- Eobs 
Ef- Eb 
where Ef is the extinction of free drug at the Amax, Eobs is the extinction of the sample 
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after each addition of DNA and Eb is the extinction of the bound drug, estimated from a 
plot of 
Eobs vs [DNA] 
CT 
CT being the total drug concentration available for binding. This allows the affinity of 
the drug for DNA to be quantified using the Scatchard plot: 
ric = -Kr + Kn 
where r is the number of moles of ligand bound per nucleotide, equal to aCT I [DNA ], 
aCT is the concentration of bound drug, and c is the concentration of free drug, (I-a )CT 
(Blake & Peacocke, 1968). 
K (the DNA affinity constant) can be calculated by linear regression and n (the 
number of drug molecules bound per DNA phosphate) from the x-axis intercept. For 
this method to be valid, the drug must obey Beer-Lambert's Law within the range of 
drug concentrations used, so that the fraction of bound drug is proportional to the 
fractional decrease in extinction. There must also be a clear isosbestic point, as this 
indicates that there is only one type of spectroscopically distinct DNA-drug complex 
present (see section 2.3.2.2). 
Results for K and n are shown in table 2.3. Individual absorbance values deviated 
no more than ± 5% from the mean. The Scatchard plots for mitoxantrone, ametantrone, 
AQ6 and AQ6N are shown in figures 2.9 to 2.12. All drugs were found to obey Beer-
Lambert's Law up to a concentration of 1 x 10-4M in O.5M NaCI, pH 7.2 (results not 
shown). As in several cases, isosbestic points could be obtained using O.5M but not 
O.05M NaCI, spectrophotometric titration was performed using O.5M NaCI for all 
compounds. At this ionic concentration, it was anticipated that surface binding would be 
minimal, so only one K value was obtained, corresponding to intercalative binding. 
As insignificant hypochromic and bathochromic shifts were obtained for AQ4N, 
and no isosbestic point was obtained for AQl1 or AQ15, K and n values for these 
compounds were not determined. 
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Table 2.3: Values ofK and n for bis-substituted alkylaminoanthraquinones 
obtained by spectrophotometric titration with calf thymus DNA 
DRUG n 
mitoxantrone 4.2 0.12 
ametantrone 3.3 0.12 
AQ3 4.6 0.13 
AQ4 s.o 0.13 
AQ4N nd nd 
AQ6 4.6 0.13 
AQ6N 3.6 0.13 
AQll nd nd 
AQ12 1.6 0.12 
AQ13 3.9 0.13 
AQ14 4.6 0.13 
AQIS nd nd 
AQ16 2.2 0.13 
AQ20 4.7 0.14 
K represents the affinity constant and n the number of drug binding sites per DNA 
phosphate. nd = not determined. Values represent the mean of three separate 
experiments performed in triplicate. The absorbance values obtained for each 
experiment deviated no more than ± 5% from the mean. 
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The K values for all compounds at 0.5M were of the same order of magnitude 
(l06M-l range). However, the 5,8-dihydroxy substituted analogues generally had higher 
K values than the non-hydroxylated analogues (3.94-4.95 x 106M-l compared to 1.63-
3.25 x 1 06M-l). Thus, for the parent compounds, hydroxylation of the chromophore 
had a greater effect on K than variations in the side chain groups, as long as their 
cationic nature was maintained. However, modification of the terminal nitrogen on the 
alkyl amino side chain to form an N-oxide resulted in a large decrease in DNA binding 
affinity. AQ6N, in which one cationic alkylamino side chain was retained, gave a 
moderate K value (3.64 x 106M-I) . 
2.3.2.4 THERMAL DENATURATION OF CALF THYMUS DNA IN THE 
PRESENCE OF ALKYLAMINOANTHRAQUINONES 
In solution, the two strands of the DNA double helix are essentially held together 
by hydrogen bonding between complementary bases and by base pair stacking. 
However, upon heating, the DNA helix unwinds and the two strands separate. This 
process is known as thermal denaturation, and can be measured by the increase in 
absorbance of the solution at 260nm (Marmur & Doty, 1959). When drug molecules 
intercalate between the base pairs of DNA, its structure is stabilized so that more heat 
energy is required to cause denaturation. In contrast, if the drug binds externally to the 
helix, there is usually little if any increase in the temperature at which denaturation takes 
place. Thus, the difference in the temperature at which denaturation takes place for 
DNA-drug complexes compared to DNA alone (known as ~Tm) gives an indication of 
the degree of intercalation for a particular compound. 
The melting profile for DNA is shown in figure 2.13 and ~ Tms for several of the 
drugs are shown in figures 2.14. to 2.20. Data are summarized in table 2.4. Tm was 
determined as being the temperature corresponding to the midway point on the slope of 
increasing absorbance, from a plot of A vs T. First derivative plots, the change in 
absorbance per degree rise in temperature vs. temperature (dAidT vs. T), allowed more 
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subtle changes in the melting process to be seen, particularly biphasic trends, where 
dAidT showed a maximum at two temperatures. 
The Tm of calf thymus DNA in the absence of drug was 70.6 ± 0.5°C. The parent 
compounds in the anthraquinone series all caused considerable increases in Tm, the 5,8 
dihydroxylated anthraquinones generally showing larger increases than the non-
hydoxylated compounds (13.5-28.0 °C compared to 13.9-21.5 °C), The effect of the di-
N-oxide AQ4N on melting temperature was minimal (1.8°C), whilst the mono-N-oxide, 
AQ6N, caused a modest increase (7.0°C). The first derivative plots of AQ4N, AQll and 
AQ 12 were symmetrical, as was that for DNA itself. First derivative plots of all other 
compounds (notably AQ3, AQ4 and AQI3) were found to be of a biphasic nature. Drug 
solutions heated without DNA showed no spectral changes over a time period of 3 
hours. 
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Table 2.4: L\Tm values of calf thymus DNA in the presence ofbis-substituted 
alky laminoanthraquinones 
DRUG 
mitoxantrone 97.0 ± 0.6 
ametantrone 92.1 ± 0.1 
AQ3 86.8±1.4 
AQ4 88.3 ± 0.5 
AQ4N 72.4 ± 0.8 
AQ6 98.6 ± 0.5 
AQ6N 77.6 ± 1.2 
AQll 84.2 ± 0.1 
AQ12 84.5 ± 0.3 
AQ13 88.7 ± 0.2 
AQ14 89.2 ± 0.2 
AQ15 89.6 ±0.7 
AQ16 86.4 ± 0.3 
AQ20 93.8 ± 0.8 
a 
L\Tm 
26.4 
21.5 
16.2 
17.7 
1.8 
28.0 
7.0 
13.6 
13.9 
18.1 
18.6 
19.0 
15.8 
23.2 
b 
biphasic first 
derivative plot 
yes 
yes 
yes 
yes 
no 
yes 
yes 
no 
no 
yes 
yes 
yes 
yes 
yes 
a: difference in melting temperature of DNA in the presence and absence of drug (Tm 
of calf thymus DNA= 70.6 ± 0.5°C); b: first derivative plots (dAidt vs. T) displayed 
absorption maxima at two temperatures. Values represent the mean ± sd for three 
separate experiments. 
85 
0.3 0.04 
E . . 
. . . 
. 
I: 
- 0.03 0 
(0 0.2 N 
-
00 as 
Q) o 0 
0 0 0.02 
I: 0 0 
as 00 
.0 0.1 - 0 ... 0 0 
0 
- 0.01 
.0 0 0 as 00 
0 0 
AO<?· 
0 
. 
°OOl) 0 0 
60 65 70 75 80 85 
temperature (OC) 
Figure 2.13: Melting profile of calf thymus DNA, showing A vs T (e) 
and dA/dT vs T (0). Values shown represent the mean of three separate 
experiments. 
0.4 ,----------------------.- 0.03 
E 
0.02 
I: 0.3 0 (0 
N 
-as 
Q) 0.2 -0 
I: 
as 
.0 
... 
0 
0 
.0 0.1 as 
60 70 80 90 100 110 
temperature (OC) 
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Figure 2.16: Melting profile of calf thymus DNA in the presence of 
AQ4N, showing A vs T (e) and dA/dT vs T (0). Values shown represent 
the mean of three separate experiments. 
87 
0.4 0.04 
E 
I: 0.3 - 0.03 0 (Q 
(\oj 
-co 
G) 0.2 -
- 0.02 (,) .0. 
I: .0 000 co 0<> 0() 
.c 
09<> 0 ... 0 00. 00 In 0.1 -
.c 0<><>· • 0.01 
co 0<>0 •• 0 
00 •• o .. 
A. .A. A. A. <><><><l~<:!· • • 0 0 
60 70 80 90 100 110 
temperature (OC) 
Figure 2.17: Melting profile of calf thymus DNA in the presence of 
AQ6, showing A vs T (e) and dAidT vs T (0). Values shown represent 
the mean of three experiments. 
0.3 -r---------------------...,.- 0.03 
E 
I: 
o 
~ 0.2 
-co 
G) 
(,) 
I: 
co 
-e 0.1 
o 
In 
.c 
co 
o 
o 
o 
o . o A.~o<>·.·· 
60 
o 
000000.1. . 
o .vo 00 
0000000 
o 
70 80 
temperature (OC) 
000 
o 
90 
..... 
. . . 
o 
000 
0000 
100 
0.02 
0.01 
o 
Figure 2.18: Melting profile of calf thymus DNA in the presence of 
AQ6N, showing A vs T (e) and dAidT (0). Values shown represent the 
mean of three experiments. 
88 
dA/dT 
dA/dT 
0.4 0.03 
E .... 
c 0.3 -0 
CD 
N 0.02 
-co 
Q) 0.2 . dA/dT 0 <> <><>9<>0<><><><><><><> c co <><><><><><> <><> 
.c <>. . 
... <> 0.01 0 <><> In 0.1 - <> 
.c 
co <> 
<> <> 
<> <><> . <><> 
0 A. A. A. A. A A . . . 0 
60 70 80 90 100 
temperature (OC) 
Figure 2.19: Melting profile of calf thymus DNA in the presence of 
AQll, showing A vs T (e) and dA/dT vs T (0). Values shown represent 
the mean of three experiments. 
E 
c 
0 
CD 
N 
-co 
Q) 
0 
c 
co 
.c 
... 
0 
In 
.c 
co 
0.5 ~----------------------------------------. 0.05 
.... 
0.4 
0.3 -
. 
0.2 
<> <><><><><><> 
<>. <> 
<> <> • <><> 
0.1 
<> <>. <><><> 
<> <> • <> 
<> <> 
<> <> 
<> •• <> 
0 
<> • <> AA~A<><><><>9~.·· ~ 
-
60 70 80 
temperature (OC) 
90 100 
- 0.04 
0.03 
0.02 
0.01 
a 
Figure 2.20: Melting profile of calf thymus DNA in the presence of 
AQ12, showing A vs T (e) and dA/dT vs T (0). Values shown represent 
the mean of three separate experiments. 
89 
dA/dT 
2.4 DISCUSSION 
2.4.1 TOPOISOMERASE II INHIBITION STUDIES 
Two methods frequently used to measure topoisomerase II activity are the 
decatenation assay and the DNA relaxation assay. However, assays based upon the 
relaxation of supercoiled DNA can be complicated by the presence of topoisomerase I 
and nucleases in partially purified fractions (Sahai & Kaplan, 1986). In contrast, the 
decatenation assay is absolutely specific for type II topoisomerase activity, because type 
I enzymes are unable to achieve decatenation unless at least one of the two substrate 
DNA molecules is nicked (Maxwell & Gellert, 1986; Barrett et ai, 1990). The 
decatenation assay was thus chosen for this study as the V79 cell topoisomerase II 
nuclear extract may have contained low levels of to poi some rase I and/or nuclease 
activity. In addition, the relaxation assay was also unsuitable as the drugs screened were 
intercalators, which are known to unwind the DNA helix per se. 
Mitoxantrone inhibited decatenation ofkDNA at 0.75/lM. Inhibition was 
presumably due to inhibition of to poi some rase II-catalysed DNA strand passing, 
resulting in stabilization of the topoisomerase II-DNA-drug cleavable complex (see 
section 1.3.2). AQ4 and AQ6 both inhibited topoisomerase activity at concentrations 
similar to mitoxantrone, and considering their structural similarity with this compound, 
they are also likely to stabilize cleavable complexes. However, the N-oxides, AQ4N and 
AQ6N, showed a marked difference to the parent compounds in their ability to inhibit 
topoisomerase II (table 2.1). This demonstrates that incorporation of the N-oxide 
functionality, which diminishes DNA intercalation (vide infra) also prevents inhibition 
of topoisomerase II. 
The fact that mitoxantrone was found to be the most potent of the parent 
compounds may be attributed to long-term trapping of to poi some rase II cleavable 
complexes by this drug. The persistence of mitoxantrone-topoisomerase II cleavable 
complexes has been demonstrated in small cell lung cancer cells (Smith et ai, 1990) and 
human fibroblast cells (Fox & Smith, 1990). The longevity of the complexes formed 
90 
could relate to its DNA-drug binding mode (see section 2.4.2) or may involve one or 
more active metabolites of the drug (see section 1.2.3). The 2'-(hydroxyethylamino)-
ethyl amino side chain of mitoxantrone is known to be metabolized to produce the 
corresponding mono- and dicarboxylic acid derivatives, detected in human hepatocytes 
(Richard et ai, 1991) and human plasma and urine samples (Ehninger et ai, 1986; 
Schleyer et ai, 1994). These metabolites have been shown to be inactive (Chiccarelli et ai, 
1986), but it is likely that oxidation of the alcohol groups proceeds via an aldehyde 
intermediate, as oxidation from an alcohol to an acid can not be accomplished in a single 
step (Fessenden & Fessenden, 1986). The aldehyde intermediates may achieve cleavable 
complex stabilization via their ability to form Schiffs bases with nucleophilic sites on 
topoisomerase II (figure 2.21; also see figure 5.24, section 5.4.2). In the presence of 
water, these are reversible, but the DNA-topoisomerase II active site appears to be 
hydrophobic (Capranico et ai, 1997). Thus, Schiffs base formation may result in 
persistently trapped topoisomerase II cleavable complexes in the hydrophobic interior of 
the topoisomerase II-DNA active site. In support of this, cell lines resistant to 
mitoxantrone have been found to contain a reduction in tightly bound, non-exchangeable 
drug (Beck et ai, 1987; Pincus & Goldman, 1990). In addition, irreversible cleavable 
complex stabilization has been demonstrated for other topoisomerase II inhibitors 
(Kawada et ai, 1991) and topoisomerase I inhibitors (Hertzberg et ai, 1990). 
A third metabolite which has been detected in urine and serum (Ehninger et ai, 
1986) could conceivably correspond to an aldehyde derivative of mitoxantrone. In 
support of this, the metabolite is more polar than mitoxantrone, but less polar than either 
of the carboxylic acid derivatives. It is also comparatively short-lived, which would be 
expected of an aldehyde in view of their highly reactive nature and rapid oxidation in 
biological systems (Beedham, 1997). In this study, activation to produce the aldehyde 
intermediate of mitoxantrone could have been mediated by enzymes in the V79 nuclear 
extract, e.g. alcohol dehydrogenase, an enzyme located notably in the soluble fraction of 
liver, kidney and lung cells (Bosron & Li, 1980; Gibson & Skett, 1986). 
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intermediate of mitoxantrone and topoisomerase II. Formation of the di -aldehyde 
intermediate may lead to Schiffs base formation on both side chains. 
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2.4.2 DNA BINDING STUDIES 
Altering the nature of both the chromophore and side chains of the anthraquinones 
was found to affect their DNA binding properties. The most significant finding was that 
modification of the terminal nitrogen of the alkyl amino side chain to form an N-oxide 
resulted in a large decrease in DNA binding affinity. This demonstrates that the 
electrically neutral N-oxide functionality prevents stabilization of intercalative binding 
normally associated with cationic alkylaminoanthraquinones. This is attributable to a 
reduction in the electrostatic attraction between amino groups of the side chains of the 
drug and the negatively charged P04- groups of the DNA backbone. As the mono N-
oxide AQ6N possessed one cationic alkyl amino side chain, some DNA binding activity 
was retained. 
All parent compounds displayed batho- and hypochromic shifts in the visible 
region of the spectrum and a large majority displayed an isosbestic point at a 
concentration of O.5M NaCl. However, for some compounds, there was no clear 
isosbestic point at a concentration of O.05M NaCl. This is consistent with the previous 
observation that mitoxantrone loses isosbestic properties below a concentration ofO.1M 
NaCl, particularly at higher DNA to drug ratios (Lown et ai, 1985, Kapuscinski & 
Darzynkiewicz, 1985). This has also been observed for daunomycin-DNA complexes 
(Chaires et ai, 1982). It would appear that at lower ionic strengths, there are various 
drug forms in equilibrium in solution due to other DNA-drug binding modes (Monnot et 
ai, 1991; figure 2.22). Firstly, the drug molecule can bind to the exterior of the DNA 
helix. This involves electrostatic interaction of the alkylamino side chains with the DNA 
phosphate backbone. Secondly, when the exterior of the DNA helix becomes saturated, 
further drug molecules can associate with those which are already surface bound via 
hydrophobic-hydrophobic interactions, in a process referred to as "stacking". 
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Figure 2.22: Three site binding model showing (A) intercalation, (B) external binding 
and (C) self association for ellipticine derivatives with poly[ d(A-T)]. Bis-substituted 
alkylaminoanthraquinones such as mitoxantrone probably display similar behaviour. 
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Surface binding and/or stacking would account for the fact that the isosbestic 
point was lost particularly at lower DNA:drug ratios, where there would be limited 
intercalation sites available for drug binding. Clear isosbestic points were seen at higher 
ionic strengths (0.5M) because the DNA surface was neutralized by Na+ ions, 
preventing electrostatic DNA-drug interactions even at higher drug concentrations (see 
Jones et ai, 1980). 
The fact that the disappearance of the isosbestic point was more evident in the 
compounds containing both side chain and chromophore hydroxy groups (particularly 
AQ11, which contains six OH groups) would suggest that surface binding and stacking 
are encouraged by these groups. Surface binding may result from hydrogen bonding 
between the side chain hydroxyl groups of the drug and the phosphate oxygen groups of 
DNA (Pohle et ai, 1990). The presence of hydroxy groups at the 5 and 8 positions of the 
chromophore appears to influence their degree of stacking by encouraging the formation 
of dimers and perhaps higher aggregates. This has been demonstrated with 
mitoxantrone, which has more than a 4-fold higher dimerization constant than 
ametantrone (Kapuscinski & Darzynkiewicz, 1985). Surface binding and stacking have 
both been suggested as reasons for the difference in potency of the two drugs (see 
section 1.2.2). However, as only the monomer should be taken into consideration in the 
intercalation process as proposed by Lerman (1961), an isosbestic point was essential 
for the determination of K and n. 
All compounds were found to have DNA binding constants in the 106 M-1 range, 
consistent with intercalation as the mode of DNA binding (Kapuscinski et ai, 1981; 
Kapuscinski & Darzynkiewicz, 1985; Lown et ai, 1985). At the ionic strength under 
which the K and n values were determined, external binding of the ligand to sugar-
phosphate backbone was effectively precluded, so that intercalation was the only 
binding mode. It was anticipated that this may have a small lowering effect on the 
binding constant due to reduced interaction of the alkyl amino side chains of the 
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intercalated drug with the DNA phosphate backbone. Overall, the K values for 
ametantrone and its congeners were found to be lower than for mitoxantrone and its 
congeners, indicating a diminished affinity for DNA, associated with the absence of 
hydroxy groups at the 5 and 8 positions. However, the K value for ametantrone was 
higher than for the other non-hydroxylated analogues, AQ12 and AQI6, which can 
probably be attributed to the presence of the 2'-(hydroxyethylamino)-ethylamino side 
chains. Other than this, variations in the groups terminal to the aliphatic amino group of 
alkylamino side chains did not significantly affect binding to DNA, as long as the 
cationic nature was maintained. This has previously been found to be the case with 
respect to the dissociation rates of alkylaminoanthraquinone-DNA complexes even 
when the alterations in side chain structure are relatively large, for example, 
introduction of morpholino or other groups terminal to the aliphatic amino group 
(Denny & Wakelin, 1990). 
The different K values obtained for mitoxantrone and ametantrone and their 
respective analogues may relate to differences in their binding kinetics. As K is an 
equilibrium constant, it will be affected by the rate at which drug molecules associate 
with, and dissociate from, DNA. While no significant difference has been found 
between the association rates of drugs such as mitoxantrone and ametantrone with 
DNA, the 5,8 hydroxy groups of the mitoxantrone chromophore have been found to 
contribute to a three- to four-fold retardation in the overall dissociation process 
compared to ametantrone (Lown et aI, 1985; Denny & Wakelin, 1990). Thus, it could 
be argued that the slower dissociation rate of the 5,8-dihydroxylated analogues from 
DNA is responsible for their higher K values. It has been proposed that the release of 
mitoxantrone from the drug-DNA complex is hindered by the bulkiness of the 5,8 
hydroxy groups, which protrude through the helix almost to the opposite groove, and 
therefore must pass through the helix as the drug disengages (Denny & Wakelin, 1990) 
Furthermore, intramolecular hydrogen bonding between the 5,8 dihydroxy groups and 
the carbonyl groups of the anthraquinone ring, by increasing the overalllipophilicity of 
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mitoxantrone compared to ametantrone, will prolong retention of the mitoxantrone 
chromophore in the hydrophobic interior of the double helix (Patterson, 1993). 
However, more recently, another explanation for the higher DNA binding affinity of 
mitoxantrone has been proposed using molecular dynamics simulations (Mazerski et ai, 
1998). It is surmised that due to the presence of the 5,8 OR groups, the mitoxantrone 
molecule is significantly wider than that of ametantrone, and as a result, lies in a more 
coplanar orientation within the intercalation site, increasing its interaction with the base 
pairs. This would make the DNA-drug complex formed by mitoxantrone more 
energetically favourable. 
The rate of DNA-drug dissociation is likely to be important in determining the 
cytotoxic activity of the alkylaminoanthraquinones, as slower dissociation of drug from 
DNA is likely to increase the probability of disrupting essential processes such as DNA 
replication and transcription (Safa et ai, 1983; Safa & Tseng, 1984) and topoisomerase 
II inhibition. This may account for the relatively high biological potency of 
mitoxantrone both in vitro (Evenson et ai, 1979; Locher & Meyn, 1983) and in vivo 
(Johnson et ai, 1979; Krapcho et ai, 1991) compared to ametantrone. In support of this, 
several previous studies have indicated that slower DNA-drug dissociation correlates 
with an increase in antitumour activity of DNA intercalating agents (Feigon et aI, 1984, 
Wakelin et aI, 1987). Moreover, ring hydroxylation has also been shown to increase the 
potency of other anthraquinone-based agents, e.g. the anthrapyrazoles (Showalter et 
al,1987). 
Although Kapuscinski & Darzynkiewicz (1985) have reported a higher affinity 
constant for ametantrone than for mitoxantrone with calf thymus DNA, these data were 
obtained by the reverse titration method (DNA titrated with drug) and thus can not be 
directly compared to the results obtained in this study. In addition, their experiments 
were carried out at the lower ionic strength of O.15M NaCl. Their reasoning for reverse 
titration was that the existence of high DNA:drug ratios may encourage DNA 
condensation. However, DNA condensation was not observed in this study, perhaps due 
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to the high ionic strength used. 
Scatchard analysis assumes independent (non-interacting) drug binding sites. 
However, the n values in particular may be influenced by binding of other drug 
molecules to DNA. The site exclusion (nearest-neighbour exclusion) model, describes a 
process whereby the binding of a drug molecule to one site is thought to influence the 
binding of subsequent molecules. In particular, subsequent drug molecules are excluded 
from binding at adjacent or nearby sites, either by physical blocking or steric alterations 
in the DNA (Crothers, 1968; McGhee & von Hippel, 1974). In addition, it is also 
possible that electrostatic interactions induced between the drug and DNA base pairs 
upon intercalation result in an alteration in charge distribution on the base pairs, such 
that intercalation of further molecules is less favourable. Computer graphics modeling 
indicates that the drug side chains are capable of forming hydrogen bonds not only with 
neighbouring nucleotides but also more distant ones, which would discourage binding 
of another drug molecule at these sites (Rehn & Pindur, 1996; Mazerski et ai, 1998). 
Site exclusion means the n value for intercalation is usually a maximum of ~0.43 
drug molecules per DNA base pair, as determined from theoretical calculations. This 
has been verified experimentally. The n values of 0.12-0.14 obtained in this study are 
consistent with the site exclusion model, but are lower than those obtained by 
Kapuscinski & Darzynkiewicz (1985) and Lown et al (1985). One explanation for this is 
that while K values are more accurate at higher DNA:drug ratios, the value of n will be 
more accurate at lower DNA:drug ratios. However, both K and n were calculated at the 
higher DNA:drug ratios (figures 2.7 to 2.10). Calculation of n at lower DNA:drug ratios 
gave n values ~0.2-0.3 (results not shown). 
All parent compounds were found to stabilize calf thymus DNA against thermal 
denaturation, as previously observed for mitoxantrone and ametantrone (Johnson et al. 
1979). In agreement with their higher K values, the 5,8 dihydroxylated anthraquinones 
caused greater increases in Tm than the non-hydroxylated compounds, indicating their 
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greater affinity for DNA. The slightly lower Tm values of AQll and AQ12 compared to 
the other compounds may be due to the more bulky nature of the side chains, each 
containing four OH groups, which may cause steric hindrance at the intercalation site. In 
contrast to its parent compound, AQ4N caused less than a 2°C rise in Tm. This was 
probably due to lack of interaction of the alkylamino side chains with the DNA 
phosphate groups, preventing intercalation and thus stabilization of the melting process. 
As expected, AQ6N, where one cationic alkylamino side chain was retained, showed 
moderate increase in Tm. 
Generation of symmetrical first derivative plots for AQll and AQ12 was 
indicative of a uniform stabilization process. However, where first derivative plots were 
biphasic in nature (showing two absorbance maxima), this suggested a more complex 
denaturation process. Biphasic denaturation curves have previously been observed by 
Patel & Canuel (1978) for poly(dA-dT)-daunomycin complexes, and by Chaires et al 
(1982) for daunomycin-DNA complexes. Patel & Canuel have shown that the first of 
the two phases results from melting of DNA regions free of drug and that the second 
phase of melting occurs in the regions where the drug is bound to DNA. Alternatively, 
the biphasic melting of DNA in the presence of the alkylaminoanthraquinones may have 
resulted from faster dissociation of drug from A-T-rich sites than G-C-rich sites due to 
an increased rate of opening of A-T sites (Malhotra & Hopfinger, 1980). The reason for 
some drugs producing biphasic curves and others not is unclear, but it appears to be a 
function of side chain rather than chromophore variation as AQ 11 and AQ 12, which 
possess identical side chains at the 1 and 4 positions of the anthraquinone chromophore, 
were the only two parent compounds not to display this behaviour. 
In summary, the nature of the chromophore and side chains of the 
alkylaminoanthraquinones was seen to influence both their DNA binding affinity and 
. 
their involvement in topoisomerase II inhibition. Overall, the 5,8 dihydroxy compounds 
had increased DNA binding affinity compared to their non-hydroxylated analogues. 
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This is presumably due to the prolonged retention of the drug chromophore in the 
hydrophobic interior of the DNA helix. Modification of the terminal nitrogen on the 
alkylamino side chains to form an N-oxide resulted in a large decrease in DNA binding 
affinity and topoisomerase II inhibition. This demonstrates the importance of the 
cationic alkyl amino side chain in intercalative binding and also shows that DNA 
intercalation is a necessary prerequisite for topoisomerase II inhibition by DNA affinic 
agents. The presence of the two 2'-(hydroxyethylamino)ethylamino side chains of 
mitoxantrone enhanced its ability to inhibit topoisomerase II. This may be due to 
oxidation of the side chains to produce aldehyde intermediates which increase the 
longevity of the topoisomerase II-DNA cleavable complex by Schiffs base formation 
with the enzyme. This is investigated further in chapters 4 and 5. 
The discovery that subtle changes in drug structure can be used to alter drug 
activity suggested that it would be possible to synthesize other 
alkylaminoanthraquinones with modified side chains, which similar to the N-oxides, 
would show diminished activity compared to the parent compounds. In view of the 
increased potency inferred upon mitoxantrone by the presence of the 2'-
(hydroxyethylamino )-ethylamino side chains, a series of acetalanthraquinones was 
synthesized (see chapter 3). These compounds were designed with the rationale that 
they could be converted to their respective aldehydes, similar to the aldehyde 
intermediates believed to be generated in the conversion of mitoxantrone to its mono-
and dicarboxylic acids. In theory, the conversion of the acetalanthraquinones to 
aldehydes should increase their cytotoxic activity due to their propensity to undergo 
nucleophilic substitution to form Schiffs bases with intracellular targets. 
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CHAPTER 3: SYNTHESIS OF ACETAL- AND 
METHOXYMORPHOLINO- ANTHRAQUINONES 
3.1 INTRODUCTION 
The aim of the synthetic work was to make a series of compounds which could 
subsequently be converted, either chemically or metabolically, to aldehydes, similar to 
the proposed aldehyde intermediate of mitoxantrone. Two amines incorporating 0-
methyl groups were synthesized and substituted onto the anthraquinone moiety to form 
1-, 1,4-, and 1,5-substituted anthraquinones. 
3.2 METHODS AND MATERIALS 
Diphenylphosphinamide, N-[2-(2' -methoxymorpholinyl) ] ethanol and 2,3-dihydro-
1,4,5,8-tetrahydroxy-anthracene-9,10-dione were synthesised as described in appendix 
A3. All other chemical reagents were supplied by Sigma Chemical Co., Poole, Dorset, 
UK, and Aldrich Chemical Co., Gillingham, Dorset, UK, and were 98-99% pure. Silica 
gel 60 (20-45 microns) was purchased from Fisons, Loughborough, UK. 
Chromatography columns (~7cm diameter x 25 em length) were packed with 20 em of 
silica. Methanol was dried with magnesium turnings, and CH2Cb was dried with CaH2 
prior to use to remove any traces of water. Ultra violet and visible spectra were recorded 
on a Beckman DU70 spectrophotometer, infra-red spectra were recorded on a Nicolet 
205 FTIR spectrophotometer and nuclear magnetic resonance spectra were recorded on 
a Brucker AC250 NMR spectrometer at 250MHz. Mass spectra were performed at the 
Chemistry Department, University College of Swansea, Singleton Park, Wales and 
micro-elemental analysis was carried out at the Department of Chemistry, University of 
Manchester, UK. Melting temperatures were determined using Gallenkamp melting 
apparatus (Gallenkamp, Loughborough, UK). Amines were stored as methanolic 
solutions at 4°C. Acetalanthraquinones were stored in vacuo over P20S. Where 
abbreviations have been used for reagents, full names can be found in appendix A8. 
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3.2.1 SYNTHESIS OF ALKYLAMINO SIDE CHAINS 
3.2.1.1 SYNTHESIS OF 2-[N'-(2,2-DIMETHOXYETHYL)AMINO]ETHYLAMINE 
Bromoacetaldehyde dimethylacetal, 34g (0.2 mol), was added dropwise to 
diaminoethane 120g (2.0 mol) over 1 h, such that the temperature did not exceed 700C. 
The mixture was heated for a further 2-3 h, until the reaction was complete (monitored 
by thin layer chromatography in MeOHINH40H 9:1), cooled to room temperature and 
distilled at 0.5mmHg to remove unreacted diaminoethane. The HBr salt of 
diaminoethane was precipitated from the solution by the addition of CH2Cb, and 
separated from the product by filtration in vacuo. The CH2Cl2 was removed by rotary 
film evaporation and the product distilled at 2mmHg, collecting the fraction between 72 
and 74°C. The distillate was stored at 4°C. The yield was 14.0g (47%). 
M.S. 118 (M-30), 86 (M-62), 75 (M-73), 73 (M-75), 58 (M-90), 56 (M-92), 44 (M-l 04) 
NMR 2.7 (m, CH2 groups, 6H), 3.4 (s, -OCH3, 6H), 4.4 (t, -CH, IH). 
BP (OC) 72-74 at 2mmHg 
3.2.1.2 SYNTHESIS OF N-[2-(2' -METHOXYMORPHOLINYL)ETHYL ] AMINE 
A solution of21g (0.18mol) methanesulfonyl chloride, in 100 ml benzene, was 
added over 1 h to a refluxing mixture of25.9g diphenylphosphinamide (0.12 mol), 29g 
N-[2-(2' -methoxymorpholinyl)] ethanol (0.18 mol), 29g finely crushed NaOH (0.72 
mol), 50g K2C03 (0.36 mol), 8.2g tetra-n-butylaminium hydrogen sulfate (0.024 mol) 
and benzene (300 ml), and then stirred for a further 1 h at reflux. The mixture was 
cooled to room temperature, diluted with 150ml benzene and separated. The solid phase 
was dissolved in 350ml water and extracted with 350ml benzene. The benzene used for 
the extraction was combined with the organic phase and washed with water (4xl00ml) 
until neutral (tested with universal indicator paper), then dried over Na2S04 for 12 h. 
The benzene was removed by evaporation in vacuo and the resulting residue dissolved 
in tetrahydrofuran and bubbled with dry HCI gas for 15 min until the amine 
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hydrochloride precipitated. The THF was removed by evaporation in vacuo and the 
solid redissolved in methanol for storage. 
The free base was prepared by removing the methanol by evaporation in vacuo, 
dissolving the solid in 5% NaOH and extracting the amine into CH2Cb, removing the 
solvent by evaporation in vacuo. The yield was approximately 6g (crude product). 
3.2.2 SYNTHESIS OF ACETAL- AND MORPHOLINOANTHRAQUINONE 
DERIVATIVES 
3.2.2.1 SYNTHESIS OF 1-N-{2-[N'-(2,2-DIMETHOXYETHYL )AMINO]-
ETHYLAMINO }-ANTHRACENE-9, 1 O-DIONE (YCG 7) 
To 2-[N'-(2,2-dimethoxyethyl)amino]ethylamine, 3g (0.02 mol), was added 19 1-
chloroanthraquinone (0.04 mol), heated so that the temperature did not exceed 50°C. On 
disappearance of the starting material, monitored by thin layer chromatography (100% 
methanol), 50 ml of methanol was added and the components of the mixture were 
separated by flash column chromatography on silica gel (100% MeOH). Crude product 
was stored in methanol at 4°C for 24 h. The recrystallized product was filtered in vacuo, 
washed with methanol (2 x 100ml) and dried over P205 in vacuo. The yield was 0.9g 
(58%). 
M.P (OC) 94-95 
TLC Rf(CH2CI2/MeOH 9:1) 0.79 
IR (cm-I) 3300 (-NH), 2800-3000 (CH2), 1670 (quinone carbonyl), 1630 (quinone 
carbonyl, hydrogen bonded), 1600 (aromatic CH) 
IHNMR (ppm) (CDCI3) 2.8 (d, - CH2, 2H), 3.0 (t, - CH2, 2H), 3.4 (s, -0 CH3, 6H), 3.5 
(q, - CH2, 2H), 4.5 (t, -CH, 1H), 7.0-8.3 (m, aromatic -CH, 7H), 9.8 (t, aromatic -NH, 
IH). 
M.S 355 (M+ 1), major fragments at 292 (M-63), 238 (M-117), 118 
CHN C 68.1, H 6.2, N 7.9. Calculated for C20H22N204 C 67.8, H 6.3, N 7.9. 
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UV/vis (in MeOH) vis Amax 496nm (E= 8334M-1cm- I). UV Amax 242 nm 
(E=37620M-1cm- l ) 
3.2.2.2 SYNTHESIS OF 1,4-BIS-N-{2-[N'-(2,2-DIMETHOXYETHYL)AMINO]-
ETHYLAMINO}-ANTHRACENE-9,1 O-DIONE (YCG8) 
To 2-[N'-(2,2-dimethoxyethyl)amino]ethylamine, 6g (0.04 mol), was added Ig 
2,3-dihydro-1,4-dihydroxyanthracene-9,10-dione (0.004 mol). The mixture was heated 
under argon, so that the temperature did not exceed 50°C. When the reaction had gone 
to completion, followed by thin layer chromatography (CH2CblMeOH 4:6) the mixture 
was re-oxidized by stirring in air for 12 h. The reaction mixture was subjected to flash 
column chromatography on silica gel (CH2Cb/MeOH 4:6) and the major blue fraction 
was collected. After removing the solvents by rotary film evaporation, the resulting 
solid was re-chromatographed under the same conditions as before. The major blue 
fraction was again collected, the solvents removed by rotary film evaporation. The solid 
dried over P205 in vacuo. The yield was 19 (47%). 
M.P (OC) 60-61 
TLC Rf (CH2Cb/MeOH 9: 1) 0.44 
IR (cm-I) 3300 (-NH), 2800-3000 (CH2), 1610 (quinone carbonyl, hydrogen bonded), 
1590 (aromatic CH) 
IHNMR (ppm) (CDCI3) 2.8 (d, - CH2, 4H), 3.0 (t, - CH2, 4H), 3.4 (s, -0 CH3, 12H), 
3.5 (m, - CH2, 4H), 4.5 (t, -CH, 2H), 7.7 (m, aromatic H, 3H), 8.3 (m, aromatic H, 3H), 
10.8 (t, -NH,2H). 
M.S 501 (M+1), major fragments at 437 (M-63), 383 (M-117), 319 (M-180), 264 (M-
236),118 
CHN C 62.4, H 7.4, N 11.2. Calculated for C26H36N406 C 62.4, H 7.3, N 11.2 
UV/vis (in MeOH) vis Amax 636nm (E=17423M- Icm- I ). UV Amax 254nm 
(E=31427M- Icm-1). 
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3.2.2.3 SYNTHESIS OF 1,5-BIS-N-{2-[N'-(2,2-DIMETHOXYETHYL)AMINO]-
ETHYLAMINO}-ANTHRACENE-9,10-DIONE (YCG9) 
To 2-[N'-(2,2-dimethoxyethyl)amino ]ethylamine, 5.5g (0.037 mol), was added 
1,5-di-chloroanthraquinone, 19 (0.0036 mol) and the mixture heated in air such that the 
temperature did not exceed 50°C. On disappearance of the starting material, followed by 
thin layer chromatography (CH2CI2/MeOH 4:6), the reaction mixture was separated by 
flash column chromatography on silica gel (CH2C12iMeOH 4:6). The major pink 
fraction was collected and after removing the solvents by rotary film evaporation, the 
resulting solid was re-chromatographed under the same conditions as before. The major 
pink fraction was again collected, the solvents removed by rotary film evaporation and 
the product was dried over P205 in vacuo. The yield was 0.8g (42%). 
M.P (OC) 79-81 
TLC Rf (CH2Cb/MeOH 9: 1) 0.57 
IR (cm-I) 3300 (-NH), 2800-3000 (CH2), 1620 (quinone carbonyl, hydrogen bonded), 
1600 (aromatic CH) 
IHNMR (ppm) (CDCb) 2.8 (d, - CH2, 4H), 3.0 (t, - CH2, 4H), 3.4 (s, -0 CH3, 12H), 
3.5 (q, - CH2, 4H), 4.5 (t, -CH, 2H), 7.0 (d, aromatic H, 2H), 7.5 (m, aromatic H, 4H), 
9.8 (t, -NH,2H). 
M.S 501 (M+ 1), major fragments at 437 (M-63), 383 (M-117), 319 (M-180), 265 (M-
235), 118 
CHN C 59.8, H 7.3, N 10.9. Calculated for C26H36N406.1.25 H20 C 59.7, H 7.4, N 
10.7 
UV/vis (in MeOH) vis Amax 516nm (E=11360M-Icm- I). UV Amax 230nm (E= 
38400M- Icm- 1 ). 
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3.2.2.4 ATTEMPTED SYNTHESIS OF 1-N-{2-[N'-(2,2-DIMETHOXYETHYL)-
AMINO]ETHYLAMINO}-5,8-DIHYDROXY-ANTHRACENE_9,1 O-DIONE (YCG5) 
A solution of 2-[N'-(2,2-dimethoxyethyl)amino ] ethyl amine, 1 g (0.0068 mol). in 
methanol, was added to 19 of 2,3-dihydro-1,4,5,8-tetrahydroxyanthracene-9,1O-dione 
(0.0037 mol) under argon, and the mixture left to react at room temperature for 4 h. The 
mixture was then separated by flash column chromatography on silica gel 
(CH2Cb/MeOH 19:1). The fraction containing the major purple band was collected and 
the solvents removed by high vacuum distillation at 21°C. The solid was 
chromatographed again, under the conditions described above, and the major purple 
component collected. After removing the solvents by high vacuum distillation at 21°C, 
the compound was dried over P20S in vacuo. 
3.2.2.5 ATTEMPTED SYNTHESIS OF 1,4-BIS-N-{2-[N'-(2,2-DIMETHOXY-
ETHYL )AMINO]ETHYLAMINO} -5,8-DIHYDROXY -ANTHRACENE-9, 1 O-DIONE 
(YCG6) 
To 11g 2-[N'-(2,2-dimethoxyethyl)amino]ethylamine (0.074 mol) under argon, 
was added 19 of2,3-dihydro-1,4,5,8 tetrahydroxyanthracene-9,1 O-dione (0.0037 mol) 
and left to react in the dark for 24 h at 21°C. The resulting mixture was then subjected to 
flash column chromatography on silica gel (CH2CblMeOH 19:1). The eluent containing 
the major blue band was collected and the solvent removed by high vacuum distillation 
at 10°C. The resulting material was further separated by flash column chromatography 
on silica gel (CH2Cb/MeOH 19:1). The major blue band was retained and the solvents 
removed as before. The resulting solid was dried over P20S in vacuo and stored at -
15°C in the dark. 
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3.2.2.6 ATTEMPTED SYNTHESIS OF 1,4-BIS-N-{[2-(2'-METHOXY-
MORPHOLINYL)ETHYL]AMINO}-S,S-DIHYDROXY-ANTHRACENE-
9,10-DIONE (YCG4) 
To 19 2,3-dihydro-1 ,4,S,S-tetrahydroxyanthracene-9, 1 O-dione under argon 
(0.0037 mol), was added S.Sg (0.036 mol) N-[2-(2' -methoxymorpholinyl)ethyl] amine, 
and left to react at SO°C for 12 h. The mixture was separated by flash column 
chromatography on silica gel (CH2Cb/TEA 99: 1). The major blue band was collected 
and the solvents removed by rotary film evaporation. The resulting solid was re-
chromatographed on silica gel (CH2Cbl TEA 99:1). The major blue fraction was 
retained, the solvent removed by rotary film evaporation and the solid dried over P20S 
in vacuo. The yield was 42mg (2%). 
3.3 RESULTS AND DISCUSSION 
3.3.1 SYNTHESIS OF ALKYLAMINO SIDE CHAINS 
2-[ N' -(2,2-dimethoxyethyl)amino] ethylamine 
N -[2-(2' -methoxymorpholinyl)ethyl] amine 
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By design, the amines synthesized were potential substrates for acid-catalyzed 
hydrolysis, and thus certain precautions had to be taken during their preparation to 
protect the acetal groups. It was absolutely essential to dry all solvents, since silica gel, 
which was used in the separation of the acetalanthraquinones, is known to be a 
particularly convenient reagent for hydrolysis of acetals in aqueous environments (Huet 
et aI, 1978). It was also critical to monitor the temperature at which reactions were 
performed in order to avoid cyclization of the products. 
Reacting a large excess of diaminoethane with bromo acetaldehyde dimethylacetal 
achieved the synthesis of 2-[N'-(2,2-dimethoxyethyl)amino Jethylamine in relatively 
good yields. The bromo acetal was susceptible to nucleophilic substitution due to the 
electron withdrawing effect of the Br group, rendering the carbon atom to which it is 
attached 8+ and therefore readily attacked by nucleophiles. The reaction proceeds via 
the SN2 mechanism, with subsequent elimination of HBr (figure 3.1). A large excess of 
diaminoethane (x10) was used to minimize reaction of the acetal at both ends of the 
amme. 
diaminoethane 
HBr 
bromoacetaldehyde 
dimethyl acetal 
2-[ N'-(2,2-dimethoxyethyl)aminojethylamine 
Figure 3.1: Synthesis of2-[N'-(2,2~dimethoxyethyl)ami.noJ~thylamine by nucleophilic 
substitution of bromo acetaldehyde dImethyl acetal wIth diammoethane 
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Due to the potential of the product to undergo cyclization, the reaction was carried 
out below 70°C. As the reaction was exothermic, it was necessary to add the acetal to 
the base very slowly. The reaction was monitored by thin layer chromatography using 
MeOHINH40H 9:1. The product, detected with iodine, had an Rf of 0.37. On 
completion of the reaction, excess diaminoethane was immediately removed in vacuo in 
order to reduce the basicity of the environment, since basic conditions would tend to 
encourage cyclization of the product by localizing the lone pair of electrons on the 
primary amino group nitrogen of the product. Once the diaminoethane had been 
removed, the principal by-product of the reaction, the hydrogen bromide salt of 
diaminoethane, was precipitated with dichloromethane. Attempting to precipitate the 
salt before evaporating diaminoethane was found to require very large amounts of 
solvent. This was presumably due to the partial solubility of the salt in diaminoethane. 
Once obtained, the crude product was distilled at O.SmmHg and characterized by NMR, 
which verified its structure. The yield, approximately 47%, was probably lowered due to 
the evaporation of some of the product during the removal of the diaminoethane. 
Synthesis of N-[2-(2' -methoxymorpholinyl)ethyl] amine was achieved using a 
method devised by Slusarska & Zwierzak (1981) for the synthesis of primary amines. 
This involved conversion of the morpholino alcohol to its corresponding 
methanesulfonate, producing a particularly convenient leaving group in the mesylate 
moiety. This was necessary because of the poor leaving group character of the 
hydroxide anion, which meant that direct conversion of the alcohol into the primary 
amine could not be achieved via simple nucleophilic displacement. As the 
methane sulfonate was immediately used for the alkylation of diphenylphosphinamide, 
there was no apparent need to isolate it, so it was generated in situ in the reaction 
medium. This made the method particularly convenient as it allowed generation of the 
amine product from the starting material in one step (figure 3.2). 
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diethanolamine 
O-CH 3 
Br- CH2 - CH< 
O-CH 3 
bromoacetaldehyde 
dimethylacetal 
N -[2-(2' -methoxymorpholinyl)] ethanol 
THF/HCI 
diphenylphosphinic 
chloride 
diphenylphosphinamide 
N-[2-(2'-methoxymorpholinyl)ethyl]amine 
Figure 3.2: Synthesis of N-[2-(2' -methoxymorpholinyl)ethyl] amine by the method 
devised by Slusarska & Zwierzak (1981). 
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Due to easy deprotection of an amino function under mild conditions, degradation 
of the N-alkyldiphenylphosphinamide is usually achieved by a standard method, for 
example, using HCI. However, to protect the morpholino ring from acid-catalysed 
hydrolysis, the product was cleaved by dissolving in THF and passing dry HCI gas 
through the solution, generating a primary amine hydrochloride. 
Advantages of using this synthetic route were that it produced only the primary 
amine, rather than a mixture containing secondary or tertiary amines. The N-
alkyldiphenylphosphinamide product should have been formed in moderate yields 
(~50%) and high purity. However, this method resulted in a low product yield (~5%) 
and difficulty was encountered in attempting to separate the amine from the other 
reaction components. Prominent mass spectrum peaks were observed at 130 and 217 
(EI) suggesting the presence of unreacted alcohol and diphenylphosphinamide 
respectively. Although the peak at 130 could have been derived from the amine, this 
seems unlikely considering the low product yield and the presence of unreacted 
diphenylphosphinamide. Nevertheless, a minor peak was observed at 160, indicating the 
presence of a small quantity of the amine product. NMR also revealed the presence of 
the N-alkyldiphenylphosphinamide. 
As alkyl methanesulfonates are easily obtained from the corresponding alcohols in 
good yields under liquid-liquid phase-transfer catalysis conditions in benzene at room 
temperature (Szeja, 1979), the yield may have been improved by isolating the alkyl 
methane sulfonate and then adding diphenylphosphinamide to produce N-
alkyldiphenylphosphinamide (figure 3.3). 
III 
N-[2-(2'-methoxymorpholinyl)]ethanol methanesulphonyl 
chloride 
Hel 
diphenylphosphinamide methanesulphonate ester 
N -alkyldiphenylphosphinamide 
Figure 3.3: Synthesis of the methane sulfonate ester of N-[2-(2'-methoxy-
morpholinyl)]ethanol followed by N-alkylation to produce the N-alkyldiphenyl-
phosphinamide. 
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There are also a number of alternative routes for synthesizing primary amines (see 
March, 1985), which were not investigated. One other route that can be used to 
synthesize primary amines exclusively, i.e. without the formation of secondary amines, 
is the Gabriel synthesis. This involves treating potassium phthalimide with an alkyl 
halide, which is subsequently hydrolysed to yield the product (Gibson & Bradshaw. 
1968). Several other methods exist for synthesizing primary amines (see March, 1985) 
but like the Gabriel synthesis, these routes would have been considerably less 
convenient than the one used bearing in mind that the starting material was an alcohol. 
3.3.2 GENERAL SYNTHESIS OF ALKYLAMINOANTHRAQUINONES 
The synthesis of mono- and bis-substituted anthraquinones is based largely on 
aromatic nucleophilic substitution (SNar), generally described as the substitution of an 
electron withdrawing group which is attached to an aromatic nucleus by a group rich in 
electrons. There are two mechanisms by which nucleophilic substitution can proceed 
(see Fessenden & Fessenden, 1986). SN 1 reactions involve elimination of the 'leaving' 
group to generate a carbocation which subsequently combines with the nucleophile. SN2 
reactions, on the other hand, proceed via a bimolecular mechanism whereby the 
nucleophile and the leaving group attack and depart simultaneously. 
The electron withdrawing property of the carbonyl groups of the anthraquinones 
facilitates SN2 nucleophilic substitution of the aromatic nucleus by promoting 
delocalization of the positive charge across the three benzene rings (figure 3.4). For l-
and 1 ,5-substituted halo-anthraquinones, delocalization activates the aromatic nucleus to 
nucleophilic substitution by increasing the positive charge at the position on the ring to 
which the halogen is attached (figure 3.5). This produces monosubstituted and 1,5-bis-
substituted products respectively. However, for l,4-bis-substituted derivatives, 
displacement of the first halogen group is relatively easy but displacement of the second 
is much harder to achieve due to the electron inductive effect of the mono-amino 
substituent, which weakens the activating effect of the carbonyl group. 
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o 
o 0 
t 
o 0 
o 0 
Figure 3.4: Delocalization of positive charge within the anthraquinone ring system. 
Delocalisation is shown across only one ring and one of the quinone carbonyl groups. 
Charge is distributed in a symmetrical manner across the other ring and carbonyl group. 
o 
Figure 3.5: The electron withdrawing effect of the anthraquinone carbonyl group 
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A more productive alternative to 1 ,4-substituted halo-anthraquinones is quinizarin 
(1 ,4-dihydroxyanthraquinone). The reactivity of quinizarin is largely governed by its 
oxidation state. In its oxidized form, the electron withdrawing effect of the quinone 
carbonyl promotes substitution of a hydroxyl group to form the mono-substituted 
compound (Zee-Cheng et at, 1979; Kikuchi et at, 1982). This reaction only occurs on 
heating. However, on reduction, quinizarin is converted to the 2,3-dihydro (leuco) form 
which has been shown by NMR to assume the 1 ,4-dione-9, 1 O-dihydroxy configuration 
(Bloom & Hutton, 1963; Kikuchi et at, 1981). Leucoquinizarin undergoes nucleophilic 
substitution with amines far more readily than the parent quinizarin, producing both 
mono amino and diaminoanthraquinone derivatives. The proportion of these products is 
dependent upon the reaction conditions (Kikuchi et at, 1981). 
Condensation of leucoquinizarin with an excess amount of the appropriate amine 
generates a series of 1,4-bis-substituted anthracene-9, 1 O-dione derivatives (Stilmer & 
Perkins, 1955; Simon, 1963). These products have been shown to exist in the 
2,3-dihydro-l ,4-bis-alkylamino-9, 10-dione form, which revert to 1,4-bis-alkylamino-
anthraquinones upon oxidation (figure 3.6). Stirring in air is usually sufficient to 
achieve oxidation of the product, although alternatives such as chloroanil (Murdock et 
at, 1979) or alkaline solution (Cheng & Zee-Cheng, 1983) have been used. The l,4-bis-
substituted anthracene-9, 10-dione derivatives have a characteristic absorbance spectrum 
in the visible region of the spectrum with "-max values between 525 and 660nm (see 
section 2.3.2.2) and hence appear blue in solution. As anthraquinone starting materials 
usually have different absorbance spectra to their substituted products, the progression 
of the reaction can be monitored relatively easily using thin layer chromatography. It is 
also possible to determine the position of substitution on the chromophore as the colour 
change is characteristic of the particular substitution pattern. 
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OH OH 
OH OH 
H 
OH OH NH-R 
OH OH NH-R 
OH 
... 
OH N-R 
H 
o NH-R o NH-R 
o NH-R o NH-R 
Figure 3.6: Reaction scheme showing the synthesis of 1,4-bis-substituted derivatives 
from 1,4-dihydroxyanthraquinone. A similar mechanism operates for the formation of 
1- and 1,4-substituted compounds from 1,4,5,8-tetrahydroxy-anthraquinone. 
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Mitoxantrone can be synthesized from the dihydro form of 1,4,5,8-tetrahyroxy-
anthracene-9,10-dione (5, 8-dihydroxy -quinizarin) and hydroxyethy laminoethy lamine. 
Other 5,8-dihydroxylated analogues can be produced in the same way using N-alkyl-
1,2-diaminoethane derivatives. On performing reactions at or below 50°C, 
1,4-bis-aminoalky lamino-anthracene-9, 1 O-dione derivatives are formed exclusi vel y. 
However, under vigorous conditions (lOO°C), a side reaction occurs, involving 
cyclization of one of the side chains to form 6-aminoalkylamino-l,2,3,4-
tetrahydronaphtho(2,3 -f)quinoxaline-12-dione (TN Q) (figure 3.7) . It appears that 
anthraquinones with hydroxy-substituted chromophores are more susceptible to TNQ 
formation due to the hydroxy groups initiating a Michael-type cyclization reaction 
(Krapcho et aI, 1991) as are compounds containing a terminal amino group which is 
either primary or secondary (e.g. mitoxantrone) rather than tertiary (Cheng & Zee-
Cheng, 1983). 
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o OH 
I 
o 
:NH-R 
l~ 
o 
OH 
o OH 
Figure 3.7: Reaction scheme showing nucleophilic substitution of leucoquinizarin with N-
alkyl-l,2-diaminoethane derivatives, followed by cyclization to produce the 
tetrahydronaphthoquinoxaline (TNQ) derivative at higher temperatures. 
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3.3.3 SYNTHESIS OF ACETALANTHRAQUINONES 
YCG4 
YCG5 R1=H, R2=R3=OH 
YCG6 Rl=NHCH2CH2NHCH2CH(OCH3h, R2=R3=OH 
YCG7 Rl=R2=R3=H 
YCG8 Rl=NHCH2CH2NHCH2CH(OCH3h, R2=R3=H 
YCG9 R2=NHCH2CH2NHCH2CH(OCH3h, Rl=R3=H 
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The amines were substituted onto the anthraquinone chromophore to give 1-, 1.4-
and 1 ,5-substituted acetalanthraquinones. Considering the possible cyclization of the 
products to form substituted TNQs, all anthraquinones were synthesized at temperatures 
below 50°C. 
Synthesis of 1-N- {2-[N'-(2,2-dimethoxyethyl ) amino ] ethy lamino } -anthracene-
9, 1 O-dione was achieved by nucleophilic substitution of 1-chloroanthraquinone with 2-
[N'-(2,2-dimethoxyethyl)amino ] ethyl amine for 9 h. The reaction was monitored by thin 
layer chromatography using methanol, the more polar, orange-red product having a 
lower Rf than the yellow starting material. On completion of the reaction, it was 
desirable to remove the excess amine. This would usually be achieved by vacuum 
distillation. As this was not possible without heating above 50°C, since it presented the 
risk of cyclization of the product, flash column chromatography in methanol was used 
and the excess amine remained on the baseline. Upon storing the fraction containing 
anthraquinone product at 4°C overnight, it was found that the product recrystallized 
from methanol. Recrystallization was therefore used to purify all subsequent 
preparations of the compound. The drug structure was verified by all analytical data (see 
section 3.2.2.1 and appendix A4). 
Synthesis of 1,4-Bis-N-{2-[N'-(2,2-dimethoxyethyl)amino ] ethyl amino }-
anthracene-9,10-dione was carried out by nucleophilic substitution of leucoquinizarin 
with a large excess of 2-[N'-(2,2-dimethoxyethyl)amino ]ethylamine. Reoxidation of 
leucoquinizarin to quinizarin was prevented by bubbling the amine with argon for 30 
min prior to addition of the anthraquinone and continuously throughout the reaction. 
The progression of the reaction was monitored by thin layer chromatography using a 
CH2Cb/methanol4:6 mixture, the characteristic 1,4 di-substituted purple-blue product 
being more polar than the starting material. After reacting for 8 h, the mixture was 
stirred vigorously in air overnight to oxidize the product. Flash column chromatography 
using a mixture of CH2Cb and methanol (4:6) was performed to remove the excess 
amine, which remained at the base line. 
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Attempts to recrystallize the product from various combinations of solvents 
including CH2Cb, methanol, ethyl acetate, chloroform, acetone and butanone proved 
unsuccessful, and as higher alcohols could not be used in case they displaced the 
methoxy groups of the side chains, the product was isolated by flash column 
chromatography. The drug structure was verified by all analytical data (see section 
3.2.2.2 and appendix A4). 
Synthesis of 1 ,5-Bis-N-{2-[N'-(2,2-dimethoxyethyl)amino ] ethyl amino }-
anthracene-9,10-dione was achieved by nucleophilic substitution of 1,5-
dichloroanthraquinone with a large excess of2-[N'-(2,2-dimethoxyethyl)amino]-
ethylamine for 9 h. The reaction was monitored by thin layer chromatography using a 
CH2Cb/methanol4:6 mixture, which showed the conversion of the pale yellow, 
relatively non-polar starting anthraquinone into a more polar pink-red product. A minor 
band, slightly pinker than the major product was also formed, probably the mono-
substituted 5-chloro derivative. After removing the excess amine by flash column 
chromatography, attempts were made to recrystallize the product. However, as for the 
1,4-bis substituted compound, these failed, and so again, the flash column 
chromatography was chosen as the method of isolation, using a mixture of CH2Cb and 
methanol (4:6). The drug structure was verified by all analytical data (see section 3.2.2.3 
and appendix A4). 
While the synthesis of the non-hydroxylated derivatives was relatively straight 
forward, synthesis of the 5,8-dihydroxylated compounds proved more difficult. 
Synthesis of I-N-{2-[N'-(2,2-dimethoxyethyl)amino ] ethyl amino }-5,8-dihydroxy-
anthracene-9,10-dione was attempted by nucleophilic substitution of2,3-dihydro-
1 ,4,5,8-tetrahydroxyanthracene-9, 1 O-dione with 2-[N'-(2,2-
dimethoxyethyl)amino ] ethyl amine, using a 2: 1 molar ratio of starting materials and 
methanol as solvent. The relatively low proportion of amine, added slowly to the 
anthraquinone, and the presence of solvent should have favoured the formation of the 
mono-substituted compound. Reoxidation of the starting material was prevented by 
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performing the reaction under argon. 
The reaction was initially performed at 50°C. After treatment with NaOH to re-
oxidise the mixture, this yielded a major purple product (-55%), a blue product (~35%) 
and a plum coloured compound (-10%) which were all more polar than the brown 
starting material (Rf 0.99). The presence of the blue and plum coloured impurities 
complicated the synthesis as they were very difficult to separate from the product and 
the hygroscopic nature of the reaction mixture made it particularly difficult to handle. 
An additional difficulty was the limitation in the combinations of solvents that could be 
used that did not include alcohols (other than methanol). In view of this, the reaction 
was subsequently performed at room temperature for 4 h. However, this yielded the 
same products in approximately the same proportions as before. After removing as 
many of the impurities as possible, the mixture was analysed. The mass spectrum of the 
reaction mixture showed major peaks at 149 (free amine), 403 (M+l), 419 and 447. It 
appears from this that the plum coloured impurity was the 2-substituted compound 
(M+ 1 =419). The peak at 447 may correspond to an asymmetrical 1,4-bis-substituted 
anthraquinone, substituted with 2-[N'-(2,2-dimethoxyethyl)amino ]ethylamine at one 
position and diaminoethane at the other. This was probably a component of the blue 
impurity seen, which may have been a mixture of several compounds. 
Synthesis of 1 ,4-Bis-N-{2-[N'-(2,2-dimethoxyethyl)amino ] ethyl amino }-5,8-
dihydroxy-anthracene-9,1 O-dione was attempted by nucleophilic substitution of2-[N-
(2,2-dimethoxyethyl)amino ] ethyl amine and 2,3-dihydro-l ,4,5,8-
tetrahydroxyanthracene-9, 10-dione in a molar ratio of 20: 1, the large excess of amine 
promoting the formation of the di-substituted compound. Synthesis was initially 
attempted by reacting 2,3-dihydro-l ,4-5,8-tetrahydroxyanthracene-9, 1 O-dione with the 
amine under argon at 50°C for 8 h. 
After re-oxidation of the mixture with NaOH, and flash column chromatography 
using a 19: 1 CH2Cl2/methanol mixture, several components were detected. These were 
a major blue product (800/0) and several other blue compounds (lower Rfvalues than the 
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major product) all being more polar than the brown starting material (Rf 0.99). The 
similar polarity of the compounds made their separation extremely difficult. In addition, 
it was thought that the product may have cyclized to form a substituted TNQ and it was 
therefore decided to carry out the reaction at room temperature for 24 h. This yielded the 
major blue product and one minor blue product. At this stage, the mixture appeared 
stable. The major blue product was isolated by flash column chromatography. However, 
this resulted in the array of blue compounds previously formed. The impurities 
comprised approximately 5% of the total material. The product was dried and stored 
over P205 in vacuo but proved unstable, the impurities increasing to ~40-50% within 
72 h. Further attempts to purify the compound, which was then stored at -15°C, still 
failed to achieve stability. Nevertheless, the impure mixture had characteristic visible 
absorbance spectrum of 1,4-bis-substituted-5,8-dihydroxy anthraquinone and its mass 
spectrum generated a molecular ion compatible with the required structure (M+ 1 =533), 
suggesting the product was present. Other peaks were detected at 149,279 and 391. 
Degradation of YCG6 may have occurred as a result of substitution of one of the 
side chains onto the 2-position of the anthraquinone chromophore, to form a substituted 
TNQ. However, while this process is known to be enhanced by the presence of hydroxy 
groups at the 5 and 8 positions of the anthraquinone ring, which initiate a Michael type 
reaction (see section 3.3.2), it usually occurs at temperatures above 50°C, and the array 
of impurities formed at 50°C were also seen when the reaction was carried out at room 
temperature. Furthermore, in all probability, the cyclized product would be of a different 
polarity and colour to the non-cyclized drug (Blanz et ai, 1991a; Mewes et ai, 1993) and 
thus would be easily distinguishable by thin layer chromatography. Alternatively, the 
drug may have polymerized, via reaction of the side chains, either inter- or intra-
molecularly. However, again, such products would be markedly different from YCG4 
and thus clearly visible by thin layer chromatography. Finally, degradation may have 
resulted from hydrolysis of the acetal groups or cyclization of the side chain(s) although 
neither of these occurred in the synthesis of the non-hydroxylated analogues. 
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Furthermore, cyclization is less likely to occur once the amine is attached to the 
anthraquinone ring as the lone pair of electrons on the amine nitrogen become more 
delocalized. Thus, side chain hydrolysis appears to be the only feasible explanation. 
This is supported by the multiple components of similar nature revealed by thin layer 
chromatography, which suggest a process in which several compounds analogous to the 
acetal anthraquinone were generated (see section 4.3.2). To test this hypothesis, the 
compound was hydrolysed in O.1M HCI for 10 min at room temperature. This produced 
an increase in all three impurities, supporting degradation of the acetal groups. It 
appears that hydrolysis was promoted by the silica used during flash column 
chromatography, as the compound was stable until this was carried out. 
Crude N-[2-(2' -methoxymorpholinyl)ethyl] amine was reacted with 2,3-dihydro-
1,4,5,8-tetrahydroxyanthracene-9,10-dione in an attempt to produce 1,4-Bis-N-{[2-(2'-
methoxymorpholinyl)ethyl] amino }-5,8-dihydroxy-anthracene-9, 1 O-dione. Synthesis 
was achieved by heating an excess of the amine mixture with the anthraquinone under 
argon for 12 h. The reaction, monitored by thin layer chromatography using a 99:1 
CH2Cl2/TEA mixture, revealed one major blue compound (RfO.72) which was more 
polar than the brown starting material (Rf 0.99) and several colourless impurities, 
detected using iodine and ninhydrin. The major blue compound, assumed to be the 
required product, was collected by flash column chromatography using a mixture of 
CH2Cl2 and TEA (99: 1). After removing silica and solvents and drying in vacuo over 
P20S, analysis of the material by thin layer chromatography revealed several of the 
colourless impurities were still present, and these subsequently proved impossible to 
separate from the anthraquinone product. One reason for the difficulty in removing 
these impurities was that there were several of them, each with different chemical 
properties. Another reason was the potential instability of the morpholino ring in acidic 
environments, which excluded the use of many reagents for separation/purification. The 
low yield (~2%) prevented full analysis of the compound but analysis by mass 
spectrometry indicated peaks at 130, 144 and 556 (M+ 1) (see appendix A4). The peaks 
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at 130 and 144 may have corresponded to either unreacted morpholino alcohol or 
fragments of amine. In addition, the mixture had characteristic visible absorbance 
spectrum of 1 ,4-bis-substituted-5,8-dihydroxy anthraquinone, with a Amax of 674nm 
(see section 2.3.2.2). The compound appeared to be of a relatively lipophilic nature 
compared to other l,4-bis-substituted anthraquinones. This is consistent with the more 
lipophilic nature of morpholino doxorubicin and methoxymorpholino doxorubicin 
compared with the parent compound doxorubicin (Acton et ai, 1984; Facchetti et ai, 
1991; Ripamonti et ai, 1992). 
As the 5,8-dihydroxylated compounds could not be isolated in a pure form, only 
the non-hydroxylated analogues (YCG7, YCG8 and YCG9) were used to investigate the 
potential conversion of acetal-containing anthraquinones to their corresponding 
aldehyde derivatives. 
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CHAPTER 4: CHEMICAL AND METABOLIC 
ACTIVATION OF ACETALANTHRAQUINONES 
4.1 INTRODUCTION 
Having synthesized the acetalanthraquinones, the purpose of this study was to 
investigate possible chemical and metabolic routes that could be used to yield their 
respective aldehyde derivatives. With this objective in mind, acid-catalysed hydrolysis 
of the acetalanthraquinones was studied at various temperatures and the physico-
chemical parameters of the reaction were then determined. Oxidative metabolism by 
NADPH-fortified mouse liver microsomes in vitro was also investigated. 
4.2 METHODS AND MATERIALS 
Acetalanthraquinones were synthesized as described in sections 3.2.2.1-3.2.2.3. 
Balb C mouse liver micro somes from 6-8 week old mice, in 100mM Tris-HCI buffer, 
pH 7.4, were supplied by the Cancer Research Campaign, Beatson Labs, University of 
Glasgow, UK. Details of the spectral determination of the cytochrome P-450 content of 
these microsomes can be found in appendix A5. Solvents were supplied by Fisons, 
Loughborough, UK and were HPLC grade. All other reagents were supplied by Sigma 
Chemical Co., Poole, Dorset, UK and Aldrich Chemical Co., Gillingham, Dorset, UK, 
unless otherwise stated and were 98-99% pure. DMSO was spectrophotometric grade. 
The activity ofNADPH was verified by absorbance measurement at 260nm and 340nm 
at pH10. A260:A340 = 2.27:1, in exact accordance with the value obtained by Sigma 
Chemical Co. Phosphate buffer for the HPLC mobile phase consisted of a mixture of 
Na2HP04 (O.lM) and KH2P04 (O.lM) pH 7.4. Where abbreviations have been used for 
reagents, full names can be found in appendix A8. 
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4.2.1 SEP ARA TION OF ACETALANTHRAQUINONES AND VALIDATION OF 
THE HPLC SYSTEM 
Solutions of acetalanthraquinone ranging in concentration from lOOIlM -1 mM in 
O.lM HCI were neutralized with an equal volume ofO.lM NaOH and 50111 samples of 
the resulting mixture analysed by HPLC. The HPLC system consisted of a Walters 501 
millipore pump, Walters 484 tunable absorbance detector and Spectra Physics data jet 
integrator, fitted with a reversed phase, C18, lOllm nucleosil column (250mm length x 
4.6mm internal diameter). Samples were injected using a valve mechanism manual 
injection port (reodine) fitted with a 20111 capacity loop. The flow rate of the mobile 
phase (O.lM phosphate buffer, pH 7.4/ CH3CN 1:1 v/v) was 2mllmin. This was 
degassed by sonication for 30 min before use. 
Chromatograms were monitored at both the UV "-max and visible "-max of the 
drugs (254 and 499nm for YCG7, 260 and 627nm for YCG8 and 232 and 519nm for 
YCG9). The peak areas obtained were then plotted against drug concentration to ensure 
linearity. The average peak area at each drug concentration was also determined and the 
mean ± sd calculated to ensure consistency of the HPLC method. 
4.2.2 CHEMICAL HYDROLYSIS OF ACETALANTHRAQUINONES 
Solutions of drug (ranging in concentration from 100IlM-lmM) in O.lM HCI, 
were heated to 90°C in sealed Eppendorftubes for 0-360 min. Drug in double distilled 
water at pH 7.4, heated to 90°C for 360 min, and drug in O.lM HCI, maintained at 37°C 
for 360 min, were also set up as controls. At intervals of 15 min, 50111 of each test 
solution was removed, neutralized with 50111 of acetone-ice-cold NaOH (O.IM) and 
analysed by HPLC, as described in section 4.2.1. The procedure was repeated at 
temperatures of 70°C and 80°C, monitoring the samples at regular intervals. The 
disappearance of the parent peak over the range of temperatures and drug concentrations 
was used to calculate the rate of hydrolysis and activation energy of the reaction for 
each compound. 
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4.2.3 OXIDATIVE METABOLISM OF ACETALANTHRAQUINONES 
A homogeneous suspension of Balb C mouse liver microsomes (final 
concentration 1 mgml- l ) was added to Erlermeyer flasks containing acetalanthraquinone 
(1mM) and NADPH (O.IM in phosphate buffer, pH 7.4) such that the total volume was 
500111 (control flasks contained phosphate buffer instead ofNADPH). The solutions 
were incubated in a shaking water bath at 37°C for 60 min. Following this, 200lli of 
each incubate was removed and added to an equal volume of acetone-ice-cold 
acetonitrile to terminate the reaction. The resulting mixture was centrifuged at 14 000 x 
g for 15 min (A14 microcentrifuge, Jouan Ltd., Milan, Italy) to spin down microsomal 
protein, and the supernatant analysed by HPLC, as described in section 4.2.1. The rate 
of metabolism of each acetal anthraquinone (nmolmg- l min- l ) was determined from the 
percentage loss of the parent compound. The effect of boiled microsomes on the 
acetalanthraquinones in the presence and absence ofNADPH was also investigated. 
4.3 RESULTS 
4.3.1 VALIDATION OF THE HPLC SYSTEM 
The HPLC system was found to be suitable for all drugs used. The relationship 
between peak area (measured at the "-max of the drug in the UV region) and drug 
concentration (1 OOIlM-lmM) was found to be linear (figures 4.1 to 4.3). The average 
peak area for each drug concentration was also determined and the standard deviations 
were found to be between 2.7 and 6.1 % for YCG7, 4.7 and 14.3% for YCG8 and 3.1 
and 4.3% for YCG9. 
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Figure 4.1: Relationship between peak area and drug concentration 
for YCG7. Values shown represent the mean ± sd of three separate 
experiments. 
180 
-In 
150 
::: 
c: 
::::J 
>- 120 
... 
ca 
-:0 
... 90 ca 
-ca 
CI) 
... 
ca 60 
~ 
ca 
CI) 
0- 30 
0 
0 200 400 600 800 1000 
drug concentration (JlM) 
Figure 4.2: Relationship between peak area and drug concentration 
for YCG8. Values shown represent the mean ± sd of three separate 
experiments. 
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4.3.2 CHEMICAL HYDROLYSIS OF THE ACETAL-ANTHRAQUINONES 
The retention times for ametantrone, YCG7, YCG8 and YCG9 were 3.05, 8.40, 
7.63, and 6.56 min respectively (figures 4.4A to 4.6A). Due to its low solubility in water 
and acid, it was necessary to dissolve YCG7 in a small amount ofDMSO (l % final 
concentration) before dissolving in aqueous solvents. This produced a peak at 1.44 min. 
Acid-catalysed hydrolysis ofYCG7 in O.IM HCI between 70 and 90°C produced 2 
peaks in addition to the acetalanthraquinone, with retention times of 4.78 and 2.36 min 
(figures 4.4B and 4.4C). Hydrolysis of YCG8 produced 3 peaks in addition to the 
acetal anthraquinone, with retention times of 5.21, 3.00 and 2.03 min (figures 4.5B and 
4.5C). Hydrolysis of YCG9 also produced 3 peaks in addition to the 
acetal anthraquinone , with retention times of 3.37, 2.06 and 1.24 min (figures 4.6B and 
4.6C). The formation of all products increased with time. 
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Figure 4.4: HPLC chromatograms for YC07 after (A) 0 minutes, (B) 45 minutes 
and (C) 90 minutes incubation with O.lM HCI at 90°C. 
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Figure 4.5: HPLC chromatograms for YC08 after (A) 0 minutes, (B) 45 minutes 
and (C) 90 minutes incubation with O.1M HCI at 90°C. 
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Figure 4.6: HPLC chromatograms for YCG9 after (A) 0 minutes, (B) 45 minutes 
and (C) 90 minutes incubation with O.lM HCI at 90°C. 
In each case, detection was carried out at the UV "-max of the starting compound, 
in order to detect the formation of any colourless products (none were produced). While 
the absorbance spectra of the hydrolysed reaction mixtures and acetalanthraquinones 
were identical in the visible region of the spectrum, there was a noticeable difference in 
the UV region, particularly for YCG8, which showed a shift in "-max from 260.3 to 
250.1nm and a 3.3-fold increase in absorbance at that wavelength (figure 4.7) 
Ametantrone was refractory to hydrolysis under the above conditions, the parent 
peak remaining intact after a 3 h incubation period (results not shown). Ametantrone 
incubated at 37°C with 0.1M HCI for 3 h or heated to 90°C in water for 3 h was also 
stable. Similarly, acetalanthraquinones incubated at 37°C with O.1M HCI for 6 h or 
heated to 90°C in water for 6 h remained intact. Hydrolysis was absent at 37°C even 
with increased concentrations of acid (up to 1M). 
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Figure 4.7: UV-visibIe absorption spectrum for YCG8 (A) before and (B) 
after 4 hours incubation with O.lM HCI at 90°C. 
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4.3.3 PHYSICO-CHEMICAL PARAMETERS OF THE HYDROLYSIS 
REACTION 
The rate constants for the hydrolysis of the acetalanthraquinones at 70-90°C are 
shown in table 4.1. Hydrolysis rates were calculated from percentage loss of the parent 
compound at its Amax value in the UV region of the spectrum. Expression of the 
hydrolysis rate in terms of loss of the acetal anthraquinone meant that the slight 
differences in Amax value between the parent compounds and the products did not 
interfere with the calculation. 
Table 4.1: Rate constants and activation energies for the acetalanthraquinones 
DRUG E (KJrnol-1) 
yeG7 3.5±0.3 11.3 ± 0.9 34.0 ± 3.4 105.8 ± 7.4 
yeG8 5.0 ± 0.4 25.7 ± 3.4 56.0 ± 9.7 117.9±10.4 
yeG9 8.8±1.4 28.5 ± 5.7 75.5 ± 8.6 104.2 ± 6.2 
All compounds were hydrolysed in O.lM HCl. The rate constant (k) at each 
temperature was calculated from a plot of log a/a-x vs. t and the values shown 
represent k xl 04 (min- 1). Activation energies (E) were calculated from a plot of 
log k vs liT (see figures 4.8, 4.1 0 and 4.12). Values represent the mean ± sd for 
three separate experiments performed in triplicate. 
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The hydrolysis reaction was found to be temperature-dependent and follO\ved 
pseudo first order kinetics (see appendix A6 for details). 
For a first order reaction: 
log [a/(a-x)] = ktl2.303 
where a is the initial concentration of the reactant (drug) and x is the concentration of 
reactant utilized during time t of the reaction (Morris, 1985). A straight line plot of log 
a/(a-x) vs t was made in order to calculate the rate constant, k, by linear regression, 
where k = gradient of the line (m) x 2.303 (figures 4.8, 4.10 and 4.12). The apparent 
rates of hydrolysis were YCG9>YCG8>YCG7. However, the third product for YCG8 
appeared to form more quickly than the corresponding product for YCG9 (5.1 % ± 0.3 in 
90 min for YCG8 compared to 2.6% ± 0.4 for YCG9). 
The activation energies for the hydrolysis ofYCG7, YCG8 and YCG9 were 
calculated from the Arrhenius equation (Morris, 1985) as follows 
log k = log A - E/2.303R x liT 
where k is the rate constant, R is the gas constant, T is the temperature (in Kelvin) and A 
is the Arrhenius constant. The activation energy can be calculated by plotting log k vs 
liT (figures 4.9, 4.11 and 4.13). The slope of this line equals -E/2.303R; as 2.303R 
equals 19.14JK-lmol-l, the value of the activation energy can be determined from the 
Arrhenius plot as being equal to -(gradient of the line x 19.14) Jmol-1. The activation 
energies were found all to be in the same order: 105.8 ± 7.4, 117.9 ± 10.4 and 104.2 ± 
6.2 KJmol- 1 for YCG7, YCG8 and YCG9 respectively. 
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Figure 4.8: Rate constants (k) for the hydrolysis of YC07 at 70°C (0) 
80°C (e) and 90°C (~). Values shown represent the mean ± sd of three' 
separate experiments. 
1.8 
1.5 
1.2 
~ 
C) 0.9 -0 
0.6 
0.3 
0 
2.7 2.75 2.8 2.85 2.9 2.95 
1fT (Kelvin) 
Figure 4.9: Activation energy for the hydrolysis of YC07, calculated 
from the rate constants at 70°C, 80°C and 90°C. Values shown 
represent the mean ± sd of three separate experiments. 
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Figure 4.10: Rate constants (k) for the hydrolysis of YCG8 at 70°C (0) 
80°C (.) and 90°C (~). Values shown represent the mean ± sd of three ' 
separate experiments. 
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Figure 4.11: Activation energy for the hydrolysis of YCG8, calculated 
from the rate constants at 70°C, 80°C and 90°C. Values shown represent 
the mean ± sd of three separate experiments. 
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Figure 4.12: Rate constants (k) for the hydrolysis of YCG9 at 70°C (0) 
80°C (.) and 90°C (~). Values shown represent the mean ± of three ' 
separate experiments. 
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Figure 4.13: Activation energy for the hydrolysis of YCG9, calculated 
from the rate constants at 70°C, 80 °C and 90° C. Values shown 
represent the mean ± sd of three separate experiments. 
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4.3.4 OXIDATIVE METABOLISM OF THE ACETALANTHRAQUINO:\ES 
Incubation ofYCG7 with Balb C male mouse liver micro somes at 37°C for 60 
min in the presence ofNADPH produced 2 peaks, with retention times of7.94 and 3.21 
min, in addition to the acetal anthraquinone which had a retention time of 10.77 min 
(figure 4.14). Incubation ofYCG8 under the same conditions resulted in 3 peaks with 
retention times of 6.84, 4.14 and 2.70 min, in addition to the acetalanthraquinone. \\"hich 
had a retention time of 10.08 min (figure 4.15). Incubation ofYCG9 also resulted in 3 
peaks with retention times of 6.13,4.12 and 3.55 min, in addition to the 
acetalanthraquinone, which had a retention time of 9.26 min (figure 4.16). All products 
were detected in both the UV and visible regions of the spectrum. The visible 
absorbance spectra of the metabolite mixtures were identical to those of the 
acetalanthraquinones, demonstrating that the chromophore remained intact following 
metabolism (results not shown). No metabolism was detected when the drugs were 
incubated in the absence ofNADPH or when using boiled microsomes. Following 
centrifugation of the microsome-drug mixtures containing NADPH, the microsomal 
pellets were seen to be coloured, indicating the binding of drug to the microsomal 
protein. A small amount of this drug remained bound to the micro somes even on the 
addition of acetonitrile. This was not observed in the absence ofNADPH, suggesting 
the metabolites generated possessed an increased affinity for microsomal protein. For 
this reason, the percentage metabolism was calculated from the loss of parent 
compound, rather than product formed. The values obtained following a 60 min 
incubation period were 7.2 ± 0.6nmol-1mg- 1min- 1 (43.2% ± 3.9) for YCG7, 9.0 ± 
0.05nmol-1mg- 1min- 1 (54.0% ± 0.3) for YCG8 and 9.1 ± 0.2nmol-1mg-1min-1 (54.7% 
± 0.9) for YCG9. 
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Figure 4.14: HPLC chromatograms for YCG7 after 60 minutes incubation 
with Balb C mouse liver microsomes (A) -NADPH and (B) +NADPH. 
A B 
time (minutes) time (minutes) 
Figure 4.15: HPLC chromatograms for YCG8 after 60 minutes incubation 
with Balb C mouse liver microsomes (A) -NADPH and (B) +NADPH. 
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Figure 4.16: HPLC chromatograms for YCG9 after 60 minutes incubation 
with Balb C mouse liver microsomes (A) -NADPH and (B) +NADPH. 
4.4 DISCUSSION 
4.4.1 CHEMICAL HYDROLYSIS OF THE ACET ALANTHRAQUINONES 
While acetals are stable in non-acidic solution (Fessenden & Fessenden, 1986), 
they are easily cleaved by dilute acids. Hydrolysis of acetals occurs due to the electron 
withdrawing effect of the methoxy groups, rendering the C atom to which they are 
attached 8+ and therefore susceptible to attack by nucleophiles such as water, under 
acidic conditions. This is enhanced by the electron donating effect of the methyl portion 
of the methoxy group, which encourages protonation of the oxygen atom, resulting in 
elimination of the O-methyl group in the form of methanol to generate a hemi-acetal. 
Elimination of another molecule of methanol by the same mechanism generates the 
geminal diol (1, I-diol), which breaks down spontaneously to produce the corresponding 
aldehyde. Although the reaction is reversible, in the equilibrium between an aldehyde. 
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hemiacetal, & acetal, the aldehyde is generally favoured (Fessenden & Fessenden 
, 
1986). In the presence of oxygen and UV light, the aldehyde product can be further 
oxidized to produce the corresponding carboxylic acid. 
Hydrolysis of acetals usually occurs by the SN 1 mechanism, a non-concerted 
process in which protonation of the acetal is followed by rate-limiting breakdown of the 
protonated substrate to an alcohol and a resonance stabilized carbocation (Fife, 1972) 
(figure 4.17). However, in some cases, there is evidence that a bimolecular (SN2) 
mechanism operates, in which preequilibrium protonation of the acetal is followed by 
rate determining attack of water on the protonated acetal, with concerted cleavage of the 
c-o bond (Elaison & Kreevoy, 1978) (figure 4.18). As SN2 reactions are strictly 
dependent on steric accessibility, this mechanism is often unfavourable due to the 
unstable nature of the transition state formed during concerted cleavage. Instability is in 
part related to the size of the O-alkyl groups at the reaction centre of the acetal (Fife & 
Jao, 1965; Jensen et ai, 1979), and thus concerted mechanisms are usually confined to 
acetals containing smaller O-alkyl groups. 
The results indicate that conversion of the acetalanthraquinones to their 
corresponding aldehyde products was acid-catalysed, as breakdown of the 
acetalanthraquinones proceeded exclusively in the presence of H30+ (March, 1985). 
Hydrolysis of the side chains is supported by the identical visible spectra of the 
acetalanthraquinones and their hydrolysed reaction mixtures, indicating that the 
chromophore remained unchanged after hydrolysis. Intramolecular cyclization of one of 
the alkyl amino side chains to form a substituted TNQ, which can sometimes occur on 
heating anthraquinones to temperatures above 50°C (see section 3.3.2) would have 
produced a bathochromic shift in the visible region of the spectrum. This has been 
shown for the TNQ metabolite of mitoxantrone, which is blue shifted by 30nm (Blanz el 
ai, 1991 a). Furthermore, the TNQ metabolite is less polar than mitoxantrone (Mewes et 
ai, 1993). None of the products generated by hydrolysis of the acetalanthraquinones 
were less polar than the original compound. 
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Figure 4.17: Scheme for the conversion of an acetal to the corresponding aldehyde by 
acid-catalysed hydrolysis, via SN 1 nucleophilic substitution. 
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Figure 4.18: Scheme for the conversion of an acetal to the corresponding aldehyde by 
acid-catalysed hydrolysis, via SN2 nucleophilic substitution. 
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In contrast to the visible spectra, a noticeable change occurred in the UV region of 
the spectrum after hydrolysis. As double bonds are known to absorb in this region, it 
could be argued that the generation of aldehyde groups is responsible for the increase in 
absorbance observed. Further oxidation of the aldehydes to their corresponding 
carboxylic acids seems unlikely in view of the fact that all solutions of 
acetal anthraquinone were protected from UV light in sealed Eppendorf tubes. 
Ametantrone was found to be stable under the experimental conditions used. The 
ametantrone side chains would be refractory to hydrolysis due to the replacement of the 
O-methyl groups of the acetalanthraquinone side chains with primary alcohol groups, 
which when protonated, do not possess the electron withdrawing properties of the 
protonated O-methyl groups. 
The two products yielded for YCG7, and three products yielded for both yeG8 
and YCG9 all had shorter retention times than the parent compounds, consistent with 
the generation of aldehydeslhemiacetals. The aldehydes would be expected to be more 
polar than the acetalanthraquinones due to the electron-withdrawing effect of the 
carbonyl oxygen, increasing the hydrogen bonding capabilities of the side chains. The 
two products yielded for YCG7 were probably the hemiacetal and aldehyde oxidation 
products of the single side chain. The products for YCG8 and YCG9 were probably the 
parent/hemiacetal, hemiacetal/aldehyde and aldehyde/aldehyde side chain combinations 
(figure 4.19). The hemiacetal/hemiacetal combination would probably not be detected, 
as the hemiacetal species is relatively short lived, its formation from the acetal usually 
being the rate-determining step (Fife, 1972; Fessenden & Fessenden, 1986). 
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Figure 4.19: Proposed intermediates formed during the hydrolysis ofYCG8 to its di-
aldehyde derivative. Similar intermediates may be generated by hydrolysis of YCG7 and 
YCG9. 
146 
The hydrolysis rates of the acetalanthraquinones was measured from loss of the parent 
compound. By this calculation, hydrolysis of YCG9 appeared to be faster than for 
YCG7 and YCG8. The slightly slower reaction rate ofYCG8 compared to YCG9 may 
be explained by the side chain positioning. It can be argued that as the side chains of 
YCG8 are in closer proximity to each other than those ofYCG9, protonation of one side 
chain would make protonation of the other less favourable due to the slight charge 
repulsion this may produce. This is reflected in the slight increase in activation energy 
for YCG8, which to a large extent determines the reaction rate (Morris, 1985; Fessenden 
& Fessenden, 1986). The slower hydrolysis rate of YCG7 may have been due to its 
slight insolubility in water, despite the presence ofDMSO. 
The first order rate constants obtained would suggest that the acetalanthraquinones 
are hydrolysed by the SN 1 mechanism. However, considering steric effects are unlikely 
to affect the reaction centre of the acetalanthraquinone side chain, hydrolysis is more 
likely to occur by the SN2 mechanism. Although bimolecular mechanisms usually 
follow second order kinetics, SN2 reactions in which one reactant (in this case water) is 
in large excess, usually display pseudo first order kinetics (Morris, 1985; see appendix 
A6). In support of this, several other methoxy-acetals have been shown to undergo 
hydrolysis by the concerted mechanism, including 2-(p-methoxyphenyl)-4,4,5,5-
tetramethyl-1 ,3-dioxolane (Fife, 1972). 
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4.4.2 OXIDATIVE METABOLISM OF THE ACETAL 
-ANTHRAQUINONES 
The acetalanthraquinones were found to undergo aerobic metabolism 
, 
demonstrated by the formation of several products in the presence of mouse liver 
microsomes. Metabolite production was shown to be NADPH-dependent, indicating the 
conversion of the acetalanthraquinones to their metabolites was enzymically catalysed. 
This was confirmed by the absence of metabolism in the presence of boiled microsomes. 
Metabolism produced 2 products for YCG7, and 3 products for YCG8 and YCG9, 
which, similar to the hydrolysis products, were all more polar than the 
acetalanthraquinones. The rate of metabolism of YCG8 and YCG9 was essentially the 
same, so it can be concluded that neither the 1,4- nor the 1,5- configuration involved 
steric hindrance between the acetal anthraquinone side chains and the active site of the 
enzyme(s) involved metabolism. 
The anthraquinone nucleus has been shown to be resistant to oxidation under the 
conditions used in this study (Wolf et ai, 1986). Thus, it is proposed that the metabolites 
were produced by oxidation of the alkylamino side chains. Further evidence for this is 
provided by the identical absorbance spectra of the metabolic mixtures and 
acetalanthraquinones in the visible region of the spectrum. It is predicted that 
metabolism occurs via cytochrome P-450-dependent mixed function oxidation, since 
MFOs are abundant in mammalian liver microsomal fractions and perform a diverse 
range offunctionalization (phase I) reactions (see section 1.5.1). The proposed route for 
the metabolic oxidation of the acetalanthraquinones is illustrated in figure 4.20 for 
YCG8. Cytochrome P-450-mediated oxidation produces a hydroxy intermediate, 
resulting in the loss of formaldehyde to generate an unstable hemiacetal. Subsequent 
protonation of the O-methyl group of the hemiacetal results in the spontaneous 
elimination of methanol to produce the aldehyde. 
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Figure 4.20: Proposed pathway for metabolic conversion of the acetalanthraquinones. yia 
oxidation, to their corresponding aldehyde derivatives. YCG7: Rl =R2=H; YCG8: 
Rl =NHCH2CH2NHCH2CH(OCH3h; R2=H; YCG9: Rl =H, R2= NHCH2CH2NHCH2CH(OCH3h· 
149 
Theoretically, the aldehyde products of the acetalanthraquinones could be 
oxidized to produce their corresponding mono- and dicarboxylic acids. However, as the 
carboxylic acid derivatives of mitoxantrone have only been detected in very small 
quantities in other rodent microsomal systems, if at all (Wolf et aI, 1986; Blanz ef aI, 
1991b; Richard et aI, 1991), this seems unlikely. Furthermore, aldehyde oxidation 
would require the involvement of enzymes such as aldehyde dehydrogenase or aldehyde 
oxidase, located in the soluble (cytosolic) fraction of the liver (Gibson & Skett 1986; 
Beedham, 1997). It is also unlikely that the aldehydes would undergo conjugation 
(phase II) reactions such as sulfate- or glutathione conjugation, as these would be 
catalysed by enzymes not predominantly found in microsomal liver fractions, and would 
require the presence of the corresponding cofactors (see Gibson & Skett, 1986). 
Conjugation reactions are also far more likely to participate in the inactivation of 
cytotoxic agents rather than enhancing their activity, as is the case for 
cyclophosphamide (Ohno & Ormstad, 1985; Lebsanft et aI, 1989). On the contrary, 
metabolism of the acetalanthraquinones was found to enhance their activity (see section 
5.3.2.4). 
The increased affinity of the metabolized drug for microsomal proteins observed 
only in incubates containing NADPH also supports the hypothesis that the drugs were 
metabolized to one or more species that could react covalently. If this species was an 
aldehyde, it would be capable of reacting with nucleophiles such as primary amines 
present in the microsomal protein, forming Schiffs bases (see section 5.4.2). This is 
further indicated by the fact that a proportion of this drug remained bound after the 
addition of acetonitrile as non-covalent binding should be disrupted under these 
conditions. Similar observations were made by Richard et al (1991), after metabolism of 
mitoxantrone using hepatocytes and by Lau et al (1989) after metabolism of morpholino 
doxorubicin. In addition, cytochrome P-450-mediated covalent binding of etoposide to 
liver and HeLa cell microsomal proteins has been observed by Van Maanen ef al (1987) 
and Haim et al (1987). It is thought that O-demethylation of the dimethoxyphenol ring 
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is probably involved in the binding process (Van Maanen et ai, 1985a). The product of 
O-demethylation has been identified as the ortho-dihydroxy derivative (Van Maanen ef 
al,1985b). 
In conclusion, acid-catalysed hydrolysis and oxidative metabolism appear to 
provide effective routes for the oxidation of acetalanthraquinones, probably generating 
aldehydes. It is feasible that hydrolysis occurs by the SN2 mechanism, as steric effects 
are unlikely to affect the reaction centre of the acetal anthraquinone side chain. 
Metabolic conversion of the acetalanthraquinones was achieved by an NADPH-
dependent oxidative process which is likely to involve one or more isoforms of 
cytochrome P-450. 
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CHAPTER 5: DNA BINDING AND CYTOTOXICITY OF 
ACETALANTHRAQUINONES 
5.1 INTRODUCTION 
DNA intercalating agents such as the anthraquinones and anthracyclines have a 
well established role in the treatment of a wide variety of human cancers. Their 
cytotoxic effects are thought to be mediated via several mechanisms, predominantly 
involving DNA intercalation and inhibition of to poi some rase II (see sections l.2.1, 1.2.2 
and 1.3.2). There is evidence that the DNA damage caused by agents that stabilize 
topoisomerase II cleavable complexes results from the interaction of these complexes 
with DNA replication and transcription forks, producing chromosome aberrations and 
genetic recombination events (see section 1.3.2.3). This commonly results in cell cycle 
arrest in either the G 1 or G2 phases, providing an opportunity for the DNA damage to be 
repaired (Wassermann, 1994; Chaney & Sancar, 1996). In cells where damage is 
unrepaired or mis-repaired, the cell ultimately responds by triggering cell death via 
apoptosis (Hickman, 1992). 
Various attempts have been made to improve the cytotoxic activity (and minimize 
the side effects) of anticancer agents by chemical or biological activation. Activated 
drugs with increased cytotoxic potency include the N-oxide AQ4N, doxorubicin 
analogues (e.g. mdox, mmdox) and cyclophosphamide (see sections l.5.2-l.5.4). In the 
previous chapter, it was shown that the acetalanthraquinones were converted via 
hydrolytic and metabolic pathways to several other compounds, one or more of which 
appeared to have an increased affinity for proteins (see sections 4.3.2,4.3.3 and 4.3.-+). It 
follows that if these products are the corresponding aldehyde derivatives, they should be 
more reactive than the acetals due to the potential for Schiffs base formation with 
intracellular enzymes, which may include topoisomerase II. With this in mind, an 
investigation was made into the DNA binding and cytotoxic activity of the 
acetalanthraquinones and their products. 
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5.2 METHODS AND MATERIALS 
Acetalanthraquinones were synthesized as described in sections 3.2.2.1-3.2.2.3. 
All sterile cell culture materials were supplied by Flowlabs, Hertfordshire, UK, unless 
otherwise stated. Reagents were supplied by Sigma Chemical Co. Poole, Dorset, UK, 
unless otherwise stated. RPMI 1640 medium was prepared as described in appendix 
A7.1. The medium was supplemented with 10% foetal calf serum, 200mM L-glutamine 
(1 % v/v) and 1% v/v penicillin (5000IU/ml)/streptomycin (5000)lg/ml) and was pre-
warmed to 37°C before use. This was used for all experiments and has been referred to 
as 'fully supplemented'. The V79 Chinese hamster lung cell line (CHL cell line; ECACC 
NO 86041102) was derived from cells spontaneously transformed from the lung 
fibroblasts of the Chinese hamster. Solutions of drug used for cytotoxicity studies were 
sterile filtered using 0.2)lm flowpore syringe filters, with the exception of those used in 
the drug metabolism studies. Bacterial contamination was avoided in such cases by 
doubling the penicillin/streptomycin concentration of the RPMI medium during and 
after the drug incubation period. Solutions ofMTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) were stored at 4°C and used within 1 week. The 
procedure used to determine the effect of DNA on the spectral properties of 
acetalanthraquinones was as described in section 2.2.2.1. Where abbreviations have been 
used for reagents, full names can be found in appendix A8. 
5.2.1 DNA BINDING STUDIES 
5.2.1.1 THE EFFECT OF ACETALANTHRAQUINONES ON THE THERMAL 
DENATURATION OF CALF THYMUS DNA 
The effect of the acetalanthraquinones on the thermal denaturation of DNA before 
and after hydrolysis was investigated. YCG 7 was hydrolysed at 90°C for 12 h and 
YCG8 and YCG9 were hydrolysed at 90°C for 9 h as described in section 4.2.2. The 
drugs were then neutralized with acetone-ice-cold O.IM NaOH and extracted into 
dichloromethane. The solvent was removed by evaporation in vacuo and detennination 
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of Tm was carried out on the acetalanthraquinones and the hydrolysed products by the 
procedure described in section 2.2.2.3. An identical procedure was carried out with 
ametantrone. 
5.2.2 CYTOTOXICITY STUDIES 
5.2.2.1 MAINTENANCE OF V79 CELLS 
V79 cells, which grow in monolayer culture, were grown in fully supplemented 
RPMI 1640 medium in 150cm3 flasks (Coming, NY, USA) in a humidified atmosphere 
of95% air, 5% C02 at 37°C. Cells were passaged twice weekly using EDTA (0.1 % in 
DPBS) as described in appendix A7.2. 
5.2.2.2 MTT FORMAZAN CALIBRATION CURVE 
MTT formazan (l-[4,5-dimethylthiazol-2-yl]-3,5-diphenyl-formazan) was 
dissolved in DMSO to give solutions ranging in concentration from 5 to lOOllgml-1. 
Aliquots (8 x 100/-l1) at each concentration, were pipetted into 96-well microtitre plates. 
The absorbance was determined against a DMSO blank at 492nm on a Titertek 
multiscan MKII microtitre plate reader (MCC/340 MKII). MTT formazan concentration 
was plotted versus absorbance at 492nm to ensure linearity. 
5.2.2.3 CALIBRATION OF MTT FORMAZAN PRODUCTION AND V79 CELL 
DENSITY 
V79 cells in exponential growth were passaged and collected in approximately 
5ml of fully supplemented RPMI 1640 culture medium. The resulting cell suspension 
was passed through a 19G needle two or three times to disperse cell clumps and the cell 
concentration determined using an electronic particle counter (Coulter Electronics Ltd; 
see appendix A7.3). The cell suspension was adjusted with fully supplemented RPMI 
medium to give cell densities between 1 x 104 and 6 x 106 cells/ml. At each cell density. 
8 x 100/-l1 was dispensed into 96-well microtitre plates (leaving one column free on each 
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plate for the blank), sealed in polythene and incubated at 37°C for 4 h to allow cells to 
adhere to the plates. The RPMI medium was then removed by inversion and gentle 
tapping of the plates, and 25~1 of pre-warmed, sterile filtered MTT solution (2mg/ml) 
was added to each well. After a further 4 h incubation at 37°C, the resulting MTT 
formazan crystals were solubilized by gentle shaking with DMSO (1 00~1 per well) for 
30 min on a vortex mixer. The absorbance was measured at 492nm versus a blank of 
MTT (2mg/ml; 25 ~l per well) and DMSO (1 OO~l/well). The absorbance at 492nm 
(equivalent to MTT formazan production) was plotted against V79 cell density to ensure 
linearity. 
5.2.2.4 DETERMINATION OF V79 CELL GROWTH CHARACTERISTICS AND 
CELL DOUBLING TIME 
V79 cells in exponential growth were passaged and collected in fully-
supplemented RPMI 1640 medium and passed through a 19G needle two or three times. 
The cell concentration was determined using a particle counter and the suspension was 
diluted in medium to give cell densities of 1 x 104 to 1 x 106 cells/m!. Cell suspension 
(8 x 1 00~1 per concentration) was added to 96-well microtitre plates, sealed in polythene 
and incubated at 37°C for 4,24,48, 72, 96 and 120 h. The culture medium was changed 
everyone or two days, where necessary, by inversion and tapping. After the appropriate 
time had elapsed, the medium was removed, 25 ~l of pre-warmed, sterile filtered MTT 
solution (2mg/ml) was added to each well and the cells were incubated for a further 4 h 
at 37°C. The resulting MTT formazan product was then solubilized, and absorbance 
measurements taken as described in section 5.2.2.2. The cell doubling time was 
calculated by linear regression, from a plot of cell number versus time. 
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5.2.2.5 EFFECT OF ACETALANTHRAQUINONES ON V79 CELL VIABILITY 
V79 cells in exponential growth were passaged, collected in pre-warmed ful1\-
, . 
supplemented RPMI 1640 medium and counted using an electronic particle counter. The 
cell suspension was adjusted to 7.5 x 104 cells/ml with RPMI medium and 100111 
aliquots pipetted into all but the last column of each 96-well microtitre plate. After 
incubation at 37°C for 48 h, the culture medium was removed by inversion and tapping. 
and replaced with fully-supplemented RPMI medium, containing the appropriate 
concentration of sterile filtered acetalanthraquinone, (l OO~l/well). Medium (100111), 
containing the appropriate volume of water in place of drug solution, was added to the 
eight wells serving as the control column. Following 4 or 24 h incubation at 37°C, the 
solutions were removed, and each well washed three times with pre-warmed DPBS. The 
cells were replenished with 1 00~1 pre-warmed, fully-supplemented medium and 
subsequently left to grow at 37°C for a further 72 h, replacing exhausted medium when 
necessary. After 72 h, the culture medium was removed and the cell survival at each 
drug concentration was then determined by the MTT assay, as described in section 
5.2.2.2. Cytotoxicity was expressed as the concentration of drug required to reduce the 
viability of the cell population by 50% (ECso). The above procedure was repeated using 
drug solutions prepared in culture medium diluted with sterile distilled water (l0% v/v) 
instead of foetal calf serum. 
5.2.2.6 EFFECT OF ACID-HYDROLYSED ACETALANTHRAQUINONES ON V79 
CELL VIABILITY 
The procedure was as described in section 5.2.2.5, except that prior to incubation 
with V79 cells, the acetalanthraquinones were hydrolysed in O.IM HCl at 90°C for 9 h 
(YCG8 and YCG9) and 12 h (YCG7) then neutralized with O.IM NaOH and cooled on 
ice-acetone (see section 4.2.2 for experimental detail). The procedure was also 
performed with drug maintained at 37°C in O.IM HCI. Drug solutions were then diluted 
in RPMI 1640 medium (with or without foetal calf serum, 10% v/v) to give drug 
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concentrations between 1.0 and 10~M. The effect of HClINaOH on cell" b·l· \la 1 Ity was 
also investigated. 
5.2.2.7 EFFECT OF ACETALANTHRAQUINONE METABOLITES ON V79 CELL 
VIABILITY 
For YCG8 and YCG9, metabolism was carried out for 60 min at 37°C. As the 
metabolic products ofYCG7 were formed more slowly than those of the bis-substituted 
compounds, metabolism of this compound was carried out for 70 min in order to obtain 
the same proportion of metabolites for all three compounds (50 ± 5%). This was 
essential if the cytotoxicity results were to be comparable. Two sets of control 
incubations were also set up, the first consisting of drug incubated for 60 (or 70) min in 
the absence ofNADPH, and the other containing NADPH but no drug. The procedure 
for metabolism was carried out as described in section 4.2.3, except that instead of 
adding acetonitrile to the samples prior to spinning down the microsomal protein after 
the incubation period, samples were immediately cooled on ice-acetone for 5 min and 
centrifuged at 14 000 x g for 15 min. A proportion (~1 00~1) of each incubate was 
removed and analysed by HPLC to verify the formation of metabolites. The remainder 
of the supernatant was serially diluted in pre-warmed RPMI 1640 medium supplemented 
with foetal calf serum, 10% v/v, 200mM L-glutamine, 1 % v/v and 2%v/v penicillin 
(5000IU/ml)/streptomycin (5000mg/ml) to give concentrations of acetal anthraquinone 
between 0.5 and 50~M. Metabolized and non-metabolized drug solutions (8 x 1 OO~I) 
were incubated with V79 cells (7.5 x 104 cells/ml) for 4 h. The drug was then removed 
and the cells were washed three times with pre-warmed DPBS, then replenished with 
medium (penicillin/streptomycin 2%v/v) and incubated at 37°C for 72 h. The cell 
survival at each drug concentration was determined by the MTT assay, as described in 
section 5.2.2.2. The effect of 2% penicillin/streptomycin on cell viability was also 
investigated, as was the effect of microsomal suspensionINADPH. 
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5.3 RESULTS 
5.3.1 DNA BINDING STUDIES 
Figures 5.1 to 5.6 show spectral shifts for the acetalanthraquinones in the presence 
of calf thymus DNA at ionic strengths ofO.5M and 0.05M NaCl. Data are summarized 
in table 5.1. The acetal anthraquinone YCG7 gave a hypochromic and a slight 
bathochromic shift in the presence of DNA but displayed no isosbestic point either at 
0.5M or 0.05M NaCl, although the spectra all converged at 415.8 and 547.3nm (0.5M) 
and 405.2 (0.05M). YCG8 and YCG9 both showed bathochromic and hypochromic 
shifts in the presence of DNA, although these were relatively small compared to those 
for ametantrone. YCG8 showed isosbestic points at 636.5nm (0.5M NaCl) and 639.7nm 
(0.05M NaCl) but YCG9 behaved in much the same way as YCG7 in that it showed no 
isosbestic point at either concentration, although the spectra converged at 571.3nm 
(0.5M). All three compounds caused an increase in the melting temperature of DNA, as 
shown in figures 5.8, 5.10 and 5.12, but it can be seen that this was very small for YCG7 
and only moderate for YCG8 and YCG9 compared with ametantrone (figure 5.7; table 
5.2). After hydrolysis, there was no change in Tm for any of the acetalanthraquinones 
(figures 5.9, 5.11, 5.13). 
158 
Table 5.1: Spectral properties of acetalanthraquinones in the presence of calf thymus 
DNA ~ 
DRUG 
ametantrone 
YCG7 
YCG8 
YCG9 
a 
isosbestic point (nm) shift in Amax (nm) 
636 12 
1.4 
637 3.5 
3.6 
% decrease in 
extinction 
16 
7 
10 
17 
b 
a: shift in Amax at a DNA to drug ratio of 10: 1; b: difference between Amax of free 
drug and fully bound drug (hypochromic shift). All experiments were performed in 
0.5M NaCII 0.008M Tris buffer. 
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Figure 5.1: Spectral properties of YCG7 in the presence of calf thymus 
DNA and O.008M Tris/O.OSM NaCl. 
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Figure 5.2: Spectral properties of YCG7 in the presence of calf thymus 
DNA and O.008M Tris/O.SM NaCl. 
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Figure 5.3: Spectral properties of YCG8 in the presence of calf thymus 
DNA and O.008M Tris/O.OSM NaCl. 
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Figure 5.4: Spectral properties of YCG8 in the presence of calf thymus 
DNA and O.008M Tris/O.SM NaCl. 
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Figure 5.5: Spectral properties of YCG9 in the presence of calf thymus 
DNA and O.008M Tris/O.OSM NaCl. 
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Figure 5.6: Spectral properties of YCG9 in the presence of calf thymus 
DNA and O.008M Tris/O.SM NaCl. 
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Table 5.2: L1Tm values of calf thymus DNA in the presence of the acetalanthraquinoncs. 
a b c 
DRUG 11 Tm - hydrolysis 11 Tm +hydrolysis increase in ~ Tm 
(OC) (OC) after hydrolysis 
(OC) 
ametantrone 21.6±0.1 21.6 ± 0.04 +0.04 
YCG7 3.6 ± 0.03 6.1 ± 0.6 +2.5 
YCG8 14.2 ± 0.1 l3.5 ± 0.4 
-0.7 
YCG9 15.7 ± 0.4 16.5 ± 0.1 +0.8 
Values were determined (a) pre- and (b) post- incubation with O.lM HCI at 90°C. 
L1 Tm is the difference in melting temperature of DNA in the presence and absence 
of drug (Tm of calf thymus DNA= 70.6 ± O.SOC). c represents the increase in 11Tm 
of hydrolysed drug compared with non-hydrolysed drug. Values represent the mean 
± sd for three separate experiments . 
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Figure 5.7: Melting profile of calf thymus DNA in the presence of 
ametantrone. (e) A vs T; (0) dAJdT vs T. Values shown represent the 
mean of three separate experiments. 
163 
dA/dT 
0.3 -
r---------------------------~ 0.03 
... 
E 
r: 
o 
0.02 
(0 
NO.2 -
-co . 
CI) 
(.) 
r: 
co 
.c 
60000 
0 000009' 0 00 
dAJdT 
o 0.1-
I/) 
.c 
co o 
0 0 0 0 
00 
o . 
000 .' 
O .A .......... 0 •• ' 
- - - - -
60 70 80 
temperature (OC) 
90 
o 
o 
o 
o 
100 
0.01 
o 
Figure 5.8: Melting profile of calf thymus DNA in the presence of 
YCG7 before drug hydrolysis. (e) A vs T; (0) dA/dT vs T. Values 
shown represent the mean of three separate experiments. 
0.06 
0.3 . . . 
E 
r: 
0 (0 0.04 N 
0.2 
-co 
CI) 
(.) 
r: 0 
co 00 0 
.c 
oQ 0.02 ... 0.1 0 00 0 0 0. I/) 
.c o . 0 co 
0 . 0 000 
. 
o . 000 
0 hAAOOO OO ' 0 
60 70 80 90 
temperature (OC) 
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Figure 5.10: Melting profile of calf thymus DNA in the presence of 
YCG8 before drug hydrolysis. (e) A vs T; (0) dA/dT vs T. Values 
shown represent the mean of three separate experiments. 
0.03 
. 
... 
0.3 
E 
c 
0 (Q 0.02 N 
-
0.2 ca . 
Q) • <>00 dA/dT 
0 <> ()<> 
c <><> ~o <>00 <> <> ca 
.c <><> <><> 0.01 
... 0.1 <> <> 0 
til 
.c <> ca 
<> <> . <> 
A <> 0 0 
60 70 80 90 100 110 
temperature (OC) 
Figure 5.11: Melting profile of calf thymus DNA in the presecne of 
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Figure 5.13: Melting profile of calf thymus DNA in the presence of 
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5.3.2 CYTOTOXICITY STUDIES 
5.3.2.1 THE MTT ASSAY 
The MTT colourimetric assay, first used by Mosmann (1983), has proved to be a 
rapid, sensitive and reproducible method for the screening of potential chemotherapeutic 
agents in a wide variety of tumour cell types (Carmichael et ai, 1987; Park et ai, 1987: 
Alley et ai, 1988). The assay is based on the ability of mitochondrial succinate 
dehydrogenase in viable cells to reduce the tetrazolium salt MTT to a purple. water-
insoluble formazan product. The quantity of formazan produced thus provides an 
indication of the number of viable living cells in culture. As the cell membrane is 
impermeable to the product, it accumulates within the cell. Following addition of 
DMSO, the product is liberated and the absorbance can be measured. 
The relationship between MTT formazan concentration and absorbance at -t92nm 
was found to be linear between 0 and 100llg/ml (figure 5.14). V79 cell density was 
proportional to the formation of MTT formazan between 1 x 104 to 6 x 106 cells/ml 
(figure 5.15). Figure 5.16 shows V79 cell growth characteristics at initial seeding 
densities between 1 x 104 and 1 x 106 cells/ml over a 5 day period. At lower seeding 
densities (l.0 x 104 - 7.5 x 104 cells/ml) there was a 24 h recovery (lag) phase before the 
onset of exponential growth. At higher cell concentrations (1 x 105 - 1 x 106 cells/mI). 
there was no apparent recovery phase and the cell growth began to reach a plateau after 
48-72 h. The cell doubling time was 18.3 ± 3.9 h, in agreement with that of ~ 18 h 
previously sited by Suzuki & Nakane (1994). 
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The linearity obtained between MTT formazan production (R2=1.0) and V79 cell 
density up to 6 x 106 cells/ml (R2=0.998) and the consistency of the values (standard 
deviations < ± 1 0%) both confirmed that this assay was suitable for determining the 
effect of the acetalanthraquinones and their products on V79 cell proliferation. An 
inoculation density of7.5 x 104 cells/ml (7.5 x 103 cells/well) was deemed to be most 
suitable for subsequent cytotoxicity studies due to the growth characteristics at this 
density. Cells were grown for two days prior to drug incubation to ensure exponential 
growth, and for a further three days post-incubation. 
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5.3.2.2 THE EFFECT OF THE ACETALANTHRAQUINONES ON V79 CELL 
VIABILITY 
The effect of the acetalanthraquinones and ametantrone on V79 cell viability 
following drug incubation periods of 4 and 24 h is shown in table 5.3. ECso represents 
the concentration of drug required to reduce the viability of the cell population by 50%. 
Figures 5.17 to 5.19 show the corresponding cytotoxicity curves for the 
acetalanthraquinones. Both exposure times produced the same order of potency 
(ametantrone >YCG9 >YCG8 >YCG7), the longer incubation period enhancing the 
cytotoxicity of all four compounds 
Table 5.3: The effect of the acetalanthraquinones and ametantrone on V79 
cell survival following drug incubation periods of 4 and 24 hours 
DRUG EC50 4 h ().tM) EC50 24 h ().tM) 
ametantrone 2.9 ± 0.6 1.6±0.01 
YCG7 150.6 ± 6.9 51.5 ± 5.0 
YCGS 35.9 ± 2.5 5.9± O.S 
YCG9 13.6 ±4.0 1.9±0.1 
EC50 represents the concentration of drug required to reduce the viability 
of the cell population by 50%. Values represent the mean ± sd for three 
separate experiments performed in triplicate (acetalanthraquinones) and the 
mean ± sd for one experiment performed in triplicate (ametantrone). 
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On the basis that the difference in activity between ametantrone and the YCG 
compounds was more marked with a 4 h than a 24 h drug exposure, 4 h was chosen for 
subsequent cytotoxicity studies as it was thought that this would also enhance any 
differences in activity between the acetalanthraquinones and their hydrolysed and 
metabolized products. As V79 CHL cells are devoid of endogenous cytochrome P-450 
mono oxygenase activity (Keyes et aI, 1984), the enzyme believed to be responsible for 0-
demethylation of the acetalanthraquinones, it was necessary to hydrolyse/metabolize the 
drugs exogenously prior to incubation with cells (see sections 4.2.2 and 4.2.3 for 
experimental detail). 
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5.3.2.3 THE EFFECT OF HYDROLYSED ACETALANTHRAQUINO ' ?\ES O"\" V79 
CELL VIABILITY 
The effect of the acetalanthraquinones and their hydrolysed d pro ucts on V79 cell 
viability is shown in table 5.4 (with serum) and table 5 5 (without ) F' --
. serum. Igures ='.20 
to 5.22 show corresponding cytotoxicity curves for each drug (wI'th ) C . . serum. ) tOtOXIC 
potentiation, CP corresponds to the ratio ofEC50 values obtained for the 
hydrolysed:unhydrolysed drug. 
Table 5.4: The effect of the acetalanthraquinones and their hydrolysed products on 
V79 cell survival in the presence of foetal calf serum 
DRUG 
YCG7 
YCG8 
YCG9 
ECso (~M) 
-hydrolysis 
150.6 ± 6.9 
35.9 ± 2.5 
13.6±4.0 
ECso (~M) 
+hydrolysis 
10.6±3.1* 
2.5 ± 0.6* 
6.1 ± 0.2 
CP 
1.+.3 
14.6 
2.3 
All drugs were incubated with cells for 4 h. EC50 represents the concentration 
of drug required to reduce the viability of the cell population by 50%. CP (cytotoxic 
potentiation) corresponds to the ratio ofEC50 values obtained for the hydrolysed: 
unhydrolysed drug. Values represent the mean ± sd for three separate experiments 
performed in triplicate. * indicates that the results were significantly different to the 
corresponding values obtained in the absence ofFCS at p = 0.01 (see table 5.5). 
Following hydrolysis, an increase in cytotoxicity was observed for all three 
compounds. This was more marked for YCG7 and YCG8 than for YCG9 and \\as 
apparent when cells were incubated either with or without foetal calf serum. Howc\er. 
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the cytotoxicity of the acetal anthraquinone products was greater when the drugs were 
incubated with serum than without (14.3-fold compared to 2.7-fold greater than the 
parent compound for YCG7 and 14.6-fold compared to 4.6-fold greater for YCG8). This 
was far less evident for YCG9 (2.3-fold compared to 2.0-fold). Using the T-test (\1iller 
& Miller, 1993), the EC50 values obtained for the hydrolysis products of YCG7 and 
YCG8 with FCS were found to be significantly different to those obtained without FCS. 
at a confidence level of99% (p = 0.01). In contrast, the cytotoxicity of the 
acetalanthraquinones per se was not affected by serum and that a different pattern of 
potency was observed for the hydrolysed products (YCG8>YCG9>YCG7) than for the 
acetalanthraquinones (YCG9> YCG8> YCG7). Cell viability was unaffected by 
HCIINaOH at the concentrations used. 
Table 5.5: The effect of the acetalanthraquinones and their hydrolysed products on 
V79 cell survival in the absence of foetal calf serum 
DRUG 
YCG7 
YCG8 
YCG9 
EC50 (/-lM) 
-hydrolysis 
153.7 ± 6.4 
3l.9 ± 3.7 
14.0 ± 0.7 
EC50 (/-lM) 
+hydrolysis 
56.9 ± 3.4* 
7.0 ± 1.2* 
7.0 ± 1.2 
CP 
2.7 
4.6 
2.0 
All drugs were incubated with cells for 4 h. EC50 represents the concentration . 
of drug required to reduce the viability of the cell population by 50%. CP (CytOtOXIC 
potentiation) corresponds to the ratio of EC50 values obtained for the hydr~lysed: 
unhydrolysed drug. Values represent the mean ± sd for three separate expenments 
performed in triplicate. * indicates that the results were significantly different to the 
. d' h fFCS at p = 001 (see table 5.-+). corresponding values obtame m t e presence 0 . 
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The values shown in tables 5.4 and 5.5 and figures 5.20 to 5.22 represent the 
maximum increase in activity for each compound (corresponding to 12 h hydrolysis for 
YCG7 and 9 h for YCG8 and YCG9). ECso values for YCG8 incubated \\-ith and 
without serum after 4.5 h hydrolysis were 6.9 ± 0.8 and 10.7 ± 1.4 respectiyely and after 
6 h hydrolysis were 5.5 ± 1.2 and 7.2 ± 0.4 respectively. ECso values for yeG9 
incubated with and without serum after 6 h hydrolysis were 7.0 ± 0.6 and 7.8 ±0.8 
respectively. Thus product formation coincided with an increase in cytotoxicity. 
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Figure 5.20: Effect of ye07 on V79 cell survival before (e) and after 
(0) drug hydrolysis. Values shown represent the mean ± sd of one of 
three separate experiments. 
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Figure 5.21: Effect of YCG8 on V79 cell survival before Ce) and after 
CO) drug hydrolysis. Values shown represent the mean ± sd of one of 
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Figure 5.22: Effect of YCG9 on V79 cell survival before Ce) and after 
CO) drug hydrolysis. Values shown represent the mean ± sd of one of 
three separate experiments. 
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5.3.2.4 THE EFFECT OF METABOLIZED ACETALANTHRAQUINONES O?\ 
V79 CELL VIABILITY 
The effect of the acetalanthraquinones and their metabolites on V79 cell yiability 
after a 4 h drug incubation period are shown in table 5.6. The concentration of 
metabolites added to cells, determined by HPLC analysis, was essentially the same for 
YCG7, YCG8 and YCG9 (50± 5%), so the cytotoxicity results were directly 
comparable. The metabolites of YCG7 and YCG8 were considerably more cytotoxic 
than their respective acetalanthraquinones (4.4-fold for both compounds). In contrast, a 
smaller increase in cytotoxicity was seen following the metabolism ofYCG9 (2.7-fold). 
For all three compounds, using the T-test (Miller & Miller, 1993), the EC50 values 
obtained after metabolism were found to be significantly different to those obtained 
before metabolism, at a confidence level of99% (p = 0.01). In the absence of drug, the 
microsomal suspension had no effect on V79 cell viability. Similarly, 2% penicillin! 
streptomycin had no effect on the viability of cells. 
Table 5.6: The effect of the acetalanthraquinones and their metabolites on V79 cell 
survival 
DRUG 
YCG7 
YCGS 
YCG9 
ECso (/J-M) 
-metabolism 
25.4 ± 2.5 
12.8 ± 1.9 
18.3 ± 2.6 
ECso (/J-M) 
+metabolism 
5.S ± 3.3* 
2.9 ± 1.7* 
6.9 ± 2.1 * 
CP 
4.4 
4.4 
2.7 
Drugs were incubated with cells for 4 h. EC50 represents the concentration of . 
drug required to reduce the viability of the cell population by 50%. CP (cyt?tOXIC 
. . . f EC I obtaI'ned for metabolIsed: potentiatIOn) corresponds to the ratIO 0 50 va ues . 
unmetabolised drug. Values represent the mean ± sd for three separate expe~lments. 
* indicates that the ECso values were significantly different from those obtamed for 
unmetabolised drug (p = 0.01). 
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5.4 DISCUSSION 
5.4.1 DNA BINDING STUDIES 
Overall, the acetalanthraquinones were weaker DNA intercalators than the 
structurally related ametantrone. The poor DNA binding affinity ofYCG7. reflected in 
its very low ~ Tm and small bathochromic and hypochromic shifts in the presence of 
DNA, was almost certainly due to the reduced ability of mono-substituted compounds to 
stabilize the intercalation complex by electrostatic attraction between the alkylamino 
side chain and the DNA phosphate backbone. Because mono-substituted compounds 
contain only one alkylamino side chain, they participate in less electrostatic binding 
with the DNA phosphate backbone, a process which usually stabilizes intercalation. In 
addition, the fact that there is only one side chain means that dissociation of the drug 
from the double helix is relatively unhindered. The results are supported by previous 
studies demonstrating that mono-substituted alkylaminoanthraquinones possess only 
weak intercalative properties (Islam et ai, 1985) and dissociate more rapidly from DNA 
than bis-substituted compounds (Gandecha et ai, 1985). 
For YCG8 and YCG9, the bathochromic and hypochromic shifts at both O.05M 
and O.5M NaCI, and moderate increases in Tm, all indicated that these compounds were 
better DNA intercalators than YCG7. However, the values obtained were still lower 
than may be expected for bis-substituted anthraquinones (see sections 2.3.2.2 and 
2.3.2.4). Two factors may contribute to the lower affinity of the acetalanthraquinones 
for DNA compared to ametantrone. Firstly, the bulky nature of the methoxy groups of 
the side chains may influence intercalation. This was also the case for AQ 11 and AQ 12. 
which each contain four hydroxyl groups in their alkyl amino side chains (see section 
2.3.2). Secondly, unlike the OH groups of the ametantrone side chains, the methoxy 
groups are not capable of hydrogen bonding with the nitrogens of the DNA base pairs 
and the DNA phosphate oxygens (Pohle et ai, 1990). which would help to stabilize the 
intercalated complex. 
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It can be concluded that the 1- and 1,5- substitution patterns ofYCG7 and YCG9 
were responsible for the absence of isosbestic points for these compounds. DNA 
binding studies performed in chapter 2 revealed a similar absence of isosbestic 
properties for the 1 ,5-bis-substituted compound AQ 15 (see figures 2.5 and 2.6, section 
2.3.2.2). The difference in the nature of DNA binding ofYCG9 compared to yeG8 
probably relates to their different modes of intercalation. Computer graphic modelling 
predicts two possible intercalative binding configurations for 1,4-substituted 
alkylaminoanthraquinones (figure 5.23), with the chromophore either perpendicular to 
the base pair axis with both side chains in the major groove or with the chromophore 
parallel to the base pair axis with the 1,4 bis alkylamino side chains lying in each groove 
'straddling' the intercalation site. (Islam et ai, 1985). High field NMR studies on 
oligonucleotide/mitoxantrone complexes (Lown & Hanstock, 1985), drug dissociation 
kinetics of DNA-drug complexes (Gandecha et ai, 1985) and thermodynamic studies 
(Bell et ai, 1989) all indicate that l,4-bis-substituted compounds such as mitoxantrone 
favour the perpendicular mode of intercalation with their alkylamino side chains resting 
in the major groove. In contrast, 1,5-bis-substituted derivatives can enter via the major 
groove and straddle the intercalation site (Islam et ai, 1985), but unlike 1,4 derivatives, 
they cannot intercalate in a perpendicular orientation. In order for straddling to be 
achieved, DNA breathing (transient base pair unstacking) must occur to allow the 
association of the 1,5 compound and the DNA receptor site. This enables a more stable 
complex to be formed, reflected in the slower dissociation rate of 1,5 derivatives from 
DNA (Bell et ai, 1989). yeG9, being a 1,5 substituted compound, would be able to 
straddle the DNA helix, whereas the 1,4 derivative would probably favour perpendicular 
mode of binding. 
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Figure 5.23: Computer graphics modelling illustrating DNA intercalation of 1.-+- and 1.5-
his-substituted alkylaminoanthraquinones. (A) shows the 1,4- major groove binding 
configuration, (B) shows 'straddling' of the intercalation site by 1,4- derivatives and (C) 
shows 'straddling' of the intercalation site by 1,5- derivatives. Reproduced from Islam et (//. 
1985. 
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In order to carry out DNA binding studies on the acetal anthraquinone products, 
the parent compounds were hydrolyzed for 12 h (YCG7) and 9 h (YCG8 and YCG9) as 
these times produced the greatest increase in cytotoxicity compared with the parent 
compounds (see section 5.3.2.3). Hydrolysis rather than metabolism was chosen to 
convert the acetalanthraquinones to their products so that potential interference from 
microsomal proteins could be avoided. 
There was no apparent increase in DNA intercalation after hydrolysis, \vhich is 
probably to be expected. Even if the acetalanthraquinones were converted to their 
corresponding aldehydes, they would be unlikely to form stable Schiffs bases with 
nucleic acids in the prevailing aqueous environment. 
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5.4.2 CYTOTOXICITY STUDIES 
Ametantrone and the acetalanthraquinones were all found to inhibit the gro\\1h of 
V79 cells. However, ametantrone was considerably more potent than the other three 
compounds. This could be due to enhanced stabilization of DNA-to poi some rase II 
cleavable complexes by ametantrone, which contains 2'-(hydroxyethylamino)-
ethylamino side chains (see section 2.4.1) and/or increased DNA binding affinity (see 
section S.4.1). The lower DNA binding affinity of the acetalanthraquinones may also 
explain why extending the drug incubation period from 4 to 24 hours greatly enhanced 
their potency, because being less DNA affinic than ametantrone, they would require 
more time to accumulate in the nucleus. 
The increase in cytotoxicity of YCG9 compared with YCG8 may be related its 
ability to 'straddle' the DNA helix, as discussed earlier (see section S.4.1). and is 
consistent with a previous study in which 1 ,S-bis-substituted anthraquinones were more 
active than their 1 ,4-bis-substituted analogues (Islam et ai, 1985). In support of this, the 
N-oxide of AQS, the 1,S-substitued analogue of AQ4, has been shown to bind to DNA 
and is cytotoxic (Professor Laurence Patterson, personal communication). In addition, 
the different pharmacophores of 1,4- and 1 ,S-substituted compounds means they may 
stack differently within the DNA-topoisomerase II cleavage site (Capranico et ai, 1997; 
see figure 1.11, section 1.3.2.4). The fact that YCG7 was considerably less potent than 
the bis-substituted compounds, can be partly attributed to its weak DNA binding 
affinity. Indeed, it is well known that higher doses of mono-substituted anthraquinones 
are required to achieve activity (Murdock et ai, 1979; Zee-Cheng & Cheng, 1979). 
After hydrolysis, the acetalanthraquinone products were still relatively non-potent 
compared with those of some other types of activated compounds, including the 
morpholino anthracyclines. Nonetheless, the hydrolysed products ofYCG7, YCG8, and 
to a much lesser extent YCG9, were far more potent than the parent compounds. This 
may be accounted for by an increase in DNA binding, or possibly relates to increased 
interaction with other drug targets. In support of this, in a study by Holmes (1995). the 
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products of YCG7 and YCG8 products derived from metabolic actl'vat' d IOn emonstrated 
significant inhibition of topoisomerase II, whereas their respective parent compounds 
were inactive. In contrast, YCG9 inhibited topoisomerase II without being metabolized. 
Thus, enhanced interaction ofYCG7 and YCG8 hydrolysis products with topoisomerase 
II may at least partly account for their enhanced potency in this study and may explain 
the smaller increase in cytotoxicity of the YCG9 hydrolysis products. 
The cytotoxicity studies produced some interesting observations, and possible 
explanations for these have been given below. However, it is recognised that while the 
findings are true for the V79 cell line, their applicability across a number of cell lines 
was not established, and further studies should be carried out in order to establish their 
significance. 
One rather unexpected discovery was the influence of foetal calf serum on the 
activity of the acetal anthraquinone products. Initially, serum was excluded from the 
culture medium during drug incubation with the aim of preventing covalent binding of 
aldehyde drug products to serum proteins, instead of their intended nuclear target(s). 
However, rather unexpectedly, incubation of the acetal anthraquinone products with 
serum actually enhanced their potency. It can be postulated that serum proteins were 
facilitating the transport of products into the cells in a similar manner to 
macromolecules such as BSA and dextran, which have been used to carry drug 
molecules into cells via endocytosis (Trouet et ai, 1982, Shih et ai, 1991). Serum-
mediated drug uptake would probably involve formation of reversible Schiffs bases 
between the aldehydes and nucleophilic sites within the proteins. Once inside the cell, 
other nucleophiles may facilitate the mobilization of aldehyde products towards the 
nucleus (see later). Due to their reduced ability to react with nucleophiles, facilitated 
drug transportation of the acetalanthraquinones by this method would be far less 
feasible. 
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The presence of serum during drug incubation may further enh th -
ance e potency ot 
acetal anthraquinone products in the V79 cells by stimulating the production of 
intracellular enzymes. In serum-starved human skin fibroblast cells, topoisomerase II 
levels were increased from 104 to 106 copies per cell by the addition of serum to the 
growth medium, corresponding to an increase in topoisomerase II rnRNA expression of 
more than 70-fold (Hsiang et ai, 1988). Although topoisomerase II in transformed cells 
is generally less sensitive to changes in serum levels than in normal cells (Holley, 1975: 
Hsiang et ai, 1988), there is evidence that actively cycling V79 cells contain eleyated 
levels of this enzyme (Dillehay et ai, 1987) and studies have generally indicated a 
positive correlation between enzyme content and sensitivity to topoisomerase II 
inhibitors in cultured cells (Sullivan et ai, 1987; Davies et ai, 1988; Deffie et ai, 1989; 
Kasahara et ai, 1992). Thus, assuming that topoisomerase II was a target of the 
acetal anthraquinone metabolites, their effect would be enhanced by serum growth 
factors. Topoisomerase II a may be a preferential target for these compounds, as high 
levels of this isoform are associated with rapidly proliferating cells, topoisomerase II P 
being the predominant isoform expressed in quiescent cells (Woessner et aI, 1991; 
Kimura et ai, 1994). 
Since V79 CHL cells are devoid of endogenous cytochrome P-450 
monooxygenase activity, it was necessary to generate the acetalanthraquinone 
metabolites exogenously. However, the advantage of this was that it allowed the effect 
of the products on V79 cells to be determined without the potential complication of 
intracellular metabolite formation. Acetalanthraquinones incubated in the presence of 
NADPH-fortified mouse liver microsomes all showed increased activity compared with 
the parent compounds, particularly YCG7 and yeG8. On this basis, a number of 
speculations can be made about the behaviour of the acetal anthraquinone metabolites. 
However, it must be stressed that these arguments are conjectural, and further 
investigations are required in order to determine the nature of the metabolites (see 
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section 6.2). 
It can be argued that the increased cytotoxicity of the YCG7 and YCG8 
metabolites (and hydrolysis products) compared with the acetalanthraquinones in V79 
cells was due to the formation of covalently reactive aldehydes. In all probability. on 
entering the cells, aldehydes would be subject to attack by molecules containing 
nucleophilic groups, for example, the a-amino groups of amino acids, resulting in the 
formation ofSchiffs bases (imines) (Rawn, 1983; Fessenden & Fessenden. 1986). This 
involves the addition of the nucleophilic amine to the partially positively charged 
carbonyl carbon of the aldehyde, resulting in loss of a proton from the nitrogen and the 
gain of a proton by the oxygen (figure 5.24). The resulting OH group is then further 
protonated and is subsequently eliminated as water. In aqueous environments this 
reaction is reversible, allowing continual formation and dissociation of the imine, so this 
process could aid the mobilization of the aldehyde metabolites through the cells. 
Assuming the metabolites follow a similar intracellular distribution pattern to 
structurally related agents (see section 1.2.2), it seems likely that they would eventually 
accumulate in the nucleus and intercalate DNA, providing an opportunity for the drug 
side chains to form Schiffs bases with amino acids within the topoisomerase II protein. 
As the DNA-topoisomerase II active site is non-aqueous (Capranico et aI, 1997) there is 
a strong possibility that the Schiffs bases formed therein would be irreversible. This 
could give rise to persistently trapped topoisomerase II cleavable complexes in the 
hydrophobic interior of the topoisomerase II-DNA active site. 
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Figure 5.24: Proposed mechanism of Schiffs base formation between the aldehyde 
product of an acetalanthraquinone and nucleophilic centres of molecules such as 
topoisomerase II. YCG7: Rl=R2=H; YCG8: R1=NHCH2CH2NHCH2CH(OCH3h, 
R2=H; YCG9: Rl =H, R2= NHCH2CH2NHCH2CH(OCH3h. 
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Covalent binding has been implicated in the activity of several other antitumour 
agents. Amongst these are the doxorubicin analogues mdox and mmdox (see section 
1.S.3). When mmdox is administered in vivo, an 80-fold increase in potency is obseryed 
compared with the parent drug (Ripamonti et aI, 1992). In vitro, incubation of this 
compound with NADPH-fortified human or murine liver microsomes potentiates its 
cytotoxic potency SO-fold in the human ovarian carcinoma line ES-2 (Lau et aI, 1994a). 
Cytotoxic potentiation is associated with the formation of activated metabolites, capable 
of forming DNA interstrand cross-links. Cytochrome P-4S0, principally the CYP3A 
subfamily, appears to playa major role in the biotransformation process (Lau et aI, 
1991, 1994a). Similar to the acetalanthraquinones, the active metabolite ofmmdox is 
thought to be the O-demethyl derivative (Lau et aI, 1991). DNA-drug adducts following 
metabolism have been detected by gel electrophoresis and HPLC but have not yet been 
identified (Graham et aI, 1992). There is also strong evidence that the 
epipodophyllotoxin etoposide is activated by cytochrome P-4S0-mediated 0-
demethylation of the dimethoxyphenol ring. The O-demethylated product has a 10-fold 
increase in binding to calf thymus DNA (Van Maanen et aI, 1987). It also induces 
inactivation of single-stranded and double-stranded ~X174 DNA and displays enhanced 
cytotoxic activity in Aux-B and H3S cells (Van Maanen et aI, 1985c, 1987). These 
findings support the hypothesis that cytotoxicity of the acetalanthraquinones may have 
been enhanced by metabolic activation to products which can cause DNA damage. 
Because a small amount of drug remained bound to microsomal protein after 
metabolism, slightly less drug was added to cells than in the case of the control drug 
incubations. This almost certainly led to an underestimation of their cytotoxicity, which 
was probably compounded by the fact that the most highly protein affinic compounds 
were also likely to be the most potent. In addition, a mixture rather than isolated 
metabolite was added to cells. However, the ECso values obtained were comparable in 
that the cells were incubated with the same proportion of acetalanthraquinone: 
metabolite (SO:SO) for each compound. 
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A discrepancy was seen in the activity of the parent compounds when comparing 
the hydrolysis and the metabolism studies. For YCG7 and YCG8, the non-metabolized 
controls were more active than the non-hydrolysed controls. This may have been due to 
the transfer of a residual amount of microsomal protein from the metabolic incubates 
into the V79 cells upon drug incubation, supplying exogenous cytochrome P-450 
mono oxygenase activity for drug metabolism. Nevertheless, the cytotoxic potentiation 
(CP) values after metabolism displayed a similar pattern to those obtained follO\ving 
hydrolysis, in the fact that CP for metabolized YCG7~YCG8 and hydrolysed 
YCG7~ YCG8. No discrepancy was observed for YCG9, which showed comparable 
results in both systems. 
In summary, the increase in cytotoxicity of the hydrolysed and metabolized 
products compared with the acetalanthraquinones YCG7 and YCG8 supports the 
concept that they were converted to their corresponding aldehydes. Increased drug 
interaction with DNA processing enzymes such as topoisomerase II via formation of 
persistent (Schiffs base) complexes between DNAItopoisomerase II and aldehyde 
products may have occurred. YCG9 was found to be relatively cytotoxic per se. This 
could be at least partly related to its mode of DNA binding, which is likely to involve 
spearing of the DNA. Cytotoxicity of the products was enhanced by the presence of 
serum during the drug incubation period, perhaps because of facilitated drug transport or 
up-regulation of intracellular topoisomerase II levels in conjunction with an increased 
rate of cell proliferation. 
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CHAPTER 6 
6.1 CONCLUSIONS 
DNA intercalating agents such as the anthraquinones and anthracyc1ines haye a 
well-established role in the treatment of a wide variety of human cancers. However, due 
to their systemic and specific toxicities, the amount of drug that can be administered to 
patients is limited. The need to reduce the toxicity of therapeutically active antitumour 
agents has resulted in extensive research into the development of new compounds \yith 
improved activity and diminished side effects. One strategy has been to synthesize 
compounds which can be targeted specifically to their site of action in the fonn of 
prodrugs. These are agents that are chemically or metabolically activated in vivo to 
produce the pharmacologically active species. Recent advances in tumour selectiye 
activation of anticancer agents had led to a renewed interest in prodrugs. This has 
primarily been due to the emergence of new techniques such as ADEPT and GDEPT, 
and exploitation of the chronic hypoxia and low external pH that is prevalent in most 
solid tumours. In addition, cytochrome P-450s (and other enzymes) are known to be 
overexpressed in a whole range of malignancies, including those of the breast colon, and 
lung - the three main refractory killers (see section 1.5.1). Moreover, the discovery of 
the human tumour specific cytochrome P-450 isoform CYP 1 B opens up new 
possibilities for tumour specific development of metabolically activated compounds 
(Murray et ai, 1997). 
The prodrug AQ4N, developed and synthesized at De Montfort University 
(Patterson et ai, 1992; Smith et ai, 1997a, 1997b), will be undergoing phase I clinical 
trials in the year 2000 for the treatment of non-small cell lung cancer. The intrinsic 
advantage of AQ4N over radiosensitizing agents and some bioreductive agents is that 
until the drug is reduced to AQ4, it is almost completely inactive. The present study 
clearly indicated that the low toxicity of AQ4N is due to modification of the tenninal 
nitrogen of the cationic alkylamino side chain to form an electrically neutral N-oxide 
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functionality. This prevents stabilization of intercalative bindI·ng norm 11 . d 
a Y assocIate 
with cationic alkylaminoanthraquinones, which in tum prevents topoisomerase II 
inhibition. Inability to achieve stable intercalation is attributable to a reduction in the 
electrostatic attraction between the amino group of side chains of drug and the 
negatively charged P04- groups of DNA backbone. 
An insight into the lack of potency of AQ4N has been gained using flow 
cytometric and confocal imaging studies of AQ4 and AQ4N in intact human cells 
(Smith et at, 1997a). These studies revealed that although the N-oxide is able to enter 
the cell nucleus, it is only retained effectively in the cytoplasm, whereas AQ4 targets the 
nucleus to a high degree. It has been suggested that due to its high affinity for DNA, 
AQ4 should remain localized in tumour tissue, hopefully long enough to kill cells when 
they resume cycling upon re-oxygenation. Similar observations have been made with 
respect to the cellular distribution of the mono-N-oxide AQ6N compared with its parent 
compound AQ6 (Smith et at, 1997a; see sections 2.3 and 2.4). However, being a mono-
N-oxide, AQ6N retains some activity (Smith et at, 1997b) and is thus less suitable as a 
selectively activated bioreductive drug than AQ4N. 
In contrast to the N-oxide functionality, the presence of the 2'-
(hydroxyethylamino )ethylamino side chains of mitoxantrone was related to enhanced 
topoisomerase II inhibition and DNA binding activity. This was possibly due to 
oxidation of the side chains to produce aldehyde intermediates, which may increase the 
longevity of the topoisomerase II -DNA cleavable complex by Schiffs base formation 
with the enzyme. Given these observations, a series of acetalanthraquinones were 
developed, possessing dimethoxy groups in place of the alcohol groups of mitoxantrone. 
These compounds were designed on the basis that they could be converted to their 
respective aldehyde derivatives. It was proposed that these derivatives would be more 
active than the acetals due to the potential for Schiffs base formation with intracellular 
enzymes such as topoisomerase II. 
Acid-catalysed hydrolysis and oxidative metabolism by NADPH-fortified mouse 
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liver micro somes both proved effective routes for the conversion of 
acetalanthraquinones. Enhanced potency was observed for both hydrolysed and 
metabolized products of YCG7 and YCG8 and an increase in drug interaction with 
topoisomerase II via formation of persistent (Schiffs base) complexes was proposed. 
YCG9 was found to be relatively cytotoxic per se, perhaps relating to its mode of DNA 
binding (Islam et at, 1985, Bell et at, 1989). Another study carried out by Holmes 
(1995) demonstrated the ability of activated YCG7 and YCG8 to inhibit topoisomerase 
II, whereas the corresponding acetals were inactive. This may indicate that non-
activated YCG7 and YCG8 target enzymes other than topoisomerase II. Structurally 
related compounds have been shown to inhibit polymerases (Fox et aI, 1996), ligases 
(Ciarrocchi et at, 1988) and helicases (Bachur et at, 1992). Further studies are required 
to establish the exact mechanisms of action of the acetalanthraquinones and their 
products (see section 6.2). 
An increase in potency of the acetal anthraquinone products was observed in the 
presence of foetal calf serum. It is proposed that this was related to stimulation of 
topoisomerase II levels (probably topoisomerase IIa) coinciding with increased cell 
proliferation. Topoisomerase IIa levels have been shown to be low in serum-starved 
cells (Feister et at, 1997) and several studies have demonstrated that encouraging cells 
to increase their levels of topoisomerase II enhances their sensitivity to cytotoxic 
agents, including mitoxantrone and doxorubicin (Sullivan et aI, 1987; Davies et aI, 
1988; Deffie et at, 1989; Kasahara et at, 1992). The association between growth factor 
stimulation of a cell population and enhanced expression of topoisomerase II offers the 
possibility of optimizing chemotherapy by manipulating the proliferative status of 
target cells. For example, stimulation of breast cancer cell lines using oestrogen results 
in the elevation of drug-induced protein-associated DNA strand breakage and a 
corresponding increase in cytotoxicity (Zwelling et aI, 1983; Epstein & Smith, 1988). 
Similarly, in myeloid leukaemic cell lines expressing G-CSF receptor. the in vitro 
cytotoxicity of the topoisomerase II inhibitors can be significantly enhanced by 
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addition of exogenous G-CSF (Towatari et ai, 1990). The results obtained in this study 
may signify the potential for development of acetal-containing compounds as 
antitumour agents in conjuction with growth factors. This would be particularly useful 
for the treatment of slow growing tumours, as cancer cells from patients containing low 
levels of topoisomerase II are often refractory to treatment (Potesmil et ai, 1988). 
The acetalanthraquinones are analogous to the morpholino compounds in the 
fact that they are cytotoxic, even without activation, and thus are not true prodrugs. 
However, preliminary studies indicate that the increased potency of 
methoxymorpholino doxorubicin means that at therapeutically effective doses, the 
cardiotoxicity associated with doxorubicin should be avoided (Sikic et ai, 1985; Danesi 
et ai, 1993). Similarly, the acetal anthraquinone products were significantly more 
cytotoxic than the parent compounds. However, unlike the morpholino anthracycline 
metabolites, they were probably not potent enough to be clinically effective. This may 
be partly due to the fact that the acetalanthraquinones contained a non-hydroxylated 
chromophore, which in all probability would reduce their activity substantially (see 
sections 1.2.2 and 1.3.2.2). In addition, assuming the aldehyde was present, and that it 
was the most active component, its cytotoxicity would have been masked by the fact 
that it was added to the V79 cells as part of a mixture of products. 
It should be pointed out that the metabolism of the acetalanthraquinones in 
humans may differ from that in mice. Indeed, a large interspecies variability in 
mitoxantrone biotransformation has also been demonstrated both in vitro and in vivo 
(Avramis, 1982; Richard et ai, 1989, 1991; Blanz et ai, 1991a, 1991b). Clearly, the 
most accurate insight into the biotransformation of cytotoxic agents in a clinical setting 
is to be gained by working with human samples rather than those from animals. Thus, 
further studies are required to investigate the metabolism of acetalanthraquinones using 
human enzyme systems (see section 6.2). 
Altered expression of drug metabolising enzymes in certain types of cancer cells 
compared with normal tissues is thought to be basis for the selectivity of the alkylating 
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agent cyclophosphamide against certain tumour types (section 1.5.2.2). Unfortunately. 
at present, there is a shortage of compounds like cyclophosphamide in clinical use. 
However, due to the increasing prevalence of cancer in modem society, there is an 
ever-growing demand for such compounds. Drugs such as mdox, mmdox, AQ4\: and 
several others already show promise in this respect (reviewed by Denny, 1996). 
Hopefully, as our understanding of cancer cell enzymology increases, it should be 
possible to exploit the differences between normal- and cancer cells to design other 
tumour specific agents. It is conceivable that one of the discoveries made could lead to 
the use of acetal-containing compounds in prodrug therapy. 
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6.2 FUTURE WORK 
Although the results obtained so far are encouraging further stud' . d 
' les are reqUIre 
to investigate the activity of the acetalanthraquinones using human enzyme systems. A 
useful approach would be to transfect human cytochrome P-450 monooxygenase 
enzymes into V79 cells. Fortuitously, this cell1ine is devoid of endogenous CYP 
activity, with the result that working with CYP-expressing V79 cells would be akin to 
using the purified enzyme. Successful transfer of several CYPs into the V79 cell line. 
including CYP1A1, CYP1A2 and the human tumour-specific isoform CYP1B1 has 
already been achieved (Doehrner & Schrnalix, 1994; Schrnalix et ai, 1996; Luch et ai, 
1998). In addition, non-P450 enzymes, such as dehydrogenases or oxidases, may also be 
involved in the oxidation of the acetalanthraquinones (see Gibson & Skett, 1986; 
Beedham, 1997; section 1.5.1). Studies should also be carried out to investigate the 
metabolism of acetalanthraquinones in tissues where the expression of cytochrome P-
450s and other drug-metabolizing enzymes is different from that in normal cells (see 
section 1.5.1). 
A common feature of cancer cells is their ability to overproduce lactic acid 
(Baggetto, 1997; Dang et ai, 1997). Extracellular accumulation of lactic acid means that 
the pH surrounding solid tumours is usually lower than normal, the precise acidity 
depending on the type of malignancy. Thus, by virtue of their instability in acidic 
environments, the acetalanthraquinones may be hydrolysed in the extracellular space, 
providing another opportunity for the exploitation of the unique properties of tumour 
cells. Although the cytosolic pH of tumour cells is not acidic, the pH of the lysosomal 
compartment is about pH 5.5 and several attempts have been made to target the 
lysosomal compartment using acid-labile proderivatives (Masquelier et ai, 1980; Sat et 
ai, 1999). This could provide another means of converting the acetalanthraquinones to 
their more active products. Although the acetalanthraquinones were stable to hydrolysis 
under conditions which mimic those of the lysosomal compartment (37°C, pHS.5), 
hydrolytic enzymes present in the lysosomes (Alberts et al. 1983) may lo\\er the 
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activation energy required for hydrolysis, so it could Occur at 37°C I b t' f h 
. ncu a Ion 0 t e 
acetalanthraquinones with isolated liver lysosomes may help to test the feasibility of 
targeting these compounds to the lysosomal compartment. 
Further studies are required to achieve a greater insight into the mechanism(s) of 
action of the acetalanthraquinones. For example, the cleavable complexes formed by 
most topoisomerase II-targeting drugs are readily reversed if exposed to high salt 
concentrations (Tewey et ai, 1984b) or heated to 65°C (Hsiang & Liu, 1989) prior to the 
addition of protein denaturants such as SDS. However, irreversible topoisomerase II 
cleavable complexes have been demonstrated for camptothecin analogues (Hertzberg et 
ai, 1990) and the terpenoides, terpentecin and clerocidin (Kawada et aI, 1991), which 
unlike the complexes formed by other topoisomerase II inhibitors, are stable to these 
treatments. The formation of irreversible cleavable complexes by the camptothecin 
analogue 10-bromoacetamidomethylcamptothecin is thought to be mediated by covalent 
linkage with the topoisomerase I-DNA adduct, preventing DNA ligation. Therefore, it 
would be interesting to investigate the stability of the cleavable complexes formed by 
the acetal anthraquinone products after activation. Formation of irreversible cleavable 
complexes by the acetalanthraquinone products would support the involvement of 
covalent linkage between aldehyde products and the topoisomerase II-DNA adduct as a 
mechanism of action. Moreover, it has not yet been determined to what extent each of 
the topoisomerase II isoforms is targeted by the acetalanthraquinones. This could be 
investigated using decatenation assay, or alternatively, a more recently developed assay 
employing Sacharomyces cerevisiae modified to express either human topoisomerase 
IIa or topoisomerase lIP (Hammonds et ai, 1998). 
Both morpholino doxorubicin and methoxymorpholino doxorubicin show 
significant activity in MDRl-expressing doxorubicin-resistant cell lines (Streeter et ai, 
1986; Ripamonti et ai, 1992; Lau et ai, 1994a) and those displaying the at-MDR 
phenotype (Capranico et ai, 1994, Mariani et ai, 1994). Similar investigation into the 
activity of the acetalanthraquinones in mitoxantrone-resistant cell lines (e.g.the HL-60 
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human leukaemia cell line ) is required. It would also be interest' t h· . 
mg 0 assess t e actIvIty 
of the acetalanthraquinones in V79 cells resistant to other topol·som 'nhib' erase I ItorS. such 
as the DC-3F/9-0H-E cell line (Khelifa et al 1994) Resistance l'n thl'S 1" . d 
,. me IS assocIate 
with a four- to five-fold reduction in topoisomerase II a and a ten-fold reduction in the 
ability of topoisomerase inhibitors to induce cleavable complex formation. The 
cytotoxicity of the acetal anthraquinone products, particularly those ofYCG7 and 
YCG8, should also be investigated in cell lines such as the VP-16- and amsacrine-
sensitive ataxia-telangiectasia cell line, which overexpresses topoisomerase II and 
shows elevated levels of drug-induced cleavable complexes (Smith & Makinson, 1989). 
The active metabolite of methoxymorpholino doxorubicin is thought to be the 0-
demethyl derivative (Lau et ai, 1991; see section 1.5.3.2). Although DNA-drug adducts 
following metabolism have been detected by gel electrophoresis and HPLC, the 
metabolite has not yet been identified (Graham et ai, 1992). Similarly, as the 
acetal anthraquinone products generated in this study were not isolated, their 
identification was not possible. Isolation of the products would be more desirable than 
adding a mixture of products to cells, so that their individual potencies could be 
assessed. Use of a preparative HPLC system would allow relatively large quantities of 
products to be separated for this purpose. Structural identification could be performed 
by mass spectroscopy, followed by comparison of the mass spectrum fragmentation 
patterns with the HPLC retention times of the isolated products and synthetic reference 
samples. Once the structure of each component was known, it would also be interesting 
to study the fates of the acetalanthraquinones and their products using flow cytometric 
and confocal imaging techniques. Such techniques are already well established in 
studying the cellular distribution of the TNQ metabolite of mitoxantrone (Feofanov et 
ai, 1997) and the N-oxides AQ4N and AQ6N (Smith et ai, 1997a). 
Despite the fact that the acetalanthraquinone products were considerably more 
active than their parent compounds, they were still poor cytotoxic agents compared to 
the metabolites generated by other activated drugs, for example. the morpholino 
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anthracyclines. Thus, there is clearly a need to produce acetal-containing compounds 
that will be sufficiently potent when activated to be effective in clinical setting. 
These should include compounds with hydroxylated chromphores and also with 
different chromophores. One option would be to attach the acetal side chains to th~ 
anthrapyrazole moiety, which appears to produce compounds that are less cardiotoxic 
than many of the anthraquinones and anthracyclines (see section 1.4.1.4). Moreover, it 
could be argued that YCG7 and YCG8 are topoisomerase II prodrugs because they do 
not inhibit the enzyme until metabolically activated (see section 5.4.2). By the same 
token, if drugs could be designed where the DNA binding activity of the parent 
compounds is reduced, this may lessen the side effects of the drug by lowering DNA 
binding in normal cells. Also, from a prodrug design point of view, a high DNA binding 
affinity is not desirable in the parent compound from which the prodrug is derived, 
because this considerably reduces drug diffusion to surrounding tumour cells. 
Although the acetalanthraquinone products were disappointing in terms of their 
potency, the results are extremely promising in that they demonstrate that it is possible 
to produce acetal-containing compounds with the potential to be metabolically or 
chemically activated to agents with novel mechanisms of action. This concept can now 
be applied to produce a variety of other acetal-containing drugs, one or more of which 
may prove suitable for clinical use. 
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APPENDICES 
At: THE TRYP AN BLUE DYE EXCLUSION ASSAY 
Trypan blue solution (lOO/-1l, at 0.4%) was added to 250)..11 ofV79 cell suspension 
and left for 5 min. A Neubauer haemocytometer (total capacity 10-4 ml) was moistened 
around the edges of the counting chamber and a cover slip pressed into position over the 
chamber ensuring the formation of Newton's rings in the surrounding area. The 
counting chamber was filled with approximately 10/-11 of cell suspension. The 
proportion of lysed cells was ascertained by microscopic examination (only cells with 
disrupted membranes accumulate the trypan blue dye). 
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A2: THE BIORAD ASSAY 
Bio-Rad reagent (a concentrate of Coomassie Brilliant Blue dye, methanol and 
phosphoric acid) was diluted five-fold with double distilled water and filtered. The 
reagent (5ml) was then added to bovine serum albumin (BSA; standard grade) solutions 
(O.lml in O.IM phosphate buffer, pH 7.4) ranging in concentration from 0-1.0 mgml- 1 
and to samples of V79 nuclear extract and Balb Cliver micro somes, which were also 
diluted in phosphate buffer, pH 7.4. The solutions were incubated at room temperature 
for 15 min and the absorbance was then measured at 595nm against a blank of double 
distilled water. A BSA calibration curve was constructed to determine the protein 
content (ml-l) of the nuclear extract/microsomes. 
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The microsomal protein concentration was 52.6 ± 2.l mgml- l . 
The protein content of the V79 nuclear extract was 855 ± 35.7 Ilgml-
1
. 
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A3: SYNTHESIS OF STARTING MATERIALS (Chapter 3) 
A3.1 SYNTHESIS OF DIPHENYLPHOSPHINAMIDE 
A 33% solution of aqueous ammonia (400ml) at O°C, was added dropwise to SOg 
(0.2 mol) diphenylphosphinic chloride, with vigorous stirring, such that the temperature 
did not exceed 10°C. The product was filtered in vacuo and washed with water 
(4x60ml). The yield was 26.5g (61%). 
diphenylphosphinic 
chloride 
diphenylphosphinamide 
200 
A3.2 SYNTHESIS OF N-[2-(2'-METHOXYMORPHOLINYL)]ETHANOL 
Bromoacetaldehyde dimethylacetall00g (0.5 mol) was added to 93g (0.75 mol) 
diethanolamine over 1 hr at 60-70°C, then heated to 100-11 O°C for 2 to 4 hr. until the 
starting material was consumed (followed by thin layer chromatography in 
CH2Cl2/MeOH 9: 1). The resulting mixture was distilled in vacuo at 2mmHg. collecting 
the distillate between 108 and 110°C. The yield was 53.1g (66%). 
N<CH2-CHZ-OH 
CH2-CH2-0H 
di(2-hydroxyethyl-amine) 
O-CH 3 
Br-CHr cH( 
O-CH3 
Bromoacetaldehyde dimethylacetal 
N-[2-(2'-methoxymorpholinyl)]ethanol 
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A3.3 SYNTHESIS OF 2,3-DIHYDRO-I,4,S,8-TETRAHYDROXY_ANTHRACE~E_ 
9, I O-DIONE 
Step I: sodium chlorate, 72g (0.067 mol) was added, over a 30 minute intervaL to 
a solution of I,S-diamino-anthracene-9,10-dione, 6g (0.02S mol) in conc. H2S04 
(100ml) on ice. The mixture was allowed to cool to room temperature. and stirring was 
continued for a further 3h, after which time the reaction mixture was poured into one 
litre of I % sodium hydrogen sulfite. The resulting precipitate was removed by filtration 
in vacuo and washed with cold distilled water (2xSOOml) and distilled water at 600C 
(2xSOOml). The solid was dried in vacuo. The yield was S.9g (88%). 
1,5-diamino-anthracene-9,lO-dione 
o OH 
OH 0 
1,5-diamino-4,8-dihydroxy-
anthracene-9,10-dione 
Step 2: to a solution of I,S-diamino-4,8-dihydroxy-anthracene-9,10-dione, 4g 
(O.OISmol) in 2.SM aqueous NaOH solution, under argon, at SO-60°C, was added 35g 
(0.2mol) sodium hydro sulfite, whilst increasing the temperature to 90-95°C. The 
mixture was heated until no starting material was present (followed by thin layer 
d 'd'fi dtopH60withlO\1 chromatography), then cooled to room temperature an aCI I Ie . 
d h d 'th d'stilled water (-+:dOOml). HCl. The resulting precipitate was filtered an was e WI I . 
and dried in vacuo. The yield was 2.9g (70%). 
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0 OH 
1,S-diamino-4,8-dihydroxy-
anthracene-9,10-dione 
OH 0 NH2 
OH OH OH 
OH OH OH 
I 
OH OH 0 
2,3-dihydro (leu co) form 
OH OH 0 
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A4.l NMR FOR YCG7 
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A4.S MASS SPECTRUM FOR YCG4 
.., 
'" 
-r> .., 
'" '" 
' L 
"' 
W OJ 
-:. '., '-
" " , ," ", I 
OJ w W !.oJ W c.: OJ w
'" 
W !.oJ c.: W
'" 
-, ~ 
()o 
'" 
oD .,. OJ W 
" 
u :.. u 
-' 
. 
" '" 
0 
'" 
><; 
N N 
"" 
'<. 
~ :;0 
'" 
'"' 
'" ., 
'" 0 
-r> 
r-
.,-. 
'" 
'" N 
01'> 
"' 0 
"' 
.c 
~ 
v 
'" 
~ 
'" 
"" 
208 
AS: SPECTRAL DETERMINATION OF CYTOCHROME P-450 CO:\TE:\T OF 
BALB C MOUSE LIVER MICROSOMES 
A homogeneous suspension of Balb C mouse liver micro somes was diluted with 
ice-cold O.IM Tris buffer, pH7.4, containing 20% v/v glycerol to give approximately 
2mgml- l protein. The suspension was divided equally between two matched glass 
cuvettes, and approximately Img of sodium dithionite was added to each, stirring their 
contents gently. The absorbance was then recorded between 400 and 500nm. The 
sample cuvette was immediately bubbled with carbon monoxide (BDH. Leicester, U.K) 
for 1 min (at a rate of approximately one bubble/sec) and the samples were re-scanned 
between 400 and 500nm. 
When the haem iron of cytochrome P-450 was reduced by sodium dithionite and 
complexed with CO, a characteristic spectrum was obtained, with an absorbance 
maximum of 450nm. The concentration of cytochrome P-450 (nmolmg-1 protein) was 
calculated from a linear graph obeying Beer-Lambert's Law, using an extinction 
coefficient of91nM- 1cm- l (see Gibson & Skett, 1986). The cytochrome P-450 content 
was 0.46 nmolmg- l protein. 
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A6: DETERMINATION OF REACTION KINETICS FOR THE HYDROLYSIS 
OF THE ACETALANTHRAQUINONES 
A6.1 THE KINETIC EQUATIONS FORZERO-, FIRST- AND SECOND ORDER 
REACTIONS 
F or a zero order reaction: x = kt 
For a first order reaction: log [a/(a-x)] = ktl2.303 
For a second order reaction, when a>b: log [b(a-x)/a(b-x)] = k(a-b)t/2.303 
In these equations, x is the concentration of the rate-determining reactant utilised during 
time t of the reaction. The initial concentration of reactant A is represented by a. so that 
after time t the remaining concentration of a is represented by (a-x). Similarly, when a 
second reactant B is rate-determining, its initial concentration is represented by b. and 
after time t the remaining concentration of b is represented by (b-x). 
By choosing the appropriate ordinates, the kinetic equations above can represented as 
straight line plots against time, which can then be used to calculate both the order and 
the rate constant (k) of the reaction: 
ZERO 0 RDER. 1ST ORDER 2ND ORDER (a>b) 
1 t >< )< 
slope I I 
k ~ ~ k(a-b) 
><" q]IZ =2.303 ..QfU slope= 2.303 
en ~ 
0 0 
t .- t t • .. 
. . h l' 1 t' s not In order to calculate k, the plot obtained must be hnear. If a stralg t me pOI 
obtained then the reaction does not follow that particular order overall. , 
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A6.2 DETERMINATION OF THE OVERALL ORDER OF THE REACTIO:': FOR 
THE HYDROLYSIS OF THE ACETALANTHRAQUINONES 
(a) Plots obtained using the kinetic equation for a zero order reaction 
For the hydrolysis reaction of acetalanthraquinones, the plots generated using the kinetic 
equation for a zero order reaction were not linear, demonstrating that the reaction was 
not zero order overall (figures 1 to 3 show the results obtained for YCG7, YCG8 and 
YCG9 at 90°C). 
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Figure 1: Plot obtained for the hydrolysis of YC?7 
using the kinetic equation for a zero order reactIOn 
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Figure 2: Plot obtained for the hydrolysis ofYCG8 
using the kinetic equation for a zero order reaction 
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Figure 3: Plot obtained for the hydrolysis ofYCG9 
using the kinetic equation for a zero order reaction 
212 
(b) Plots obtained using the kinetic equation for a fi t d . Irs or er reactIon 
Taking a as the initial concentration of the drug (100"M) d h . 
r an x as t e concentratIon of 
drug utilised during time t of the reaction a plot of log a/ - t d . 
, a x vs pro uced a straIght 
line, demonstrating that the hydrolysis reaction followed fi t d k' . IrS or er metIcs: 
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Figure 4: Plot obtained for the hydrolysis of YCG7 
using the kinetic equation for a first order reaction 
Because hydrolysis of the acetalanthraquinones is likely to occur by the SN2 mechanism 
(see section 4.4.1), the reaction would usually be expected to follow second order 
kinetics overall. However, SN2 reactions in which one reactant is in large excess usually 
display pseudo first order kinetics, because only one reactant is rate-determining. Thus, 
as water was in great excess throughout the hydrolysis reaction, it followed pseudo first 
order kinetics, where the rate was only dependent on the concentration of drug. 
213 
A7: MAINTENANCE OF V79 CELLS 
A7.1 PREPARATION OF RPMI 1640 CULTURE MEDIUM 
Powdered RPMI 1640 medium (supplied by Gibco BRL, UK) consisted of25m!\1 
N-2- hydroxyethylpiperazine-N'-2-ethane sulfonic acid buffer (HEPES) and L-
glutamine. The powder was added to 1 litre of distilled water and the pH adjusted to 7.2 
using NaOH. After sterile filtration into pre-autoclaved bottles using a Millipore bottle 
filter, the medium was incubated for a minimum of three days at 37°C before checking 
for contamination. The medium was supplemented immediately prior to use. 
A7.2 PROCEDURE FOR PASSAGING V79 CELLS 
RPMI medium was removed from culture flasks and replaced with EDTA (Sml at 
0.1 % in DPBS) for 30 sec, ensuring contact with all cells. The flasks were then 
incubated vertically at 37°C for approximately 15 min, or until the cells detached from 
the flask surface. The cells were then resuspended in fully supplemented RPMI medium 
(5ml) and any cell clumps were dispersed by passing the cells through a 19 gauge 
needle 2-3 times. The cells were reseeded in culture flasks to give a five-fold reduction 
in original cell concentration. 
A7.3 COUNTING OF V79 CELLS USING A PARTICLE COUNTER 
Cells were passaged and collected in RPMI medium as described in section A 7.2 
and after dispersing any cell clumps, a 1 in 20 dilution of the cell suspension was made 
using saline. After thorough mixing, the number of cells in the saline suspension was 
determined using a particle counter Model ZM (Coulter Electronics Ltd, Luton. U.K). 
The cell suspension was adjusted with fully supplemented RPMI medium to gi\'t~ the 
required cell concentration(s). These were recounted to ensure accurate dilution. 
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A8: ABBREVIATIONS 
AML: Acute myelocytic leukaemia 
ALL: Acute lymphocytic leukaemia 
ATP: Adenosine triphosphate 
BSA: Bovine serum albumin 
CHF: Congestive heart failure 
CLL: Chronic lymphocytic leukaemia 
DMSO: Dimethyl sulfoxide 
DPBS: Dulbecco's phosphate buffered saline 
EDT A: Ethylenediaminetetraacetic acid 
E.I: Electron impact 
EGT A: Ethylenebis( oxyethylenenitrilo )tetraacetic acid 
FCS: Foetal calf serum 
FTIR: Fourier transform infra-red 
G-CSF: Granulocyte colony-stimulating factor 
KDNA: Kinetoplast DNA 
m-AMSA: 4' -(9-acridinylamino )-methanesulfon-m-anisidide 
MFO: Mixed function oxidase 
NADPH: Nicotinamide adenine dinucleotide phosphate 
NSCLC: Non-small cell lung cancer 
PMSF: Phenyl methane sulphonyl fluoride 
SCLC: Small cell lung cancer 
SDS: Sodium dodecyl sulphate 
215 
TEA: Triethyl-amine 
TNQ: Tetrahydronaphthoquinoxaline 
Topo II: Topoisomerase II 
Tris: 2-Amino-2-(hydroxymethyl)-1,3-pronanediol 
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